Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 124
Encontrada(s) 2 página(s)

Docta Complutense
Publicación Artículo científico (JournalArticle)

Prospects for γ-ray observations of the Perseus galaxy cluster with the Cherenkov Telescope Array

  • Alvarez-Crespo, N.
  • Barrio Uña, Juan Abel
  • Contreras González, José Luis
  • Láinez, M.
  • López Moya, Marcos
  • Martinez, O.
  • Mas-Aguilar, A.
  • Miener, Tjark
  • Miranda, J.M.
  • Morcuende Parrilla, Daniel
  • Nieto Castaño, Daniel
  • Rosado Vélez, Jaime
  • Sinha, Atreyee
  • Tejedor Álvarez, Luis Ángel
  • Zamanillo, V.M.
Galaxy clusters are expected to be both dark matter (DM) reservoirs and storage rooms for the cosmic-ray protons (CRp) that accumulate along the cluster’s formation history. Accordingly, they are excellent targets to search for signals of DM annihilation and decay at γ-ray energies and are predicted to be sources of large-scale γ-ray emission due to hadronic interactions in the intracluster medium (ICM). In this paper, we estimate the sensitivity of the Cherenkov Telescope Array (CTA) to detect diffuse γ-ray emission from the Perseus galaxy cluster. We first perform a detailed spatial and spectral modelling of the expected signal for both the DM and the CRp components. For each case, we compute the expected CTA sensitivity accounting for the CTA instrument response functions. The CTA observing strategy of the Perseus cluster is also discussed. In the absence of a diffuse signal (non-detection), CTA should constrain the CRp to thermal energy ratio X500 within the characteristic radius R500 down to about X500 < 3 × 10−3, for a spatial CRp distribution that follows the thermal gas and a CRp spectral index αCRp = 2.3. Under the optimistic assumption of a pure hadronic origin of the Perseus radio mini-halo and depending on the assumed magnetic field profile, CTA should measure αCRp down to about ∆αCRp ≃ 0.1 and the CRp spatial distribution with 10% precision, respectively. Regarding DM, CTA should improve the current ground-based γ-ray DM limits from clusters observations on the velocity-averaged annihilation cross-section by a factor of up to ∼ 5, depending on the modelling of DM halo substructure. In the case of decay of DM particles, CTA will explore a new region of the parameter space, reaching models with τχ > 1027 s for DM masses above 1 TeV. These constraints will provide unprecedented sensitivity to the physics of both CRp acceleration and transport at cluster scale and to TeV DM particle models, especially in the decay scenario.
Dipòsit Digital de Documents de la UAB
Publicación Capítulo o parte de un libro (BookPart)

Análisis de la recepción y canonización de las comedias del Siglo de Oro a partir de sus adaptaciones cinematográficas

  • Carmona, Alba|||0000-0002-7486-6160
Esta investigación predoctoral pretende aportar información en dos niveles. El primer apartado versará sobre el proceso de recepción internacional, a través del cine, en la actualidad y a lo largo del siglo pasado, de las obras de autores como Lope de Vega, Calderón de la Barca, Tirso de Molina, Agustín Moreto y Guillén de Castro. Trataré de perfilar cuál es, en expresión de Jauss, el horizonte de expectativas que las transposiciones cinematográficas de la comedia, españolas y extranjeras, han creado en el espectador acerca del teatro del Siglo de Oro. Como ya hizo Wheeler para las adaptaciones nacionales, deberé evaluar hasta qué punto este horizonte de expectativas concuerda con el que se ha desprendido, durante largo tiempo, de la crítica académica. Y es que esta, como ya indicó Arellano, ha contribuido, en ocasiones, a la consolidación de una serie de tópicos y prejuicios que afectan a la recepción del teatro clásico español. En segundo lugar, la tesis quiere determinar cuál es el papel del cine, un factor extraliterario, en el proceso de canonización de las comedias áureas. Como ya señaló Mata Induráin, a partir de la transposición de El perro del hortelano (P. Miró, 1996), se multiplicaron las ediciones y estudios de la pieza lopesca; además, después de su estreno, su presencia en los escenarios también ha sido constante. Es preciso, en consecuencia, comprobar si tal fenómeno se ha producido con el resto de adaptaciones, y valorar qué otros factores pueden haber intervenido en la entrada en el canon de determinadas obras.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Premature Death, Suicide, and Nonlethal Intentional Self-Harm After Psychiatric Discharge

  • Mortier, Philippe|||0000-0003-2113-6241
  • Conde, Susana
  • Alayo, Itxaso|||0000-0002-7333-3450
  • Amigo, Franco|||0000-0002-3602-5168
  • Ballester, Laura
  • Cirici Amell, Roser
  • Guinart, Daniel
  • Contaldo, Salvatore Fabrizio
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
  • Leis, Angela
  • Mayer, Miguel Angel|||0000-0003-0362-6298
  • Portillo-Van Diest, Ana|||0000-0001-7199-8339
  • Puértolas-Gracia, Beatriz
  • Ramírez-Anguita, Juan Manuel|||0000-0002-8509-0927
  • Peña-Salazar, Carlos
  • Sanz, Ferran|||0000-0002-7534-7661
  • Kessler, Ronald|||0000-0003-4831-2305
  • Palao, Diego|||0000-0002-3323-6568
  • Pérez Solà, Víctor|||0000-0002-5825-2337
  • Mehlum, Lars|||0000-0003-2813-0045
  • Qin, Ping
  • Vilagut, Gemma|||0000-0002-3714-226X
  • Alonso, Jordi|||0000-0001-8627-9636
This cohort study estimates rates of all-cause premature death, suicide, and nonlethal intentional self-harm after discharge from a psychiatric hospitalization among patients in Spain and investigates associations of these outcomes with variables including sex and mental disorders. What is the risk for premature death, suicide, and nonlethal intentional self-harm following discharge from psychiatric hospitalization? In this cohort study including 49 108 patients, risk for postdischarge premature death (age <70 years) and suicide was significantly higher compared with the general population. Premature death was associated with cognitive disorders and alcohol-related disorders in both sexes; suicide was associated with postdischarge nonlethal intentional self-harm in both sexes, with depressive and adjustment disorders in males, and with bipolar disorder in females. The findings suggest individuals discharged from psychiatric inpatient care constitute a vulnerable population for premature death and suicidal behavior. There is a need for representative research on serious adverse outcomes following discharge from psychiatric hospitalization. To compare rates of premature death, suicide, and nonlethal intentional self-harm after psychiatric discharge with rates in the general population and investigate associations of these outcomes with relevant variables associated with the index psychiatric hospitalization. This retrospective cohort study included all residents from Catalonia, Spain (7.6 million population), who had psychiatric hospitalizations between January 1, 2014, and December 31, 2018, and were older than 10 years at the index (first) hospitalization. Follow-up was until December 31, 2019. Statistical analysis was performed from December 1, 2022, through April 11, 2024. Socioeconomic status, psychiatric diagnoses, duration of index hospitalization, and number of previous psychiatric hospitalizations. Postdischarge premature death (ie, all-cause death before age 70 years) and suicide (International Statistical Classification of Diseases and Related Health Problems, Tenth Revision [ICD-10] code range X60-X84), identified using mortality data, and postdischarge nonlethal intentional self-harm, identified using electronic health record and self-harm case register data. Standardized mortality ratios (SMRs) compared rates of premature death and suicide between the cohort and the general population. Fully adjusted, multivariable, cause-specific Cox proportional hazards regression models for the 3 outcomes were fitted. A total of 49 108 patients discharged from psychiatric hospitalization were included (25 833 males [52.6%]; mean [SD] age at discharge, 44.2 [18.2] years). During follow-up, 2260 patients (4.6%) died prematurely, 437 (0.9%) died by suicide, and 4752 (9.7%) had an episode of nonlethal intentional self-harm. The overall SMR for premature death was 7.5 (95% CI, 7.2-7.9). For suicide, SMR was 32.9 (95% CI, 29.9-36.0) overall and was especially high among females (47.6 [95% CI, 40.2-54.9]). In fully adjusted sex-stratified hazard models, postdischarge premature death was associated with cognitive disorders (adjusted hazard ratio [AHR], 2.89 [95% CI, 2.24-3.74] for females; 2.59 [95% CI, 2.17-3.08] for males) and alcohol-related disorders (AHR, 1.41 [95% CI, 1.18-1.70] for females; 1.22 [95% CI, 1.09-1.37] for males). Postdischarge suicide was associated with postdischarge intentional self-harm (AHR, 2.83 [95% CI, 1.97-4.05] for females; 3.29 [95% CI, 2.47-4.40] for males), with depressive disorders (AHR, 2.13 [95% CI, 1.52-2.97]) and adjustment disorders (AHR, 1.94 [95% CI, 1.32-2.83]) among males, and with bipolar disorder among females (AHR, 1.94 [95% CI, 1.21-3.09]). Postdischarge intentional self-harm was associated with index admissions for intentional self-harm (AHR, 1.95 [95% CI, 1.73-2.21] for females; 2.62 [95% CI, 2.20-3.13] for males) as well as for adjustment disorders (AHR, 1.48 [95% CI, 1.33-1.65] for females; 1.99 [95% CI, 1.74-2.27] for males), anxiety disorders (AHR, 1.24 [95% CI, 1.10-1.39] for females; 1.36 [95% CI, 1.18-1.58] for males), depressive disorders (AHR, 1.54 [95% CI, 1.40-1.69] for females; 1.80 [95% CI, 1.58-2.04] for males), and personality disorders (AHR, 1.59 [95% CI, 1.46-1.73] for females; 1.43 [95% CI, 1.28-1.60] for males). In this cohort study of patients discharged from psychiatric hospitalization, risk for premature death and suicide was significantly higher compared with the general population, suggesting individuals discharged from psychiatric inpatient care are a vulnerable population for premature death and suicidal behavior.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Biocontrol potential of Aspergillus section Nigri strains against Aspergillus carbonarius

  • Marquès, Júlia
  • Parra, Kaitlyn
  • Castellá, Gemma|||0000-0002-8404-0688
  • Cabañes Sáenz, Francisco Javier|||0000-0002-2244-5778
Aspergillus carbonarius is the main producer of ochratoxin A (OTA) in grape and grape products. Good agricultural practices and preventive measures such as the use of biological control agents are key to decreasing OTA concentration in the final product. This study evaluated non-ochratoxigenic strains from Aspergillus section Nigri isolated from grape environments for their ability to control OTA production. In vitro interactions between an ochratoxigenic strain of A. carbonarius and 22 non-ochratoxigenic strains were evaluated using microtiter plates. Biocontrol potential was determined by measuring OTA reduction, while competitiveness was quantified through a specific qPCR assay. Results showed that both OTA reduction and competitive ability were strain-dependent. Co-inoculation experiments revealed that most non-OTA-producing strains reduced OTA levels, with Aspergillus uvarum showing the strongest inhibition. Aspergillus japonicus and Aspergillus trinidadensis also reduced OTA, whereas biseriate species such as Aspergillus niger, Aspergillus welwitschiae, and Aspergillus brasiliensis had minimal impact. The qPCR competitiveness assays revealed that A. carbonarius typically dominated mixed cultures, except when co-cultured with highly competitive A. uvarum strains. Notably, strain A-6760 reduced A. carbonarius abundance to below 6%. This strong competitiveness aligned with significant OTA suppression, suggesting competitive exclusion as the main biocontrol mechanism. Overall, the developed qPCR assay provides a rapid, precise method for fungal interaction evaluation. A. uvarum strains showed great promise for mitigating OTA contamination in grapes and wine through its combined dominance and toxin reduction capacity. Future research should evaluate their effectiveness under field conditions.
Repisalud
Publicación Artículo científico (JournalArticle)

Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry

  • Marrugal, Ángela
  • Ferrer, Irene
  • Pastor, Maria Dolores
  • Ojeda, Laura
  • Quintanal-Villalonga, Alvaro
  • Carnero, Amancio
  • Molina-Pinelo, Sonia
  • Paz Ares, Luis Gonzaga
Heat shock protein 90 (HSP90) is an important chaperone in lung adenocarcinoma, with relevant protein drivers such as EGFR (epidermal growth factor receptor) and EML4-ALK (echinoderm microtubule-associated protein-like protein4 fused to anaplastic lymphoma kinase) depending on it for their correct function, therefore HSP90 inhibitors show promise as potential treatments for lung adenocarcinoma. To study responses to its inhibition, HSP90 was pharmacologically interrupted by geldanamycin and resorcinol derivatives or with combined inhibition of HSP90 plus HSP70 in lung adenocarcinoma cell lines. Two-dimensional electrophoresis was performed to identify proteomic profiles associated with inhibition which will help to understand the biological basis for the responses. HSP90 inhibition resulted in altered protein profiles that differed according the treatment condition studied. Results revealed 254 differentially expressed proteins after treatments, among which, eukaryotic translation initiation factor3 subunit I (eIF3i) and citrate synthase demonstrated their potential role as response biomarkers. The differentially expressed proteins also enabled signalling pathways involved in responses to be identified; these included apoptosis, serine-glycine biosynthesis and tricarboxylic acid cycle. The proteomic profiles identified here contribute to an improved understanding of HSP90 inhibition and open possibilities for the detection of potential response biomarkers which will be essential to maximize treatment efficacy in lung adenocarcinoma.
Repisalud
Publicación Artículo científico (JournalArticle)

Histology-dependent prognostic role of pERK and p53 protein levels in early-stage non-small cell lung cancer

  • Quintanal-Villalonga, Alvaro
  • Mediano, Mariló
  • Ferrer, Irene
  • Meléndez, Ricardo
  • Carranza-Carranza, Andrés
  • Suárez, Rocío
  • Carnero, Amancio
  • Molina-Pinelo, Sonia
  • Paz Ares, Luis Gonzaga
Lung tumors represent a major health problem. In early stage NSCLC tumors, surgical resection is the preferred treatment, but 30-55% of patients will relapse within 5 years after surgery. Thus, the identification of prognostic biomarkers in early stage NSCLC patients, especially those which are therapeutically addressable, is crucial to enhance survival of these patients. We determined the immunohistochemistry expression of key proteins involved in tumorigenesis and oncogenic signaling, p53, EGFR, pAKT and pERK, and correlated their expression level to clinicopathological characteristics and patient outcome. We found EGFR expression is higher in the squamous cell carcinomas than in adenocarcinomas (p=0.043), and that nuclear p53 staining correlated with lower differentiated squamous tumors (p=0.034). Regarding the prognostic potential of the expression of these proteins, high pERK levels proved to be an independent prognostic factor for overall (p<0.001) and progression-free survival (p<0.001) in adenocarcinoma patients, but not in those from the squamous histology, and high p53 nuclear levels were identified as independent prognostic factor for progression-free survival (p=0.031) only in squamous cell carcinoma patients. We propose a role as early prognostic biomarkers for pERK protein levels in adenocarcinoma, and for nuclear p53 levels in squamous cell lung carcinoma. The determination of these potential biomarkers in the adequate histologic context may predict the outcome of early stage NSCLC patients, and may offer a therapeutic opportunity to enhance survival of these patients.
Repisalud
Publicación Artículo científico (JournalArticle)

IL7RA rs10491434 polymorphism is related to spontaneous HIV infection control in naïve HIV-infected patients: A retrospective study.

  • Sepulveda-Crespo, Daniel
  • Jimenez-Sousa, Maria Angeles
  • Fernandez-Rodriguez, Amanda
  • Muñoz-Fernández, María A
  • Jiménez, José L
  • Caraciolo, Begoña B
  • Reus Bañuls, Sergio
  • Vilchez, Helem
  • Mothe, Beatriz
  • Martinez, Isidoro
  • Benito, José M
  • Rallón, Norma
  • Resino, Salvador
Interleukin 7 receptor (IL7R) is vital in the adaptive immune response against human immunodeficiency viruses (HIV). We assessed IL7RA polymorphisms (SNPs) in antiretroviral therapy (ART)-naïve HIV patients for their association with spontaneous HIV infection control. We conducted a retrospective cohort study involving 667 ART-naïve patients categorized by HIV progression (ordinal variable): 150 rapid progressors, 334 moderate/typical progressors, 86 long-term nonprogressors elite controllers (LTNPs-EC), and 97 LTNPs-non-EC. We genotyped three IL7RA SNPs using Agena Bioscience's MassARRAY platform. The association between IL7RA SNPs and spontaneous HIV infection control was evaluated using ordinal logistic regression. Individuals carrying the rs10491434 G allele have a higher likelihood of spontaneous HIV infection control (adjusted odds ratio [aOR] = 1.33; p = 0.023). Moreover, the IL7RA GCT haplotype, consisting of three specific SNPs (rs6897932, rs987106, and rs10491434), demonstrated an association with the control of untreated HIV infection (aOR = 1.34; p = 0.050). Remarkably, the rs10491434 SNP and the IL7RA GCT haplotype exhibited similar aOR values, suggesting that rs10491434 may be primarily responsible for the observed effect of the haplotype. IL7RA rs10491434 G allele is associated with a higher likelihood of spontaneous HIV infection control, indicating its significant role in the pathogenesis of HIV, possibly influencing infection course and viral replication control.
Repisalud
Publicación Artículo científico (JournalArticle)

Low plasma levels of BTLA and LAG-3 before HCV therapy are associated with metabolic disorders after HCV eradication in persons with HIV/HCV coinfection: a retrospective study

  • Martín-Escolano, Rubén
  • Virseda-Berdices, Ana
  • Berenguer, Juan
  • González-García, Juan
  • Brochado-Kith, Oscar
  • Fernandez-Rodriguez, Amanda
  • Díez, Cristina
  • Hontañón, Víctor
  • Marathon Study Group
  • Resino, Salvador
  • Jimenez-Sousa, Maria Angeles
Background: Understanding the predictors of metabolic disorders in persons with HIV/HCV coinfection post-HCV therapy is crucial for improving patient outcomes. Since immune checkpoint proteins are usually upregulated in these persons with HIV/HCV coinfection, we aimed to evaluate the association between plasma immune checkpoint proteins at baseline (before HCV therapy) and metabolic disturbances during the follow-up (about 5 years after successful HCV treatment) in persons with HIV/HCV coinfection. Methods: We performed a retrospective study on 80 persons with HIV/HCV coinfection with advanced fibrosis or cirrhosis who cleared HCV infection after successful HCV therapy and were followed for about 5 years after completion of HCV treatment. Plasma samples were collected at baseline. Immune checkpoint proteins were analyzed using a Luminex 200™ analyzer. Outcomes were the development of a metabolic event (type 2 diabetes mellitus and/or dyslipidemia) and the change in Triglycerides and glucose (TyG) index. Results: During follow-up, 21 (26%) patients developed metabolic events (type 2 diabetes mellitus/dyslipidemia), and 29 (46.0%) patients had an increase in TyG during the follow-up. Low baseline values of BTLA and LAG-3, two immune checkpoint proteins, were associated with the development of metabolic events (aAMR = 0.69 and aAMR = 0.71, respectively) and with increases in TyG values (aAMR = 0.72 and aAMR = 0.70, respectively). In addition, other immune checkpoint proteins were also inversely associated with increases in TyG. Conclusion: We discovered that low plasma levels of BTLA and LAG-3 before HCV therapy significantly correlate with an increased risk of developing metabolic disorders after treatment.
Repisalud
Publicación Artículo científico (JournalArticle)

Immune checkpoint proteins are associated with persistently high liver stiffness after successful HCV treatment in people with HIV: a retrospective study

  • Martín-Escolano, Rubén
  • Virseda-Berdices, Ana
  • Berenguer, Juan
  • Resino, Salvador
  • González-García, Juan
  • Brochado-Kith, Oscar
  • Fernandez-Rodriguez, Amanda
  • Díez, Cristina
  • Hontañón, Víctor
  • Resino, Salvador
  • Jimenez-Sousa, Maria Angeles
Various immune checkpoint proteins have been linked to cirrhosis. This study aimed to explore the association between plasma levels of these proteins measured one year after successful HCV treatment and persistently liver stiffness (defined as liver stiffness measurement (LSM) ≥ 12.5 kPa) five years after HCV treatment in people with HIV (PWH). We conducted a retrospective study involving 39 patients with HIV/HCV-coinfection who had advanced fibrosis or cirrhosis and achieved sustained virologic response (SVR). Plasma samples were obtained one year after treatment, and levels of immune checkpoints along with inflammatory biomarkers were evaluated using a Luminex 200 analyzer. Statistical analyses were performed using Generalized Linear Models (GLMs) with a gamma distribution. Spearman correlation tests were used to analyze the correlation between significant immune checkpoints and inflammatory biomarkers. Although LSM values showed a decreasing trend over the years following successful HCV treatment, this trend was not statistically significant due to substantial variability among PWH. Persistently high liver stiffness was observed in 61.5% of patients five years after HCV treatment. Elevated plasma levels of soluble BTLA, PD-1, and TIM-3 one year after HCV treatment were associated with persistently liver stiffness five years later. These significant immune checkpoints were found to correlate with inflammatory biomarkers in PWH with persistently high liver stiffness. In conclusion, increased plasma concentrations of immune checkpoints one year after successful HCV therapy were linked to persistently high liver stiffness five years later, particularly BTLA, PD-1, and TIM-3. This suggests a potential immunopathological mechanism in ongoing liver stiffness post-HCV eradication.
Repisalud
Publicación Artículo científico (JournalArticle)

Plasma metabolomic profile is near-normal in people with HIV on long-term suppressive antiretroviral therapy

  • Virseda-Berdices, Ana
  • Martín-Escolano, Rubén
  • Berenguer, Juan
  • González-García, Juan
  • Brochado-Kith, Oscar
  • Rojo, David
  • Fernandez-Rodriguez, Amanda
  • Pérez-Latorre, Leire
  • Hontañón, Víctor
  • Barbas, Coral
  • Resino, Salvador
  • Jimenez-Sousa, Maria Angeles
Background: Combination antiretroviral therapy (ART) has transformed human immunodeficiency virus (HIV) infection in people with HIV (PWH). However, a chronic state of immune activation and inflammation is maintained despite achieving HIV suppression and satisfactory immunological recovery. We aimed to determine whether the plasma metabolomic profile of PWH on long-term suppressive ART and immunologically recovered approximates the normality by comparison with healthy controls with similar age and gender. Methods: We carried out a cross-sectional study in 17 PWH on long-term ART (HIV-RNA <50 copies/mL, CD4+ ≥500 cells/mm3, and CD4+/CD8+ ≥1) and 19 healthy controls with similar age and gender. Metabolomics analysis was performed by gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-mass spectrometry (LC-MS). The statistical association analysis was performed by principal component analysis (PCA), partial least squares discriminant analysis (PLS-DA), and Generalized Linear Models (GLM) with a gamma distribution (log-link). Significance levels (p-value) were corrected for multiple testing (q-value). Results: PCA and PLS-DA analyses found no relevant differences between groups. Adjusted GLM showed 14 significant features (q-value<0.20), of which only three could be identified: lysophosphatidylcholine (LysoPC) (22:6) (q-value=0.148), lysophosphatidylethanolamine (LysoPE) (22:6) (q-value=0.050) and hydroperoxy-octadecatrienoic acid (HpOTrE)/dihydroperoxy-octadecatrienoic acid (DiHOTrE)/epoxy-octadecadienoic acid (EpODE) (q-value=0.136). These significant identified metabolites were directly correlated to plasma inflammatory biomarkers in PWH and negatively correlated in healthy controls. Conclusion: PWH on long-term ART have a metabolomic profile that is almost normal compared to healthy controls. Nevertheless, residual metabolic alterations linked to inflammatory biomarkers persist, which could favor the development of age-related comorbidities among this population.
Repisalud
Publicación Artículo científico (JournalArticle)

Differential Diagnosis of Fungal Pneumonias vs. Tuberculosis in AIDS Patients by Using Two New Molecular Methods.

  • Bernal-Martinez, Leticia
  • Herrera-Leon, Laura
  • Valero, Clara
  • de la Cruz, Paula
  • Ghimpu, Larisa
  • Mesa-Arango, Ana Cecilia
  • Santoni, Gabriela
  • Goterris, Lidia
  • Millán, Rosario
  • Buitrago, Maria Jose
Opportunistic fungal pneumonias (OFP) are the main cause of death in AIDS patients worldwide. Diagnosis of these infections is often late as tuberculosis (TB) is frequently the first suspicion. In addition, diagnostic tools have limitations and are unavailable in disadvantaged regions. To perform the differential diagnosis of the main fungi causing OFP in AIDS patients (Histoplasma capsulatum, Cryptococcus neoformans/C. gattii and Pneumocystis jirovecii) vs. the Mycobacterium tuberculosis complex (MTBC), two new assays were developed: (i) a multiplex real-time PCR (MRT-PCR) and (ii) a simple and cost-effective method based on real-time PCR and the analysis of melting curves after amplification (MC-PCR). Both of the techniques were optimized and standardized "in vitro", showing a suitable reproducibility (CV ranged between 1.84 and 3.81% and 1.41 and 4.83%, respectively), a 100% specificity and detection limits between 20 and 2 fg of genomic DNA per 20 µL of reaction. A validation study was performed by retrospectively using 42 clinical samples from 37 patients with proven fungal infection or TB, and 33 controls. The overall sensitivity for the MRT-PCR assay and the MC-PCR assay was 88% and 90.4%, respectively. Both techniques were fast, sensitive and reproducible, allowing for the detection of these pathogens and the performance of a differential diagnosis.
Repisalud
Publicación Artículo científico (JournalArticle)

Immune and senescence profiles associated with non-AIDS-defining cancer risk in people with HIV: a case-cohort study.

  • Pita-Martínez, Carlos
  • Jimenez-Sousa, Maria Angeles
  • Martinez-Picado, Javier
  • Rodríguez, Carmen Elena Gómez
  • Fariñas, Carmen
  • Galindo, Pepa
  • Roca-Oporto, Cristina
  • Santos, Jesús
  • Muñoz-García, Paula
  • Rava, Marta
  • Resino, Salvador
  • Martín-Escolano, Rubén
Introduction: People with HIV (PWH) on effective antiretroviral therapy (ART) have an increased risk of developing Non-AIDS Defining Cancers (NADCs) compared to the general population, partly due to chronic inflammation and immune dysregulation. This study aimed to identify plasma biomarkers associated with the risk of developing NADCs in a cohort of PWH on ART. Methods: A case-cohort study was conducted within the Spanish CoRIS cohort, including 316 PWH on ART (71 cases and 245-individuals subcohort). Plasma levels of 24 immune regulation and senescence-associated secretory phenotype (SASP) biomarkers were quantified using Luminex technology. Cox proportional hazards regression models with Borgan II weights were used to assess the association between biomarker levels and the risk of NADC development (hazard ratios), adjusting for confounders. Effect modification by gender was also evaluated. Results: Higher baseline plasma levels of twelve biomarkers were significantly associated with increased NADC risk. The strongest associations were found for PD-L2 (aHR=3.33), PAI-1 (aHR=2.27), and MMP-1 (aHR=2.32). However, a distinct, gender-specific pattern was observed, with significant interactions found for nine biomarkers. Most interactions indicated a higher NADC risk increase in females, with the exception of CD80, TNF-β and IP-10, which indicated a relatively lower risk in females compared to males. Discussion: Plasma biomarkers of immune regulation and SASP are associated with NADC risk in PWH on long-term ART, highlighting the importance of gender-specific pathways in NADC development among PWH. Understanding these distinct profiles may guide future strategies for risk stratification, early detection, and personalized preventive care.
Repisalud
Publicación Artículo científico (JournalArticle)

Plasma biomarkers of immune regulation and senescence are associated with incident skeletal-related events in people with HIV: a case-cohort study.

  • Pita-Martínez, Carlos
  • Rava, Marta
  • Virseda-Berdices, Ana
  • Martinez, Isidoro
  • Moreno, Santiago
  • Gómez Rodríguez, Carmen Elena
  • Armiñanzas, Carlos
  • Mena de Cea, Álvaro
  • Gisbert Pérez, Laura
  • Rodríguez-Rosado, Rafael
  • Jimenez-Sousa, Maria Angeles
  • Resino, Salvador
  • Martín-Escolano, Rubén
Background: persistent immune dysregulation in people with HIV (PWH) on antiretroviral therapy (ART) contributes to an increased risk of skeletal-related events (SREs), serving as a critical paradigm for understanding accelerated aging and age-related diseases. We investigated the association between plasma biomarkers of immune regulation and senescence with incident SRE risk and evaluated potential effect modification by sex. Methods: in a case-cohort study nested within the Spanish CoRIS cohort (65 incident SRE cases; 252 subcohort, including 5 overlapping cases), we quantified 24 baseline biomarkers of immune checkpoints and senescence-associated secretory phenotype factors. We estimated adjusted hazard ratios (aHR) using Borgan II-weighted cause-specific Cox regression models adjusted for clinical confounders (age, region of origin, prior AIDS diagnosis, CD4 + T-cell count, coinfections, and lifestyle factors). Sex-biomarker interactions were assessed as exploratory endpoints. Results: nineteen biomarkers were independently associated with increased SRE risk (p < 0.05 & q < 0.10). Angiogenic factors (VEGF-A; aHR = 1.94; 95% CI, 1.40–2.68), immune checkpoints (PD-L2; aHR = 1.95; 95% CI, 1.09–3.49), and tissue remodeling markers (MMP-1; aHR = 1.91; 95% CI, 1.08–3.39) displayed independent associations, alongside consistent signals for TIM-3, PD-L1, and IL-8. Pairwise correlation analysis demonstrated clustering between checkpoints and inflammatory cytokines. Exploratory interaction analysis indicated that sex modified these associations; signals for seven markers (e.g., IL-1α, VEGF-A) were stronger in females, although the limited number of events warrants caution. Conclusions: circulating biomarkers of immune exhaustion, inflammation, and senescence are independently associated with incident SREs in PWH on long-term ART. Our findings indicate a systemic pro-inflammatory signature and suggest that females exhibit higher sensitivity to inflammatory damage.
Repisalud
Publicación Artículo científico (JournalArticle)

HIV status defines distinct immunological drivers of persistent portal hypertension after HCV cure in people with advanced cirrhosis.

  • Martín-Escolano, Rubén
  • Fernandez-Rodriguez, Amanda
  • Tarancon-Diez, Laura
  • Berenguer, Juan
  • Codina Márquez, Helena
  • Amigot-Sánchez, Rafael
  • González-García, Juan
  • Hontañón, Víctor
  • Pérez-Latorre, Leire
  • Ibañez-Samaniego, Luis
  • Llop-Herrera, Elba
  • Olveira, Antonio
  • Díaz, Laura
  • Martinez, Isidoro
  • Jimenez-Sousa, Maria Angeles
  • Resino, Salvador
Introduction: The immunological drivers of portal hypertension regression after hepatitis C virus (HCV) cure are poorly understood, particularly in the context of human immunodeficiency virus (HIV) coinfection We aimed to identify baseline immune signatures predicting the evolution of the hepatic venous pressure gradient (HVPG) in people with and without HIV (PWH/PWoH). Methods: We prospectively followed 41 individuals with advanced cirrhosis (18 PWoH, 23 PWH) who were cured of HCV with direct-acting antivirals (DAA). Baseline plasma and cellular immune markers were extensively profiled using multiplex assays and flow cytometry. We used mixed-effects modeling to test for associations between these baseline immune features and the change in HVPG over a 48-week follow-up period, with q-values controlling for false discoveries. Results: Two distinct immunological profiles of impaired HVPG regression emerged. In PWoH, impaired regression was linked to a broad proinflammatory profile [TNF-α (AMR = 1.13; q=0.012), IL17A (AMR = 1.28; q=0.012), and IL10 (AMR = 1.2; q=0.028)], a widespread total CD4+ T-cell activation [HLA-DR+ (AMR = 1.44; q<0.001) and CD38+HLA-DR+ (AMR = 1.3; q=0.007)], and robust activation across central memory (CM) and effector memory (EM) subsets. Conversely, in PWH, impaired HVPG regression was associated with sVCAM-1 (AMR = 1.58; q=0.096), and a more focused activation within EM (HLA-DR+, AMR = 1.08; q=0.030) and TemRA (CD38+HLA-DR+, AMR = 1.12; q=0.030) CD4+ T-cells. Discussion: HIV coinfection fundamentally reshapes the immunological landscape of post-cure portal hypertension recovery. The shift from systemic inflammation in PWoH to endothelial dysfunction and T-cell exhaustion in PWH reveals distinct pathological pathways. Understanding these signatures is a crucial step toward developing targeted therapies to promote complete hepatic recovery.
Repisalud
Publicación Artículo científico (JournalArticle)

MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma

  • Ferrer, Irene
  • Quintanal-Villalonga, Alvaro
  • Molina-Pinelo, Sonia
  • Garcia-Heredia, Jose Manuel
  • Perez, Marco
  • Suárez, Rocío
  • Ponce-Aix, Santiago
  • Paz Ares , Luis Gonzaga
  • Carnero, Amancio
BACKGROUND: The high incidence and mortality of lung tumours is a major health problem. Therefore, the identification both of biomarkers predicting efficacy for therapies in use and of novel efficacious therapeutic agents is crucial to increase patient survival. MAP17 (PDZK1IP1) is a small membrane-bound protein whose upregulation is reported as a common feature in tumours from diverse histological origins. Furthermore, MAP17 is correlated with tumour progression. METHODS: We assessed the expression of MAP17 in preclinical models, including cell lines and patient-derived xenografts (PDXs), assessing its correlation with sensitivity to different standard-of-care drugs in lung adenocarcinoma, as well as novel drugs. At the clinical level, we subsequently correlated MAP17 expression in human tumours with patient response to these therapies. RESULTS: We show that MAP17 expression is induced during lung tumourigenesis, particularly in lung adenocarcinomas, and provide in vitro and in vivo evidence that MAP17 levels predict sensitivity to therapies currently under clinical use in adenocarcinoma tumours, including cisplatin, carboplatin and EGFR inhibitors. In addition, we show that MAP17 expression predicts proteasome inhibitor efficacy in this context and that bortezomib, an FDA-approved drug, may be a novel therapeutic approach for MAP17-overexpressing lung adenocarcinomas. CONCLUSIONS: Our results indicate a potential prognostic role for MAP17 in lung tumours, with particular relevance in lung adenocarcinomas, and highlight the predictive pot0065ntial of this membrane-associated protein for platinum-based therapy and EGFR inhibitor efficacy. Furthermore, we propose bortezomib treatment as a novel and efficacious therapy for lung adenocarcinomas exhibiting high MAP17 expression.
Repisalud
Publicación Artículo científico (JournalArticle)

Lipid and immune dysregulation and risk of metabolic disorders after HCV clearance in HIV/HCV-coinfected participants with cACLD: a retrospective study.

  • Virseda-Berdices, Ana
  • Requena, Belen
  • Berenguer, Juan
  • González-García, Juan
  • Gonzalez-Riano, Carolina
  • Díez, Cristina
  • Hontañon, Victor
  • Fernandez-Rodriguez, Amanda
  • Barbas, Coral
  • Resino, Salvador
  • Martín-Escolano, Rubén
  • Jimenez-Sousa, Maria Angeles
Introduction: People with HIV and chronic hepatitis C may develop metabolic complications after sustained virologic response (SVR), possibly due to persistent molecular alterations induced by HCV. This study aimed to identify baseline (pre-treatment) lipid and immune biomarkers associated with post-SVR metabolic events in HIV/HCV-coinfected participants with compensated advanced chronic liver disease (cACLD) receiving long-term suppressive antiretroviral therapy. Methods: We conducted a retrospective study of 56 HIV/HCV-coinfected participants with cACLD. Untargeted lipidomic profiling was performed on baseline plasma samples using a liquid-chromatography-mass spectrometer. The outcome was the development of metabolic events (diabetes mellitus and/or hyperlipidemia) during follow-up, up to seven years post-HCV treatment. Statistical analyses included orthogonal partial least squares discriminant analysis (OPLS-DA), Cox regressions models, and Spearman correlations with inflammation-related biomarkers and immune checkpoint proteins, with multiple comparison corrections using the false discovery rate. Results: 25% participants developed metabolic events after SVR. OPLS-DA identified 163 lipid species (VIP scores≥1) associated with these events, and adjusted Cox regression confirmed significant associations for 24 of them. Lysophosphatidylcholines (LPCs) were the most prevalent, with higher baseline levels linked to increased metabolic risk. Participants who developed events also had higher levels of plasmalogens LPC (O-LPC), lysophosphatidylethanolamine (LPE), lysophosphatidylinositol (LPI), lysophosphatidic acid (LPA), and phosphosphatidylcholine (PC). Several lipid species correlated positively with the pro-inflammatory cytokine IL-18, the anti-inflammatory suppressor IL-1RA, and the immune checkpoint proteins IDO and S100A8/A9. Discussion: Pre-treatment lipid and immune dysregulation was associated with post-SVR metabolic events in HIV/HCV-coinfected participants, suggesting that HCV may leave a lasting metabolic imprint that contributes to adverse outcomes after viral clearance.
Repisalud
Publicación Artículo científico (JournalArticle)

Long-term effects of HCV eradication on lipid profiles associated with MASLD among people with HIV with advanced fibrosis or cirrhosis.

  • Virseda-Berdices, Ana
  • Requena, Belen
  • Berenguer, Juan
  • Gónzalez-García, Juan
  • Gonzalez-Riano, Carolina
  • Díez, Cristina
  • Hontañón, Victor
  • Muñoz-García, Paula
  • Fernandez-Rodriguez, Amanda
  • Barbas, Coral
  • Resino, Salvador
  • Martín-Escolano, Rubén
  • Jimenez-Sousa, Maria Angeles
  • the Marathon Study Group
Background: Despite successful hepatitis C virus (HCV) clearance, some individuals continue to experience liver disease progression. Metabolic dysfunction-associated steatotic liver disease (MASLD) may play a key role in this ongoing progression. This study aims to characterize the lipidomic profiles associated with MASLD in individuals coinfected with human immunodeficiency virus (HIV) and HCV with advanced fibrosis or cirrhosis after sustained virologic response (SVR). Methods: We conducted cross-sectional studies in fifty-two HIV/HCV-coinfected individuals. Untargeted lipidomics was performed on plasma samples collected at 1 year and 6 years post-SVR using liquid chromatography-mass spectrometry. The primary outcome was MASLD. Statistical analyses included orthogonal partial least squares discriminant analysis (OPLS-DA) and generalized linear models (GLM), with corrections for multiple comparisons. Results: The prevalence of MASLD was 28.9 % one year after SVR, increasing to 44.8 % six years after SVR. OPLS-DA models identified 225 lipids at 1 year and 167 at 6 years, with a VIP score ≥ 1, distinguishing individuals based on MASLD status. Adjusted GLMs confirmed significant associations between MASLD and 116 lipids at 1 year and 49 at 6 years. At 1 year, most significant lipids were glycerophospholipids (GP), with increased phosphatidylcholines (PC) and phosphatidylethanolamines (PE), and decreased lysophosphatidylcholines (LPC) and lysophosphatidylethanolamines (LPE). By 6 years, LPC was the most abundant differential lipid, while triglycerides increased significantly. Conclusions: MASLD was common during follow-up, with changes in lipidomic profiles over time suggesting ongoing metabolic disturbances that may contribute to liver disease progression despite SVR. These findings highlight the need for long-term metabolic and liver health monitoring after HCV eradication in these individuals.
Repisalud
Publicación Artículo científico (JournalArticle)

The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction

  • Quintanal-Villalonga, Alvaro
  • Ojeda-Marquez, Laura
  • Marrugal, Ángela
  • Yagüe, Patricia
  • Ponce-Aix, Santiago
  • Salinas, Ana
  • Carnero, Amancio
  • Ferrer, Irene
  • Molina-Pinelo, Sonia
  • Paz Ares , Luis Gonzaga
The FGFR4-388Arg variant has been related to poor prognosis in several types of cancer, including lung cancer. The mechanism underlying this association has not been addressed in detail in patients with this pathology. Here, we report that this FGFR4 variant induces MAPK and STAT3 activation and causes pro-oncogenic effects in NSCLC in vitro and in vivo. This variant induces the expression of EMT-related genes, such as N-cadherin, vimentin, Snail1 and Twist1. Indeed, the induction of N-cadherin protein expression by this variant is essential for its pro-tumorigenic role. The presence of the FGFR4-388Arg variant correlates with higher N-cadherin expression levels in clinical NSCLC samples and with poorer outcome in patients with FGFR expression. These results support the prognostic role of this FGFR variant in lung cancer and show that these effects may be mediated by the induction of N-cadherin expression and an EMT phenotype.
Repisalud
Publicación Artículo científico (JournalArticle)

Low sensitivity of conventional fungal agars in fungemia by Rhodotorula mucilaginosa: description of two cases

  • Garcia-Gutiérrez, Carmen Alicia
  • Cuétara-García, María Soledad
  • Moragues, María Dolores
  • Ligero, Jorge
  • Quevedo, Sara Maria
  • Buitrago, Maria Jose
Although most bloodstream yeast infections are caused by Candida spp., infections by rare or less common species have increased in recent years. Diagnosis of infections caused by these species is difficult due to the lack of specific symptoms and adequate diagnostic tools. We describe two cases of fungemia by Rhodotorula mucilaginosa within a few months of each other, in a secondary Spanish hospital. In both cases, diagnosis was challenging. Blood subcultures in conventional fungal media were persistently negatives and the use of non-conventional fungal media was essential for isolating the yeasts and achieving a correct diagnosis. 1-3 beta-D-glucan detection and a panfungal PCR assay were helpful techniques to confirm the diagnosis CONCLUSION: It is highly important to establish an early diagnosis for fungemia. The process is challenging because often non-specific symptoms are presents. When yeasts grow in blood cultures other genera than Candida spp. could be the cause of infection. Patient risk factors should be assessed to incorporate alternative culture media and the available rapid diagnostic test, in order to provide an early recognition of the pathogen.
Repisalud
Publicación Artículo científico (JournalArticle)

IRF5-TNOP3 polymorphisms are associated with elite control of HIV infection: A retrospective study.

  • Sepulveda-Crespo, Daniel
  • Jimenez-Sousa, Maria Angeles
  • Fernandez-Rodriguez, Amanda
  • Muñoz-Fernández, María A
  • Jiménez, José Luis
  • Moreno, Santiago
  • Garcia, Felipe
  • Martinez, Isidoro
  • Benito, José M
  • Rallón, Norma
  • Resino, Salvador
IRF5-TNPO3 polymorphisms have previously been related to immune response, and TNPO3 plays a role in human immunodeficiency virus (HIV)-1 infection after nuclear import. Therefore, we analyzed the genetic association between IRF5-TNPO3 polymorphisms and the HIV elite control in long-term nonprogressors (LTNPs). We performed a retrospective cohort study on 183 LTNPs, who were antiretroviral therapy-naïve with CD4  ≥ 500 cells/mm , viral load ≤10 000 copies/mL, and asymptomatic over 10 years after HIV seroconversion. The primary outcome variable was HIV elite control (undetectable viral load in at least 90% of the measurements for at least 1 year). Seven IRF5-TNPO3 polymorphisms were genotyped using Agena Bioscience's MassARRAY platform. We found a significant association between specific IRF5-TNPO3 genotypes and HIV elite control: rs2004640 TT (aOR = 2.05; p = 0.041), rs10954213 AA (aOR = 1.95; p = 0.035), rs2280714 TT (aOR = 2.02; p = 0.031), and rs10279821 CC (aOR = 2.12; p = 0.017). We also found a significant association between IRF5-TNPO3 haplotype TATC composed of the favorable significant polymorphisms (rs2004640, rs10954213, rs2280714, and rs10279821) and the HIV elite control (aOR = 1.59; p = 0.048). IRF5-TNPO3 rs2004640, rs10954213, rs2280714, and rs10279821 polymorphisms were related to HIV elite control in LTNPs. Our data provide new knowledge about the impact of IRF5-TNPO3 polymorphisms on HIV pathogenesis to understand the phenomenon of natural HIV control.
Repisalud
Publicación Artículo científico (JournalArticle)

Diverse Large HIV-1 Non-subtype B Clusters Are Spreading Among Men Who Have Sex With Men in Spain

  • Delgado, Elena
  • Benito, Sonia
  • Montero, Vanessa
  • Cuevas, Maria Teresa
  • Fernandez-Garcia, Aurora
  • Sanchez-Martinez, Monica
  • Garcia-Bodas, Elena
  • Díez-Fuertes, Francisco
  • Gil, Horacio
  • Cañada-Garcia, Javier Enrique
  • Carrera, Cristina
  • Martinez-Lopez, Joaquin
  • Sintes Puertas, Marcos
  • Perez-Alvarez, Lucia
  • Thomson, Michael M
In Western Europe, the HIV-1 epidemic among men who have sex with men (MSM) is dominated by subtype B. However, recently, other genetic forms have been reported to circulate in this population, as evidenced by their grouping in clusters predominantly comprising European individuals. Here we describe four large HIV-1 non-subtype B clusters spreading among MSM in Spain. Samples were collected in 9 regions. A pol fragment was amplified from plasma RNA or blood-extracted DNA. Phylogenetic analyses were performed via maximum likelihood, including database sequences of the same genetic forms as the identified clusters. Times and locations of the most recent common ancestors (MRCA) of clusters were estimated with a Bayesian method. Five large non-subtype B clusters associated with MSM were identified. The largest one, of F1 subtype, was reported previously. The other four were of CRF02_AG (CRF02_1; n = 115) and subtypes A1 (A1_1; n = 66), F1 (F1_3; n = 36), and C (C_7; n = 17). Most individuals belonging to them had been diagnosed of HIV-1 infection in the last 10 years. Each cluster comprised viruses from 3 to 8 Spanish regions and also comprised or was related to viruses from other countries: CRF02_1 comprised a Japanese subcluster and viruses from 8 other countries from Western Europe, Asia, and South America; A1_1 comprised viruses from Portugal, United Kingom, and United States, and was related to the A1 strain circulating in Greece, Albania and Cyprus; F1_3 was related to viruses from Romania; and C_7 comprised viruses from Portugal and was related to a virus from Mozambique. A subcluster within CRF02_1 was associated with heterosexual transmission. Near full-length genomes of each cluster were of uniform genetic form. Times of MRCAs of CRF02_1, A1_1, F1_3, and C_7 were estimated around 1986, 1989, 2013, and 1983, respectively. MRCA locations for CRF02_1 and A1_1 were uncertain (however initial expansions in Spain in Madrid and Vigo, respectively, were estimated) and were most probable in Bilbao, Spain, for F1_3 and Portugal for C_7. These results show that the HIV-1 epidemic among MSM in Spain is becoming increasingly diverse through the expansion of diverse non-subtype B clusters, comprising or related to viruses circulating in other countries.
Repisalud
Publicación Artículo científico (JournalArticle)

Altered blood microbiome in patients with HCV-related Child-Pugh class B cirrhosis

  • Brochado-Kith, Oscar
  • Rava, Marta
  • Berenguer, Juan
  • González-García, Juan
  • Rojo, David
  • Díez, Cristina
  • Hontañón, Víctor
  • Virseda-Berdices, Ana
  • Ibañez-Samaniego, Luis
  • Llop-Herrera, Elba
  • Olveira, Antonio
  • Pérez-Latorre, Leire
  • Barbas, Coral
  • Fernandez-Rodriguez, Amanda
  • Resino, Salvador
  • Jimenez-Sousa, Maria Angeles
  • ESCORIAL Study Group
Background: Altered bacterial translocation is associated with changes in hepatic function and the progression from compensated to decompensated cirrhosis. Child-Turcotte-Pugh (CTP) score is an essential indicator of liver severity. Thus, we aimed to study differences in the blood microbiome together with metabolome profile between HCV-infected patients with CTP class B (CTP-B, significant functional compromise) and patients with CTP class A (CTP-A, well-compensated cirrhosis). Methods: We conducted a cross-sectional study in patients with advanced HCV-related cirrhosis (n = 88) stratified by CTP-B and CTP-A. Bacterial 16S rRNA sequencing was sequenced by MiSeq Illumina technology and non-targeted metabolomics was performed by GC-MS and LC-MS ESI+ and ESI- to complement the analysis. Results: Patients with CTP-B had lower levels of richness (Chao1), and alpha diversity (Shannon and Simpson indexes) at phylum level than patients with CTP-A. Likewise, we observed significant differences in beta diversity between groups at phylum, class, and order levels, showing lower diversity in patients with CTP-B. Higher relative abundance of Proteobacteria (p = 0.012), Alphaproteobacteria (p = 0.005), Sphingomonadales (p = 0.012) and Sphingomonadaceae (p = 0.016) were significantly associated with CTP-B. The phylum Proteobacteria was positively correlated with ethanolamine and oleic acid (p = 0.005 and p = 0.004, respectively) and negatively with p-cresol (p = 0.006). In addition, the order Sphingomonadales and the family Sphingomonadaceae was also negatively correlated with p-cresol (p = 0.001 and p = 0.001). Conclusions: Blood microbial diversity was significantly decreased in patients with CTP-B, who presented an enrichment of Proteobacteria, Alphaproteobacteria, Sphingomonadales and Sphingomonadaceae compared to patients with CTP-A.
Repisalud
Publicación Artículo científico (JournalArticle)

Elevated Zonulin-1 is Associated With an Increased Risk of Non-AIDS-Defining Cancers in People With HIV With Suboptimal Immune Recovery: A Case-Cohort Study.

  • Pita-Martínez, Carlos
  • Muñoz-García, Paula
  • Martinez, Isidoro
  • Rava, Marta
  • Bautista Hernández, Azucena
  • Pérez-Somarriba, Juncal
  • Campins, Antoni
  • Novella Mena, María
  • Vera, Francisco
  • Montero-Alonso, Marta
  • Jimenez-Sousa, Maria Angeles
  • Resino, Salvador
  • Martín-Escolano, Rubén
  • CoRIS cohort
People with HIV (PWH) on antiretroviral therapy (ART) exhibit a heightened risk of non-AIDS-defining cancers (NADCs), linked to chronic inflammation driven by microbial translocation. We investigated whether plasma biomarkers of gut barrier dysfunction are associated with NADC risk, hypothesizing this association is modified by immune status. We conducted a case-cohort study nested within the Spanish CoRIS cohort. Plasma levels of zonulin-1, lipopolysaccharide, LPS-binding protein, and flagellin were measured in 71 incident NADC cases and a 261-individuals subcohort. Multivariable Cox proportional hazards models were used to estimate NADC risk, testing for effect modification by baseline CD4 + T-cell count. Zonulin-1 was not independently associated with NADC risk. However, a strong statistical interaction with baseline CD4 + T-cell count was detected (p = 0.001). Among individuals with suboptimal immune recovery (defined as CD4 + T-cell count < 500 cells/mm³), higher zonulin-1 levels were associated with a nearly threefold increased NADC risk (aHR = 2.94 (1.28-6.76)). Conversely, no association was observed in those with robust immune reconstitution (≥ 500 cells/mm³; aHR= 0.84 (0.41-1.72)). Other biomarkers showed no association. This supports a "two-hit" model of carcinogenesis where a compromised gut barrier and impaired immune competence are associated with an increased risk of cancer. Zonulin-1 is a key biomarker for identifying this high-risk phenotype, suggesting targeted cancer prevention strategies restoring gut integrity.
Repisalud
Publicación Artículo científico (JournalArticle)

The Roles of Imprinted SLC22A18 and SLC22A18AS Gene Overexpression Caused by Promoter CpG Island Hypomethylation as Diagnostic and Prognostic Biomarkers for Non-Small Cell Lung Cancer Patients.

  • Noguera-Uclés, José Francisco
  • Boyero, Laura
  • Salinas, Ana
  • Cordero Varela, Juan Antonio
  • Benedetti, Johana Cristina
  • Bernabé-Caro, Reyes
  • Sánchez-Gastaldo, Amparo
  • Alonso, Miriam
  • Molina-Pinelo, Sonia
  • Paz Ares, Luis Gonzaga
Genomic imprinting is a process that involves one gene copy turned-off in a parent-of-origin-dependent manner. The regulation of imprinted genes is broadly dependent on promoter methylation marks, which are frequently associated with both oncogenes and tumor suppressors. The purpose of this study was to assess the DNA methylation patterns of the imprinted solute-carrier family 22 member 18 (SLC22A18) and SLC22A18 antisense (SLC22A18AS) genes in non-small cell lung cancer (NSCLC) patients to study their relevance to the disease. We found that both genes were hypomethylated in adenocarcinoma and squamous cell carcinoma patients. Due to this imprinting loss, SLC22A18 and SLC22A18AS were found to be overexpressed in NSCLC tissues, which is significantly more evident in lung adenocarcinoma patients. These results were validated through analyses of public databases of NSCLC patients. The reversed gene profile of both genes was achieved in vitro by treatment with ademetionine. We then showed that high SLC22A18 and SLC22A18AS expression levels were significantly associated with worsening disease progression. In addition, low levels of SLC22A18AS were also correlated with better overall survival for lung adenocarcinoma patients. We found that SLC22A18 and SLC22A18AS knockdown inhibits cell proliferation in vitro. All these results suggest that both genes may be useful as diagnostic and prognostic biomarkers in NSCLC, revealing novel therapeutic opportunities.
Repisalud
Publicación Artículo científico (JournalArticle)

Genetic Diversity and Drug Resistance Mutations in Reverse Transcriptase and Protease Genes of HIV-1 Isolates from Southwestern Siberia.

  • Rudometova, Nadezhda B
  • Shcherbakova, Nadezhda S
  • Shcherbakov, Dmitry N
  • Mishenova, Elena V
  • Delgado, Elena
  • Ilyichev, Alexander A
  • Karpenko, Larisa I
  • Thomson, Michael M
The analysis of a gene fragment encoding protease and part of reverse transcriptase was carried out for 55 sera collected in 2016 and 2018 from HIV-1-infected patients diagnosed in 2014-2018 living in the south of Western Siberia, Russia: Altai Territory ( = 11), Republic of Altai ( = 15), Kemerovo region ( = 18), and Novosibirsk region ( = 11). CRF63_02A was the dominant genetic form (>70%) in the Altai Territory and Kemerovo and Novosibirsk regions, with subsubtype A6 comprising <30% of samples. In the Altai Republic, subsubtype A6 was predominant (53%), with 33% of viruses belonging to CRF63_02A. Four CRF63_02A/A6 unique recombinant forms were identified in the Altai Territory, Kemerovo Region, and the Altai Republic. A majority (11 of 15) of CRF63_02A viruses from Kemerovo were grouped in a cluster. Antiretroviral (ARV) drug resistance mutations were found in 6 (14%) of 43 drug-naive patients. This study provides new insights in HIV-1 molecular epidemiology and prevalence of transmitted ARV drug resistance mutations in Southwestern Siberia.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Mutant PRPF8 Causes Widespread Splicing Changes in Spliceosome Components in Retinitis Pigmentosa Patient iPSC-Derived RPE Cells

  • Arzalluz-Luque, Ángeles
  • Cabrera, Jose Luis
  • Skottman, Heli
  • Benguria, Alberto
  • Bolinches-Amorós, Arantxa
  • Cuenca, Nicolás
  • Lupo, Vincenzo
  • Dopazo, Ana
  • Delás, Bárbara
  • Carballo, Miguel
  • Pascual, Beatriz
  • Hernán, Imma
  • Erceg, Slaven
  • Lukovic, Dunja
  • Tarazona, Sonia|||0000-0001-5346-1407
[EN] Retinitis pigmentosa (RP) is a rare, progressive disease that affects photoreceptors and retinal pigment epithelial (RPE) cells with blindness as a final outcome. Despite high medical and social impact, there is currently no therapeutic options to slow down the progression of or cure the disease. The development of effective therapies was largely hindered by high genetic heterogeneity, inaccessible disease tissue, and unfaithful model organisms. The fact that components of ubiquitously expressed splicing factors lead to the retina-specific disease is an additional intriguing question. Herein, we sought to correlate the retinal cell-type-specific disease phenotype with the splicing profile shown by a patient with autosomal recessive RP, caused by a mutation in pre-mRNA splicing factor 8 (PRPF8). In order to get insight into the role of PRPF8 in homeostasis and disease, we capitalize on the ability to generate patient-specific RPE cells and reveal differentially expressed genes unique to RPE cells. We found that spliceosomal complex and ribosomal functions are crucial in determining cell-type specificity through differential expression and alternative splicing (AS) and that PRPF8 mutation causes global changes in splice site selection and exon inclusion that particularly affect genes involved in these cellular functions. This finding corroborates the hypothesis that retinal tissue identity is conferred by a specific splicing program and identifies retinal AS events as a framework toward the design of novel therapeutic opportunities., This work was supported by Institute of Health Carlos III/ERDF (European Regional Development Fund), Spain [PI16/00409 (DL), PI20/01119 (DL), CP18/00033 (DL), PI15/00227 (MC), CPII16/00037 (SE), and PI18-00286 (SE)], Platform for Proteomics, Genotyping and Cell Lines; PRB3 of ISCIII (PT17/0019/0024); National Science Foundation GACR 18-04393S and the project "Centre of Reconstructive Neuroscience", registration number CZ.02.1.01/0.0./0.0/15_003/0000419PI15/00227; Spanish Ministry of Economy and Competitiveness grant BES-2016-076994 (AA-L); and Academy of Finland (HS).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

External validation of models to predict hepatocellular carcinoma in Hepatitis C Virus cured F3-F4 patients

  • Carvalho-Gomes, Ângela
  • Valcheva, Tsveta Vladi
  • Sahuco, Ivan
  • Vidal, Enrique
  • Martínez-Arenas, Laura
  • Vinaixa, Carmen
  • Aguilera, Victoria
  • García García, Sonia
  • Berenguer, Marina
[EN] Background & AimsSeveral hepatocellular carcinoma (HCC) risk-models have been developed to individualise patient surveillance following sustained viral response (SVR) in Hepatitis C Virus patients. Validation of these models in different cohorts is an important step to incorporate a more personalised risk assessment in clinical practice. We aimed at applying these models to stratify the risk in our patients and potentially determine cost-saving associated with individualised HCC risk-stratification screening strategy. MethodsPatients with baseline F3-4 fibrosis treated with new oral direct-acting antivirals who had reached a SVR were regularly followed as part of the HCC surveillance strategy. Six models were applied: Pons, aMAP, Ioannou, HCC risk, Alonso and Semmler. Validation of the models was performed based on sensitivity and the proportion of patients labelled as "high risk". ResultsAfter excluding 557 with less than 3 fibrosis, 12 without SVR, 18 with a follow up (FU) <1 year, 17 transplant recipients, 16 lost to FU and 31 with HCC at time of antiviral therapy, our cohort consisted of 349 F3-4 SVR patients. Twenty-three patients (6.6%) developed HCC after a median FU of 5.12 years. The sensitivity of the different models varied between 0.17 (Semmler7noalcohol) and 1 (Alonso A and aMAP). The lowest proportion of high-risk patients corresponded to the Semmler-noalcohol model (5%). Sixty-three and 90% of the Alonso A and aMAP patients, respectively were labelled as high risk. The most reliable HCC risk-model applied to our cohort to predict HCC development is the Alonso model (based on fibrosis stage assessed by liver stiffness measurements or Fibrosis-4 index (FIB-4) at baseline and after 1 year, and albumin levels at 1 year) with a-100% sensitivity in detecting HCC among those at high risk and 63% labelled as high risk. The application of the model would have saved the cost of 1290 ultrasound no longer being performed in the 37% low-risk group. ConclusionIn our cohort, the Alonso A model allows the most reliable reduction in HCC screening resulting in safely stopping life-long monitoring in about a third of F3-F4 patients achieving SVR with DAAs.; image, Instituto de Salud Carlos III, Grant/Award Numbers: FI20/00033, INT20/00061, PI19/01360; Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas; Gilead Research Scholars, Grant/Award Number: GLD18-192
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Search for Spatial Correlations of Neutrinos with Ultra-high-energy Cosmic Rays

  • Albert, A.
  • Alves, S.
  • Andre, M.
  • Anghinolfi, M.
  • Aubert,, J.J.
  • Aublin, J.
  • Baret, B.
  • Basa, S.
  • Belhorma, B.
  • Bendahman, M.
  • Bertin, V.
  • Biagi, S.
  • M. Bissinger
  • Martínez Mora, Juan Antonio
  • Poirè, Chiara
  • Ardid, Miguel|||0000-0002-3199-594X
  • Ardid, S.|||0000-0003-4821-6655
[EN] For several decades, the origin of ultra-high-energy cosmic rays (UHECRs) has been an unsolved question of high- energy astrophysics. One approach for solving this puzzle is to correlate UHECRs with high-energy neutrinos, since neutrinos are a direct probe of hadronic interactions of cosmic rays and are not de¿ected by magnetic ¿elds. In this paper, we present three different approaches for correlating the arrival directions of neutrinos with the arrival directions of UHECRs. The neutrino data are provided by the IceCube Neutrino Observatory and ANTARES, while the UHECR data with energies above ~50 EeV are provided by the Pierre Auger Observatory and the Telescope Array. All experiments provide increased statistics and improved reconstructions with respect to our previous results reported in 2015. The ¿rst analysis uses a high-statistics neutrino sample optimized for point- source searches to search for excesses of neutrino clustering in the vicinity of UHECR directions. The second analysis searches for an excess of UHECRs in the direction of the highest-energy neutrinos. The third analysis searches for an excess of pairs of UHECRs and highest-energy neutrinos on different angular scales. None of the analyses have found a signi¿cant excess, and previously reported over¿uctuations are reduced in signi¿cance. Based on these results, we further constrain the neutrino ¿ux spatially correlated with UHECRs., The authors of the ANTARES collaboration acknowledge the financial support of the funding agencies: Centre National de la Recherche Scientifique (CNRS), Commissariat a l'energie atomique et aux energies alternatives (CEA), Commission Europeenne (FEDER fund and Marie Curie Program), Institut Universitaire de France (IUF), LabEx UnivEarthS (ANR-10-LABX-0023 and ANR-18-IDEX-0001), Region Ile-de-France (DIM-ACAV), Region Alsace (contrat CPER), Region Provence-Alpes-Cote d'Azur, Departement du Var and Ville de La Seyne-sur-Mer, France; Bundesministerium fur Bildung und Forschung (BMBF), Germany; Istituto Nazionale di Fisica Nucleare (INFN), Italy; Nederlandse organisatie voor Wetenschappelijk Onderzoek (NWO), the Netherlands; Council of the President of the Russian Federation for young scientists and leading scientific schools supporting grants, Russia; Executive Unit for Financing Higher Education, Research, Development and Innovation (UEFISCDI), Romania; Ministerio de Ciencia, Innovacion, Investigacion y Universidades (MCIU): Programa Estatal de Generacion de Conocimiento (refs. PGC2018-096663-B-C41, -A-C42, -B-C43, -B-C44) (MCIU/FEDER), Generalitat Valenciana: Prometeo (PROMETEO/2020/019), Grisolia (refs. GRISOLIA/2018/119,/2021/192) and GenT (refs. CIDEGENT/2018/034,/2019/043,/2020/049,/2021/023) programs, Junta de Andalucia (ref. A-FQM-053-UGR18), La Caixa Foundation (ref. LCF/BQ/IN17/11620019), EU: MSC program (ref. 101025085), Spain; Ministry of Higher Education, Scientific Research and Innovation, Morocco, and the Arab Fund for Economic and Social Development, Kuwait. We also acknowledge the technical support of Ifremer, AIM and Foselev Marine for the sea operation and the CC-IN2P3 for the computing facilities. The ANTARES collaboration acknowledges the significant contributions to this manuscript from Julien Aublin.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Cytomegalovirus Reactivation Is Associated With Lower Rates of Hepatocellular Carcinoma Recurrence After Liver Transplantation

  • Aguilera, Victoria
  • Romero Moreno, Sarai
  • Conde, Isabel
  • Rubín, Angel
  • Carvalho-Gomes, Angela
  • Romero, Mario
  • Zamora-Olaya, Javier
  • Gómez-Bravo, Miguel Angel
  • Fuentes-Valenzuela, Esteban
  • Dopazo, Cristina
  • Bilbao, Nikita
  • Gonzalez, Antonio
  • Sanchez-Martinez, Ana
  • Pascual, Sonia
  • Rivera-Esteban, Jesus
  • Martínez-Arenas, Laura
[EN] In patients with hepatocellular carcinoma (HCC), undergoing liver transplantation (LT), cytomegalovirus reactivation (CMVr) may modulate the immune system to prevent tumor recurrence. In this multicenter retrospective study (2010-2015) involving 15 institutions, we assessed the effect of early CMVr in tumor recurrence rates among 771-LT HCC patients with tacrolimus-based immunosuppression (88% men, mean age 58 years). CMV prophylaxis was implemented for 19.7% of patients, while the rest were managed with preemptive therapy. The Milan criteria were met by 88% of patients. Microvascular invasion was present in 12.7% of explanted livers. The serum AFP level before transplantation was 5.1 (3-15) ng/mL. After a median follow-up of 7.4 years, 101 patients (13%) experienced HCC recurrence. CMVr occurred in 235 patients (30.5%) at a median of 41.5 days post-LT and 42 patients (5.6%) had CMV disease. Cumulative exposure to tacrolimus within the first 3 months after LT was similar among patients with and without CMVr. In a multivariate Cox regression analysis, factors associated with an increased rate of HCC recurrence included microvascular invasion [HR:2.82, CI95%:1.55-5.14; p 0.0001], donation after circulatory determination of death [HR:4.43,CI95%:1.52-12.9; p 0.006) and diameter of the main nodule at explant [HR:1.04, CI95%:1.02-1.06; p < 0.001]. Meanwhile CMVr [HR:0.46, CI95%:0.23-0.93, p 0.031] and MELD [HR:0.93, CI95%:0.87-0.99; p0.017] exhibited protective effects. In conclusion, early CMVr may protect against HCC recurrence. The underlying immune mechanisms warrant further investigation., The author(s) declare that financial support was received for the research and/or publication of this article. This study was supported by competitive grants from the Instituto de Salud Carlos III (grant numbers: PI13/01770 and PI18/01759), and co-financed by the European Regional Development Fund "A way to achieve Europe." AC-G and MB were also supported by the Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd) (https://www.ciberehd.org/), which is funded by the Instituto de Salud Carlos III (co-financed by the European Regional Development Fund). VA has received a grant from the AEEH (Asociacion Espanola para el Estudio del Higado, Spain): Beca de Intensificacion. AC-G received a postdoctoral Fellowship from CiberEHD and MB was supported by competitive grants from the Instituto de Salud Carlos III (grant numbers PI23/00088 and INT24/00021) and by Generalitat Valenciana (grant numbers AICO/2021/035 and CIPROM/2023/16). Victoria Aguilera received a grant from the AEEH "Beca de intensificacion para investigadores" in 2021. LM-A was supported by the Instituto de Salud Carlos III (grant numbers FI20/00033 and MV22/00053).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Tesis doctoral (DoctoralThesis)

The impact of metabolic dysfunction-associated steatotic liver disease in the liver transplant setting

  • Martínez Arenas, Laura
[ES] La enfermedad hepática esteatósica asociada a la disfunción metabólica (MASLD, por sus siglas en inglés) se ha convertido en la enfermedad hepática crónica más prevalente a nivel mundial. La incidencia creciente de obesidad, diabetes mellitus tipo 2 y síndrome metabólico ha impulsado este aumento, posicionando a la MASLD como una causa significativa de enfermedad hepática avanzada, incluyendo la cirrosis y el carcinoma hepatocelular. A medida que estas condiciones progresan, se espera que la MASLD sea la principal indicación de trasplante de hígado (TH) en el mundo, con importantes implicaciones para la carga sanitaria. Dado que el TH sigue siendo el único tratamiento curativo para la cirrosis descompensada y es un recurso limitado, mejorar la concienciación, el diagnóstico precoz y la prevención de la MASLD y promover una vida longeva del injerto es imprescindible. Esta tesis doctoral examinó el impacto de la MASLD en el contexto del TH en España, abordando su relevancia tanto como indicación de TH como de condición recurrente después del TH, al mismo tiempo que exploró el papel potencial de varios biomarcadores periféricos no invasivos para optimizar la monitorización de la fibrosis del injerto a largo plazo. Los resultados obtenidos en esta tesis doctoral demostraron que la carga de TH por MASLD en España está creciendo, con predicciones que sugieren un aumento del 5,4% al 10,8% para 2028. En comparación con los datos de América del Norte, la trayectoria de crecimiento de TH por MASLD en España mostró una velocidad menos pronunciada, aunque las comorbilidades metabólicas asociadas a la MASLD fueron frecuentes en todas las poblaciones. En el contexto post-TH, los datos histológicos mostraron que la recurrencia de la esteatosis fue común (63,6%), con un 25% con diagnóstico de esteatohepatitis asociada a la disfunción metabólica (MASH, por sus siglas en inglés), pero solo un 4,6% y un 2,3% con fibrosis significativa y avanzada, respectivamente, a 2 años post-TH. Aunque la biopsia hepática sigue siendo el estándar de oro para detectar la fibrosis del injerto, los valores de la medición de la rigidez hepática (LSM, por sus siglas en inglés) por elastografía transitoria controlada por vibración <8kPa después del TH por MASH se asociaron estrechamente con la ausencia de fibrosis significativa y avanzada (valor predictivo negativo=100%). Por el contrario, en aquellos pacientes con valores de LSM >=8kPa, el uso de herramientas no invasivas complementarias para mejorar la detección no invasiva de fibrosis significativa y avanzada estaba justificado (valor predictivo positivo=20%). En este contexto, los biomarcadores periféricos, en particular la adiponectina, la citoqueratina (CK)-18 M30 y la CK-18 M65, podrían ser herramientas no invasivas potencialmente prometedoras para evaluar la estratificación de la fibrosis en receptores trasplantados por MASH, por enfermedad hepática asociada al alcohol y a la disfunción metabólica (MetALD, por sus siglas en inglés) y por enfermedad hepática asociada al alcohol (ALD, por sus siglas en inglés) (área bajo la curva [AUC]=0,786). Además, una firma del microbioma intestinal en sangre basada en los géneros Parabacteroides, Kocuria, Curvibacter y Ruminococcus también podría ser útil para detectar la fibrosis del injerto en receptores trasplantados por MASH, MetALD y ALD (AUC = 0,68), lo que reduciría la necesidad de procedimientos invasivos en la vigilancia post-TH., [EN] Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the most prevalent chronic liver disease worldwide. The increasing incidence of obesity, type 2 diabetes mellitus, and metabolic syndrome has driven this surge, positioning MASLD as a significant cause of advanced liver disease, including cirrhosis and hepatocellular carcinoma. As these conditions progress, MASLD is projected to be the leading indication for liver transplantation (LT) globally, with major implications for healthcare burden. Given that LT remains the only curative treatment for decompensated cirrhosis and is a limited resource, improving awareness, early diagnosis, and prevention of MASLD and promoting a long-term graft survival is essential. This doctoral thesis examined the impact of MASLD within the LT setting in Spain, addressing its relevance both as a LT indication and as a recurrent condition after LT, while exploring the potential role of several peripheral non-invasive biomarkers in optimizing long-term graft fibrosis monitoring. The results obtained in this doctoral thesis demonstrated that the burden of MASLD-related LT in Spain is growing, with predictions suggesting a rise to 5.4%-10.8% by 2028. Compared to North American data, the growth trajectory of MASLD-related LT in Spain showed a less pronounced speed, although MASLD-associated metabolic comorbidities were frequent in all populations. In the post-LT setting, biopsy data showed that steatosis recurrence was common (63.6%), with 25% having a metabolic dysfunction-associated steatohepatitis (MASH) diagnosis but only 4.6% and 2.3% having significant and advanced fibrosis, respectively, at 2 years post-LT. Although liver biopsy remains the gold standard for detecting graft fibrosis, values of liver stiffness measurement (LSM) by vibration-controlled transient elastography <8kPa after LT for MASH strongly correlated with the absence of significant and advanced fibrosis (negative predictive value=100%). In contrast, in those patients with LSM values >=8kPa, complementary non-invasive tools to improve non-invasive detection of significant and advanced fibrosis were warranted (positive predictive value=20%). In this context, peripheral biomarkers, particularly adiponectin, cytokeratin (CK)-18 M30 and CK-18 M65, may be potentially promising non-invasive tools for assessing fibrosis stratification in LT recipients transplanted for MASH, metabolic dysfunction and alcohol-associated liver disease (MetALD) and alcohol-associated liver disease (ALD) (area under the curve [AUC]= 0.786). Additionally, a gut microbiome signature in blood based on the genera Parabacteroides, Kocuria, Curvibacter and Ruminococcus may be also useful to detect graft fibrosis in recipients transplanted for MASH, MetALD and ALD (AUC=0.68), reducing the need for invasive procedures in post-LT surveillance., [CA] La malaltia hepàtica esteatósica associada a la disfunció metabòlica (MASLD, per les seues sigles en anglés) s'ha convertit en la malaltia hepàtica crònica més prevalent a nivell mundial. La incidència creixent d'obesitat, diabetis mellitus tipus 2 i síndrome metabòlica ha impulsat este augment, posicionant a la MASLD com una causa significativa de malaltia hepàtica avançada, incloent-hi la cirrosi i el carcinoma hepatocel·lular. A mesura que estes condicions progressen, s'espera que la MASLD siga la principal indicació de trasplantament hepàtic (TH) en el món, amb importants implicacions per a la càrrega sanitària. Atés que el TH continua sent l'únic tractament curatiu per a la cirrosi descompensada i és un recurs limitat, millorar la conscienciació, el diagnòstic precoç i la prevenció de la MASLD i promoure una vida longeva de l'empelt és imprescindible. Esta tesi doctoral va examinar l'impacte de la MASLD en el context del TH a Espanya, abordant la seua rellevància tant com indicació de TH com a condició recurrent després del TH, al mateix temps que va explorar el paper potencial de diversos biomarcadores perifèrics no invasius per a optimitzar el monitoratge de la fibrosi de l'empelt a llarg termini. Els resultats obtinguts en esta tesi doctoral van demostrar que la càrrega de TH per MASLD a Espanya està creixent, amb prediccions que suggerixen un augment del 5,4% al 10,8% per a 2028. En comparació amb les dades d'Amèrica del Nord, la trajectòria de creixement de TH per MASLD a Espanya va mostrar una velocitat menys pronunciada, encara que les comorbiditats metabòliques associades a la MASLD van ser freqüents en totes les poblacions. En el context post-TH, les dades histològiques van mostrar que la recurrència de la esteatosis va ser comuna (63,6%), amb un 25% amb diagnòstic de esteatohepatitis associada a la disfunció metabòlica (MASH, per les seues sigles en anglés), però només un 4,6% i un 2,3% amb fibrosi significativa i avançada, respectivamente, a 2 anys post-TH. Encara que la biòpsia hepàtica continua sent l'estàndard d'or per a detectar la fibrosi de l'empelt, els valors de mesurament de la rigidesa hepàtica (LSM, per les seues sigles en anglés) per elastografia transitòria controlada per vibració <8kPa després del TH per MASH es van associar estretament amb l'absència de fibrosi significativa i avançada (valor predictiu negatiu=100%). Per contra, en aquells pacients amb valors de LSM >=8kPa, l'ús de ferramentes no invasives complementàries per a millorar la detecció no invasiva de fibrosi significativa i avançada estava justificat (valor predictiu positiu=20%). En este context, els biomarcadores perifèrics, en particular la adiponectina, la citoqueratina (CK)-18 M30 i la CK-18 M65, podrien ser ferramentes no invasives potencialment prometedores per a avaluar l'estratificació de la fibrosi en receptors trasplantats per MASH, per malaltia hepàtica associada a l'alcohol i a la disfunció metabòlica (MetALD, per les seues sigles en anglés) i per malaltia hepàtica associada a l'alcohol (ALD, per les seues sigles en anglés) (àrea sota la corba [AUC]=0,786). A més, una firma del microbioma intestinal en sang basada en els gèneres Parabacteroides, Kocuria, Curvibacter i Ruminococcus també podria ser útil per a detectar la fibrosi de l'empelt en receptors trasplantats per MASH, MetALD i ALD (AUC = 0,68), la qual cosa reduiria la necessitat de procediments invasius en la vigilància post-TH., This study was funded by the Instituto de Salud Carlos III and co-funded by the European Union (grant PI19/01360), by the Generalitat Valenciana (grant AICO/2021/035), and by the CIBEREHD (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – European Regional Development Fund.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

FibroScan compared to liver biopsy for accurately staging recurrent hepatic steatosis and fibrosis after transplantation for MASH

  • Martínez-Arenas, Laura
  • Vinaixa, Carmen
  • Conde, Isabel
  • Lorente, Sara
  • Díaz-Fontenla, Fernando
  • Marques, Patrice
  • Pérez-Rojas, Judith
  • Montalvá, Eva
  • Carvalho-Gomes, Ângela
  • Berenguer, Marina
[EN] Background and aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) recurrence after liver transplantation (LT) seems unavoidable and gradual. We aimed to evaluate the diagnostic accuracy in the post-LT setting of patients transplanted for metabolic dysfunction-associated steatohepatitis (MASH) of recurrent hepatic steatosis and fibrosis identified with FibroScan, compared to biopsy findings. Methods: This prospective cohort study included adults transplanted for MASH between 2010 and 2022 in three LT centres in Spain who underwent FibroScan and biopsy at least 1-year after LT. Results: In total, 44 patients transplanted for MASH after LT were included. The median time from LT to biopsy and FibroScan was 24.5 (interquartile range [IQR]:16-46) and 26.0 (IQR: 16.8-41.5) months, respectively. The median time between biopsy and FibroScan was 2.0 (IQR: 0-5) months. On FibroScan, significant steatosis was diagnosed in about half of the patients (n = 21, 47.7%), yet advanced fibrosis in only two cases (4.6%). On biopsy, a quarter of biopsied patients (n = 11, 25%) had a MASH diagnosis, two (4.6%) with significant fibrosis and one (2.3%) with cirrhosis. All patients with liver stiffness measurement (LSM) values <8 kPa (n = 35, 79.5%) had a fibrosis stage ¿F1 (negative predictive value = 100%). The combination of post-LT hypertension (odds ratio [OR]: 12.0, 95% confidence interval [CI]: 1.8-80.4, p = .010) and post-LT dyslipidaemia (OR: 7.9, 95% CI: 1.3-47.1, p = .024) with LSM (OR: 1.7, 95% CI: 1.1-2.8, p = .030) was independently associated with MASLD. Conclusions: Although biopsy remains the gold standard for detecting fibrosis, our results suggest that LSM values <8 kPa after LT for MASH are strongly correlated with absence of significant/advanced fibrosis., Generalitat Valenciana; Instituto de Salud Carlos III; Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas; Sociedad Espanola de Trasplante Hepatico This research was funded by the Instituto de Salud Carlos III and co- funded by European Regional Development Fund 'A way to make Europe' (grant PI19/01360 to MB, grant INT20/00061 to MB, grant FI20/00033 to LMA, grant MV22/00053 to LMA, grant CD22/00045 to PM, grant PI23/00088 to MB, and grant INT24/00021 to MB), by the Generalitat Valenciana (grant AICO/2021/035 to MB, grant CIGE/2023/073 to PM, and grant CIPROM/2023/16 to MB), by the CIBER -Consorcio Centro de Investigacion Biomedica en Red- [CB06/04/0065], Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion and Union Europea-European Regional Development Fund, and by the Spanish Society of Liver Transplantation (SETH, grant 2022/295 to MB).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Effect of hot-water treatmens in vitro on conidial germination and mycelial growth on grapevine trunk pathogens

  • Gramaje, D.
  • Alaniz, S.
  • García-Jiménez, J.
  • Abad Campos, Paloma|||0000-0002-5979-4349
  • Armengol Fortí, Josep|||0000-0003-3815-8578
[EN] In this study, the sensitivity of Cadophora luteo-olivacea, Cylindrocarpon liriodendri, Cn. macrodidymum and eight species of the genus Phaeoacremonium to hot-water treatments (HWTs) in vitro was evaluated. Conidial suspensions and plugs of agar with mycelia were placed in Eppendorf vials and incubated for 30, 45 or 60 min in a hot-water bath at 41, 42, 43, 44, 45, 46, 47, 48 or 49 degrees C for Cylindrocarpon spp. and at 49, 50, 51, 52, 53, 54 or 55 degrees C for Ca. luteo-olivacea and Phaeoacremonium spp. In general, conidial germination and the colony growth rate of all pathogens decreased with increased temperature and time combinations. Cylindrocarpon spp. were more sensitive than Ca. luteo-olivacea and Phaeoacremonium spp. to HWT temperatures. Conidial germination of Ca. luteo-olivacea was inhibited by treatments above 51 degrees C-30 min, while treatments up to 54 degrees C-60 min were necessary to inhibit the mycelial growth. For Cylindrocarpon spp., conidial germination was inhibited by treatments above 45 degrees C-45 min, while treatments above 48 degrees C-45 min were necessary to inhibit the mycelial growth. Regarding Phaeoacremonium spp., treatments up to 54 degrees C-60 min were necessary to completely inhibit both conidial germination and mycelial growth. These results suggest that current HWT protocols at 50 degrees C for 30 min may be sufficient to control Cylindrocarpon spp. However, it would be necessary to develop HWT using higher temperatures to reduce the incidence of Ca. luteo-olivacea and Phaeoacremonium spp. infections., This research was financially supported by the Projects AGL2006-11884-C04-01 (Ministerio de Educacion y Ciencia, Spain) and TRT2006-00033-00-0 and RTA2007-00023-C04-03 (Programa Nacional de Recursos y Tecnologias Agrarias, Ministerio de Educacion y Ciencia, Spain). We acknowledge E. Sala, A. Ramon and E. Moscardo for technical assistance.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Establishing and Validating a Biomolecular Signature of Ischemia/Reperfusion Injury in a Porcine Pancreas Allotransplantation Model

  • Ray, Samrat
  • Ganesh, Sujani
  • Martínez-Arenas, Laura
  • Parmentier, Catherine
  • Kawamura, Masataka
  • Arulratnam, Bhranavi
  • Hobeika, Christian
  • Nogueira, Emmanuel
  • Calderon Novoa, Francisco
  • Selzner, Markus
  • Reichman, Trevor W.
[EN] Background. Despite considerable advancement in surgical and immunological management in pancreas transplantation, graft pancreatitis remains a feared complication after pancreas transplantation. Identification of molecular mechanisms of underlying ischemia/reperfusion injury (IRI) in pancreas transplantation could, therefore, pave the path for targeted therapy to improve surgical outcomes. The aim of the study was to identify and validate the genes differentially expressed in the early period (24 h) of graft reperfusion in pancreas transplantation. Methods. A porcine pancreas allotransplant model (n = 4) was used to identify and validate the genes aberrantly expressed in 60 min postreperfusion tissue samples (phase 1). Trends of expression of selected genes from phase 1 and corresponding protein product levels in serum were validated at defined time points for >24 h in a technically replicated external cohort (n = 3; phase 2). Results. A total of 104 genes were found to be upregulated at 60 min after pancreas graft reperfusion. The most consistently overexpressed genes were IL6, THBS1, and MIR-21 (micro-RNA) mapped to protein kinase and intracellular signaling molecular pathways. Levels of expression of these genes correlated significantly with serum interleukin-6 (R = 0.60-0.81; P < 0.01) and tumor necrosis factor-alpha levels (R = 0.34-41; P > 0.05) at corresponding time points. Conclusions. The results provide new insights into biomolecular pathways (THBS1-IL6-MIR-21 crosstalk and hydroxymethylglutarate coenzyme A reductase-linked nuclear factor kappa B activation) linked to pancreatic IRI in porcine transplantation model. Identification and validation of some novel molecular pathway interactions in human pancreas transplantation could pave the path for potential targeted therapy in alleviating graft injury in the early phases of pancreatic IRI., S.R. and T.W.R. supported by Ajmera Transplant Centre Felowship award (March 2022-2023), Ajmera Transplant Centre, and Toronto General Hospital, Toronto, Canada. L.M.-A. was funded by the Instituto de Salud Carlos III and co-funded by European Regional Development Fund "A way to make Europe" (grant FI20/00033 and MV22/00053).
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Secretos y supercherías en una comedia de Lope de Vega: El gran duque de Moscovia, Secrets and Tricks in a Lope de Vega’s Comedy: El gran duque de Moscovia

  • Iglesias Feijoo, Luis
Esta comedia de Lope de Vega no ha merecido mucha atención crítica. Casi todos los trabajos se han centrado en la fecha de su redacción, siendo hoy el año de 1613 el que suele aceptarse. Aquí se propone el de 1608. Se lleva a cabo también un intento de considerar su segmentación en cuadros para acercarse a su estructura
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Literatura y parto en la Iberia de la temprana Modernidad: apuntes para una propuesta de corpus y análisis de fuentes literarias, Literature and Childbirth in Early Modern Iberia: A Proposal on Creating a Corpus and Analyzing Literary Sources

  • Casariego Castiñeira, Paula
Para una investigación interdisciplinar de la historia cultural del parto en la Iberia de la temprana Modernidad, la Historia de la Literatura ofrece las herramientas necesarias para abordar el estudio y la clasificación de las fuentes literarias escritas. Este artículo pretende reflexionar sobre la construcción de un corpus de trabajo diverso, ofrecer una propuesta de categorías de clasificación y plantear unas primeras posibles pautas de análisis de las representaciones literarias, con especial atención a la presencia femenina, tanto en su papel como autora como en su construcción literaria
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

La labor editorial de Vera Tassis, The Editorial Work of Vera Tassis

  • Rodríguez Gallego, Fernando
En este artículo se repasan y analizan las diferentes aportaciones sobre la labor de Vera Tassis, en especial en lo que respecta a los textos editados por él, y se señalan los mayores puntos de conflicto que existen en la actualidad, particularmente el valor que se quiera dar a los textos que Vera pudo haber seguido como texto base, así como su relevancia a la hora de detectar posibles dobles versiones de obras de Calderón de la Barca. En estos ámbitos sería deseable que avanzase la investigación en torno al polémico amigo de Calderón.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Machine Learning for Perovskite Solar Cells: A Comprehensive Review on Opportunities and Challenges for Materials Scientists

  • de la Asunción-Nadal, Víctor
  • Sprague, Christopher Iliffe
  • Guijarro-Berdiñas, Bertha
  • Cappel, Ute
  • García-Fernández, Alberto
[Abstract] Perovskite solar cells (PSCs) have emerged as a promising technology due to their tunable optoelectronic properties, low-cost fabrication and high efficiency. Despite this progress, key challenges such as long-term stability, large-scale manufacturability, and recyclability remain unsolved. Moreover, traditional methods for discovering new materials and optimizing device architectures rely on trial-and-error experiments. Machine learning (ML) offers powerful tools to address these bottlenecks by uncovering hidden patterns in data, accelerating discovery, and guiding rational design. However, the growing number of ML-driven studies in PSC research can be difficult to navigate, particularly for experimentalists and scientists without a computational background. To address this gap, this review is written with accessibility in mind, and it is structured to serve as a bridge between ML experts and the broader materials science community. We provide an overview of how ML can be applied to PSCs, from databases and data preprocessing to model training, evaluation, and interpretability. Advantages and limitations of different approaches are critically assessed, with emphasis on how dataset choice, algorithms, and metrics affect reliability. We conclude by outlining current challenges and open questions, as well as potential directions where the integration of ML with experimental and theoretical research could further advance the development of perovskite solar cells., We thank the Swedish Research Council (Grant No. VR 2022-03168) and the Göran Gustafsson foundation for funding. This work was partially supported by the Wallenberg Initiative Materials Science for Sustainability (WISE) funded by the Knut and Alice Wallenberg Foundation. We also acknowledge Project PID2023-147404OB-I00 funded by MCIN/AEI/10.13039/501100011033/ERDF, UE, and Xunta de Galicia (Grant ED431C 2022/44). A. G.-F. acknowledges support from a Beatriz Galindo junior fellowship (BG23/00033) from the Spanish Ministry of Science and Innovation, Suecia. Vetenskapsrådet; 2022-03168, Xunta de Galicia; ED431C 2022/44
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Tuning Multifunctional Stimuli-Responsive Behaviour Through Halogen Exchange in Hybrid Ionic [(CH3CH2)3N(CH2X)]2[MnCl4] (X = Cl, Br)

  • García Ben, Javier
  • Gelpi, María
  • Dafonte Rodríguez, Pedro
  • Ferradanes Martínez, Ángel
  • Delgado Ferreiro, Ignacio
  • López-Beceiro, Jorge
  • Artiaga, Ramón
  • Llamas-Saiz, Antonio L.
  • Walker, Julian
  • McMonagle, Charles James
  • García-Fernández, Alberto
  • Cappel, Ute
  • Castro-García, Socorro
  • Señarís-Rodríguez, M. A.
  • Bermúdez-García, Juan Manuel
  • Sánchez-Andújar, Manuel
Financiado para publicación en acceso aberto: Universidade da Coruña/CISUG, [Abstract] Hybrid metal halide materials have attracted significant attention due to their diverse functional properties. In this study, we prepared, characterized, and evaluated the multifunctional properties of two hybrid tetrachloromanganate(II) compounds with the general formula [(CH3CH2)3N(CH2X)]2[MnCl4], where X is Cl or Br. From the structural point of view, these compounds consist of two isolated ionic species with an antifluorite crystal arrangement: 0D tetrahedral [MnCl4]2− anions and large, quasi-spherical and polar [(CH3CH2)3N(CH2X)]+ cations. These cations are responsible for the first-order phase transition observed at Tt ∼ 318 K for the Cl-compound and Tt ∼ 343 K for the Br-compound. We investigated various functional properties—specifically dielectric, photoluminescent, and pressure responses—and our results demonstrate that these compounds are highly versatile, exhibiting broad responses to external stimuli. Furthermore, we found that substituting the halogen in the ammonium cations from Cl to Br induces important modifications in their functional properties. In particular, this halogen exchange increases the phase transition temperature, reduces the thermal hysteresis, improves the photoluminescence quantum yield, and enhances the reversible entropy changes under compression–decompression cycles., The authors thank financial support from grant PID2021-122532OB-I00 funded by MCIN/AEI/10.13039/501100011033 and ERDF A way of making Europe, the project PDC2021-121076-I00 funded by MCIN/AEI/10.13039/501100011033 and by the European Union Next GenerationEU/PRTR, and the projects ED431C 2022/39 and ED431F 2023/33 funded by Xunta de Galicia. This publication is part of the grant RYC2021-033040-I, funded by MCIN/AEI/10.13039/501100011033 and from European Union “NextGenerationEU”/PRTR”, and granted to J. M. B.-G. This researcher is also grateful for the support received by UDC-Inditex InTalent Programme. J. G.-B. and M. G. acknowledge Xunta de Galicia for Postdoctoral (ED481B-2024) and Predoctoral (ED481A-2023) Fellowships, respectively. P. D.-R. thanks Ministerio de Ciencia, Innovación y Universidades for a FPU Fellowship (FPU23/00091). A. G.-F. and U. B. C. thank the Swedish Research Council (Grant No. VR 2022-03168) and the Göran Gustafsson foundation for funding. This work was partially supported by the Wallenberg Initiative Materials Science for Sustainability (WISE) funded by the Knut and Alice Wallenberg Foundation. A. G.-F acknowledges support from a Beatriz Galindo junior fellowship (BG23/00033) from the Spanish Ministry of Science and Innovation. The authors thank ESRF for the award of beam time (A01-2-1291 on BM01). Open access publication fees were covered by Universidade da Coruña/CISUG, Xunta de Galicia; ED431C 2022/39, Xunta de Galicia; ED431F 2023/33, Xunta de Galicia; ED481B-2024, Xunta de Galicia; ED481A-2023, Suecia. Vetenskapsrådet; VR 2022-03168
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Quantitative Proteomic Analysis of Host—Pathogen Interactions: A Study of Acinetobacter baumannii Responses to Host Airways

  • Méndez Arredondo, José Antonio
  • Mateos, Jesús
  • Beceiro Casas, Alejandro
  • López Díaz, María
  • Tomás, María
  • Poza, Margarita
  • Bou, Germán
Additional files: 1. Workflow of the proteomic experiment -- 2. Histopathology shows signs of consolidated pneumonia in infected animals -- 3. Prediction of exoproteins -- 4. RT-PCR analysis of different genes. Primers and Univesal ProbeLibrary (UPL, Roche) probes used in this study -- 5. Protein identification data., [Abstract] Background: Acinetobacter baumannii is a major health problem. The most common infection caused by A. baumannii is hospital acquired pneumonia, and the associated mortality rate is approximately 50 %. Neither in vivo nor ex vivo expression profiling has been performed at the proteomic or transcriptomic level for pneumonia caused by A. baumannii. In this study, we characterized the proteome of A. baumannii under conditions that simulate those found in the airways, to gain some insight into how A. baumannii adapts to the host and to improve knowledge about the pathogenesis and virulence of this bacterium. A clinical strain of A. baumannii was grown under different conditions: in the presence of bronchoalveolar lavage fluid from infected rats, of RAW 264.7 cells to simulate conditions in the respiratory tract and in control conditions. We used iTRAQ labelling and LC-MALDI-TOF/TOF to investigate how A. baumannii responds on exposure to macrophages/BALF. Results: 179 proteins showed differential expression. In both models, proteins involved in the following processes were over-expressed: (i) pathogenesis and virulence (OmpA, YjjK); (ii) cell wall/membrane/envelope biogenesis (MurC); (iii) energy production and conversion (acetyl-CoA hydrolase); and (iv) translation (50S ribosomal protein L9). Proteins involved in the following were under-expressed: (i) lipid metabolism (short-chain dehydrogenase); (ii) amino acid metabolism and transport (aspartate aminotransferase); (iii) unknown function (DNA-binding protein); and (iv) inorganic ion transport and metabolism (hydroperoxidase). Conclusions: We observed alterations in cell wall synthesis and identified 2 upregulated virulence-associated proteins with >15 peptides/protein in both ex vivo models (OmpA and YjjK), suggesting that these proteins are fundamental for pathogenesis and virulence in the airways. This study is the first comprehensive overview of the ex vivo proteome of A. baumannii and is an important step towards identification of diagnostic biomarkers, novel drug targets and potential vaccine candidates in the fight against pneumonia caused by A. baumannii., This study was funded by grants from the European Community, FP7, ID: 278232 (MagicBullet), and by the Plan Nacional de I+D+I 2008-2011 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD12/0015/0014), cofinanced by the European Development Regional Fund (EDRF) “A Way to Achieve Europe.” M. T. and A.B. were financially supported by the Miguel Servet Programme ISCIII-FEDER (CP09/00033 and CP13/00226, respectively). This work was supported by the National Plans for Scientific Research, Development and Technological Innovation 2008-2011 and 2013-2016 and funded by the ISCIII- General Subdirection of Assesment and Promotion of the Research – European Regional Development Fund (ERDF) “A way of making Europe”: PI10/00056 and PI13/02390 to M. T., PI11/01034 to M.P., PI12/00552 to G.B. and PI14/00059 to M.P. and A.B.
eBiltegia. Repositorio Institucional de Mondragon Unibertsitatea
Publicación

The establishment of cow’s milk protein allergy in infants is related with a deficit of regulatory T cells (Treg) and vitamin D

eBiltegia. Repositorio Institucional de Mondragon Unibertsitatea
Publicación

Real-Time Servo Press Force Estimation Based on Dual Particle Filter

  • Olaizola, Jon
  • Bouganis, Christos Savvas
  • Sáenz de Argandoña, Eneko
  • Iturrospe, Aitzol
  • José Manuel, Abete
Helvia. Repositorio Institucional de la Universidad de Córdoba
Publicación Artículo científico (JournalArticle)

Threats to conservation from artificial-intelligence-generated wildlife images and videos

  • Guerrero Casado, José Manuel
  • Murillo-Jiménez, Tamara
  • Carpio, Antonio J.
  • Sánchez Tortosa, Francisco
  • Serrano Rodríguez, Rocío
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Resequencing the Vrs1 gene in Spanish barley landraces revealed reversion of six-rowed to two-rowed spike

  • Casas Cendoya, Ana Maria
  • Contreras‐Moreira, Bruno
  • Cantalapiedra, Carlos P.
  • Sakuma, Shun
  • Gracia Gimeno, Ma. Pilar
  • Moralejo Vidal, Mª Angeles
  • Molina Cano, José Luis
  • Komatsuda, Takao
  • Igartua Arregui, Ernesto
Six-rowed spike 1 (Vrs1) is a gene of major importance for barley breeding and germplasm management as it is the main gene determining spike row-type (2-rowed vs. 6-rowed). This is a widely used DUS trait, and has been often associated to phenotypic traits beyond spike type. Comprehensive re-sequencing Vrs1 revealed three two-rowed alleles (Vrs1.b2; Vrs1.b3; Vrs1.t1) and four six-rowed (vrs1.a1; vrs1.a2; vrs1.a3; vrs1.a4) in the natural population. However, the current knowledge about Vrs1 alleles and its distribution among Spanish barley subpopulations is still underexploited. We analyzed the gene in a panel of 215 genotypes, made of Spanish landraces and European cultivars. Among 143 six-rowed accessions, 57 had the vrs1.a1 allele, 83 were vrs1.a2, and three showed the vrs1.a3 allele. Vrs1.b3 was found in most two-rowed accessions, and a new allele was observed in 7 out of 50 two-rowed Spanish landraces. This allele, named Vrs1.b5, contains a ‘T’ insertion in exon 2, originally proposed as the causal mutation giving rise to the six-row vrs1.a2 allele, but has an additional upstream deletion that results in the change of 15 amino acids and a potentially functional protein. We conclude that eight Vrs1 alleles (Vrs1.b2, Vrs1.b3, Vrs1.b5, Vrs1.t1, vrs1.a1, vrs1.a2, vrs1.a3, vrs1.a4) discriminate two and six-rowed barleys. The markers described will be useful for DUS identification, plant breeders, and other crop scientists., This work was supported by the Spanish Ministry of Economy, Industry and Competitiveness grants AGL2010-21929, AGL2013-48756-R, RFP2012-00015-00-00, RTA2012-00033-C03-02, and EUI2009-04075 (national code for Plant-KBBE project ExpResBar). CPC was funded by the Spanish Ministry of Economy, Industry and Competitiveness grant no. BES-2011-045905 (linked to project AGL2010-21929). TK and SS were supported by a research fund by the Ministry of Agriculture, Forestry, and Fisheries of Japan (Genomics for Agricultural Innovation grants no. TRS1002). SS was supported by a Grant-in-Aid from the Japan Society for the Promotion of Science (JSPS) Postdoctoral Fellow for Research Abroad and a Grant-in-Aid for Young Scientists (B) (no. 16 K18635).
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Rachis brittleness in a hybrid–parent barley (Hordeum vulgare) breeding germplasm with different combinations at the non‐brittle rachis genes

  • Fernández Calleja, Miriam
  • Casas Cendoya, Ana Maria
  • Pérez Torres, Antonio
  • Gracia Gimeno, Ma. Pilar
  • Igartua Arregui, Ernesto
Two dominant, closely linked and complementary genes, Btr1 and Btr2, control rachis brittleness in barley. Recessive mutations in any of these genes turn the fragile rachis (brittle) into a tough rachis phenotype (non‐brittle). The cross of parents with alternative mutations in the btr genes leads to a brittle F1 hybrid that presents grain retention problems. We evaluated rachis fragility through a mechanical test and under natural conditions, in F1 crosses with different compositions at the btr genes. Brittleness was significantly higher in Btr1btr1Btr2btr2 crosses compared to hybrids and inbred parents carrying one of the mutations (btr1btr1Btr2Btr2/Btr1Btr1btr2btr2). This fact could jeopardize the efficient harvest of hybrids bearing alternative mutations, reducing the choice of possible crosses for hybrid barley breeding and hindering the exploitation of potential heterotic patterns. Furthermore, non‐brittle hybrids showed higher brittleness than inbreds, suggesting the presence of other dominant factors affecting the trait. In conclusion, this work encourages a deeper study of the genetic control of the rachis brittleness trait and urges the consideration of rachis tenacity as a target for hybrid barley breeding., This work was supported by the Spanish Ministry of Economy, Industry and Competitiveness grants RFP2015 00006‐00‐00, and RTA2012‐00033‐C03‐02, and by the contract “Iberia region hybrid barley variety development and understanding effects of adaptation genes in hybrids,” between CSIC and Syngenta Crop Protection AG, which included funding for MFC PhD scholarship.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Dynamics of African swine fever virus (ASFV) infection in domestic pigs infected with virulent, moderate virulent and attenuated genotype II ASFV European isolates

  • Gallardo, Carmina
  • Soler, Alejandro
  • Nurmoja, Imbi
  • Cano-Gómez, Cristina
  • Cvetkova, Svetlana
  • Frant, Maciej
  • Woźniakowski, Grzegorz
  • Simón, Alicia
  • Pérez, Covadonga
  • Nieto, Raquel
  • Arias, Marisa
This study aimed to compare the infection dynamics of three genotype II African swine fever viruses (ASFV) circulating in Europe. Eighteen domestic pigs divided into three groups were infected intramuscularly or by direct contact with two haemadsorbent ASFVs (HAD) from Poland (Pol16/DP/ OUT21) and Estonia (Est16/WB/Viru8), and with the Latvian non-HAD ASFV (Lv17/WB/Rie1). Parameters, such as symptoms, pathogenicity, and distribution of the virus in tissues, humoral immune response, and dissemination of the virus by blood, oropharyngeal and rectal routes, were investigated. The Polish ASFV caused a case of rapidly developing fatal acute disease, while the Estonian ASFV caused acute to sub-acute infections and two animals survived. In contrast, animals infected with the ASFV from Latvia developed a more subtle, mild, or even subclinical disease. Oral excretion was sporadic or even absent in the attenuated group, whereas in animals that developed an acute or sub-acute form of ASF, oral excretion began at the same time the ASFV was detected in the blood, or even 3 days earlier, and persisted up to 22 days. Regardless of virulence, blood was the main route of transmission of ASFV and infectious virus was isolated from persistently infected animals for at least 19 days in the attenuated group and up to 44 days in the group of moderate virulence. Rectal excretion was limited to the acute phase of infection. In terms of diagnostics, the ASFV genome was detected in contact pigs from oropharyngeal samples earlier than in blood, independently of virulence. Together with blood, both samples could allow to detect ASFV infection for a longer period. The results presented here provide quantitative data on the spread and excretion of ASFV strains of different virulence among domestic pigs that can help to better focus surveillance activities and, thus, increase the ability to detect ASF introductions earlier., This study was supported by the INIA (Projects RTA2015-00033-C02-01, AT2015-002) and the European Union Reference laboratory for ASF (Grant no.: UE- LR PPA/03). We would like to thank all the staff at the INIA-CISA who worked in the animal facilities department., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

  • Alonso-García, Miriam
  • Sánchez-Gastaldo, Amparo
  • Muñoz-Fuentes, Miguel A.
  • Molina-Pinelo, Sonia
  • Boyero, Laura
  • Benedetti, Johanna
  • Bernabé Caro, Reyes
Nivolumab (anti-PD-1 antibody) and atezolizumab (anti-PD-L1 antibody) have shown superior survival outcomes and improved adverse effects compared to standard chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. However, the efficacy of both treatments has not been directly compared in clinical trials. This retrospective, single-centre study was performed from June 2015 to December 2020 and included a cohort of 158 previously treated patients with stage IV or recurrent NSCLC who received PD-1 (nivolumab) (n = 89) or PD-L1 (atezolizumab) (n = 69) inhibitors at the Virgen del Rocío Hospital in Seville. The objective response rate (ORR) was 22.5% in the nivolumab group and 14.5% in the atezolizumab group (p = 0.140). Multivariate analysis did not show significant differences between the two groups for PFS and OS (PFS hazard ratio (HR): 0.80, 95% confidence interval (CI): 0.55−1.17, p = 0.260; OS HR: 0.79, 95% CI: 0.52−1.21, p = 0.281). Adverse events of all grades occurred in 68 patients in the nivolumab group (76.4%) and in 34 patients in the atezolizumab group (49.3%) (p < 0.001). Atezolizumab and nivolumab did not show statistically significant differences in survival outcomes in patients with NSCLC, even when stratified by histological subtype (squamous versus nonsquamous). However, the safety analysis suggested a more favourable toxicity profile for atezolizumab., RBC was funded by the Andalusian Research, Development and Innovation Plan (PY20_00951) and co-financed by the European Regional Development Fund (ERDF). SMP was funded by the Ministry of Health and Social Welfare of Junta de Andalucía (PI-0046-2012, Nicolas Monardes Program RC-0004-2020, OH-0022-2018 and PECART-0091-2020), Andalusian Research, Development and Innovation Plan (PY20_00992), and ISCIII (PI17/00033 and PI20/01109) and co-funded by FEDER from Regional Development European Funds (European Union). LB was funded by the Ministry of Health and Social Welfare of Junta de Andalucía (RH-0051-2020). JCB was funded by ISCIII (CM20/00178) and co-funded by FEDER from Regional Development European Funds (European Union)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

African swine fever (ASF) diagnosis, an essential tool in the epidemiological investigation

  • Gallardo, Carmina
  • Fernández-Pinero, Jovita
  • Arias, Marisa
10 Pág., Since there is no vaccine available, prevention, control, and eradication of African swine fever (ASF) is based on the implementation of appropriated surveillance and strict sanitary measures. Success of surveillance activities depends on the availability of the most appropriate diagnostic tests. Although a number of good validated ASF diagnostic techniques are available, the interpretation of the ASF diagnostic results can be complex. The reasons lie in the complexity of the epidemiology with different scenarios, as well as in the characteristics of the viruses circulating giving rise to a wide range of clinical forms of ASF. This review provides guidance for an accurate interpretation of ASF diagnostic results linked to the different clinical presentations ranging from per-acute to chronic disease, including apparently asymptomatic infections., This review was supported by the Spanish governmental project RTA2015-00033-C02-01, the INIA funds AT2015-002, and the European Union Reference laboratory for ASF (grant nº UE- LR PPA/03)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

La indumentaria del figurón en entremeses y comedias

  • Farré Vidal, Judith
Este trabajo se inscribe en el marco del programa Ramón y Cajal (RYC-2008-02362) y del Proyecto Edición y estudio del teatro breve de Antonio de Solís, del Plan Nacional de I+D+i (FFI2011-25118). Cuenta con el patrocinio de TC/12, en el marco del Programa Consolider-Ingenio 2010, del Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica (SD2009-00033)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Corrigiendo a Cervantes. Signos de teatralidad y puesta en escena La Gran Sultana (1992)

  • García Lorenzo, Luciano
Este trabajo se incluye en el proyecto de investigación CONSOLIDER «TC/12. Patrimonio teatral clásico español. Textos e instrumentos de investigación», Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

El teatro de Juan Ruiz de Alarcón en la escena española (1938-2010)

  • García Lorenzo, Luciano
Este trabajo se inserta en el Proyecto CONSOLIDER "Patrimonio teatral clásico español. Textos e instrumentos de investigación, Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Harnessing Novel Diversity From Landraces to Improve an Elite Barley Variety

  • Monteagudo, A.
  • Casas, A.M.
  • Cantalapiedra, C.P.
  • Contreras-Moreira, B.
  • Gracia, M.P.
  • Igartua, E.
The Spanish Barley Core Collection (SBCC) is a source of genetic variability of potential interest for breeding, particularly for adaptation to Mediterranean environments. Two backcross populations (BC2F5) were developed using the elite cultivar Cierzo as the recurrent parent. The donor parents, namely SBCC042 and SBCC073, were selected from the SBCC lines due to their outstanding yield in drought environments. Flowering time, yield and drought-related traits were evaluated in two field trials in Zaragoza (Spain) during the 2014-15 and 2015-16 seasons and validated in the 2017-18 season. Two hundred sixty-four lines of each population were genotyped with the Barley lllumina iSelect 50k SNP chip. Genetic maps for each population were generated. The map for SBCC042 x Cierzo contains 12, 893 SNPs distributed in 9 linkage groups. The map for SBCC073 x Cierzo includes 12, 026 SNPs in 7 linkage groups. Both populations shared two QTL hotspots. There are QTLs for flowering time, thousand-kernel weight (TKW), and hectoliter weight on a segment of 23 Mb at similar to 515 Mb on chromosome 1H, which encompasses the HvFT3 gene. In both populations, flowering was accelerated by the landrace allele, which also increased the TKW. In the same region, better soil coverage was contributed by SBCC042 but coincident with a lower hectoliter weight. The second large hotspot was on chromosome 6H and contained QTLs with wide intervals for grain yield, plant height and TKW. Landrace alleles contributed to increased plant height and TKW and reduced grain yield. Only SBCC042 contributed favorable alleles for "green area, " with three significant QTLs that increased ground coverage after winter, which might be exploited as an adaptive trait of this landrace. Some genes of interest found in or very close to the peaks of the QTLs are highlighted. Strategies to deploy the QTLs found for breeding and pre-breeding are proposed.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Identification of a New HIV-1 BC Intersubtype Circulating Recombinant Form (CRF108_BC) in Spain

  • Cañada, J.E.
  • Delgado, E.
  • Gil, H.
  • Sánchez, M.
  • Benito, S.
  • García-Bodas, E.
  • Gómez-González, C.
  • Canut-Blasco, A.
  • Portu-Zapirain, J.
  • Sáez de Adana, E.
  • De la Peña, M.
  • Ibarra, S.
  • Cilla, G.
  • Iribarren, J.A.
  • Martínez-Sapiña, A.
  • Thomson, M.M.
The extraordinary genetic variability of human immunodeficiency virus type 1 (HIV-1) group M has led to the identification of 10 subtypes, 102 circulating recombinant forms (CRFs) and numerous unique recombinant forms. Among CRFs, 11 derived from subtypes B and C have been identified in China, Brazil, and Italy. Here we identify a new HIV-1 CRF_BC in Northern Spain. Originally, a phylogenetic cluster of 15 viruses of subtype C in protease-reverse transcriptase was identified in an HIV-1 molecular surveillance study in Spain, most of them from individuals from the Basque Country and heterosexually transmitted. Analyses of near full-length genome sequences from six viruses from three cities revealed that they were BC recombinant with coincident mosaic structures different from known CRFs. This allowed the definition of a new HIV-1 CRF designated CRF108_BC, whose genome is predominantly of subtype C, with four short subtype B fragments. Phylogenetic analyses with database sequences supported a Brazilian ancestry of the parental subtype C strain. Coalescent Bayesian analyses estimated the most recent common ancestor of CRF108_BC in the city of Vitoria, Basque Country, around 2000. CRF108_BC is the first CRF_BC identified in Spain and the second in Europe, after CRF60_BC, both phylogenetically related to Brazilian subtype C strains.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Graphene-encapsulated magnetic nanoparticles for safe and steady delivery of ferulic acid in diabetic mice

  • Zhong, Baihua
  • Mateu-Roldán, Adán
  • Fanarraga, Mónica L.
  • Han, Wei
  • Muñoz-Guerra, Débora
  • González, Jesús
  • Tao Weng, Lu
  • Ibarra, M. Ricardo
  • Marquina, Clara
  • Lun Yeung, King
Iron nanoparticles encapsulated within graphene shells (Fe@C) were examined for cellular internalization, subcellular behavior, biocompatibility, and influence on cell viability and proliferation. Studies on human lung (adenocarcinoma human alveolar basal epithelial) and skin (epidermoid carcinoma) cells indicate Fe@C is less toxic and more biocompatible than the magnetite nanoparticles coated by an amorphous carbon (Fe3O4@C). Fe3O4@C exhibited more signs of degradation than Fe@C when exposed to murine macrophages (mouse monocyte-macrophages J774). Unlike Fe3O4@C, Fe@C has a high drug loading capacity (0.18 g/g) for ferulic acid, an active pharmaceutical ingredient found in the traditional Chinese herb Angelica sinensis and releases the drug at a constant dosing rate of 8.75 mg/g/day over 30 days. Ferulic acid released by Fe@C injected subcutaneously in diabetic BALB/c mice is effective in lowering the blood glucose level.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

The placental transcriptomic profile determined by maternal COVID-19 disease encompasses alterations reminiscent of preeclampsia

  • Medel-Martinez, Ana
  • Strunk, Mark
  • Cebollada-Solanas, Alberto
  • Puente-Santamaría, Laura
  • Gómez-Muñoz, Sonia
  • Fabre, Marta
  • Paules, Cristina
  • Oros, Daniel
  • Schoorlemmer, Jon
Introduction. During initial stages of the pandemic, SARS-CoV-2 infection during pregnancy was related to adverse pregnancy outcomes and alterations in the placenta. Whether placental abnormalities in pregnant women with COVID-19 still persist afterwards remains poorly studied. Here, we determined whether the absence of obstetric complications after maternal COVID-19 disease, including preeclampsia, is accompanied by a complete return to normalcy in terms of placental physiology. Methods. Placental RNA was purified from placental samples from SARS-CoV-2 positive mothers taken either in 2022, when Omicron was the predominant variant of concern (termed Omicron) (n = 21); or from healthy pregnancies predating the pandemic (termed preCOVID-19). Our cohort included samples from pregnant women who got infected weeks and even months before term. We performed RNA-seq, identified differentially expressed genes and examined to which biological, biochemical and cellular pathways they belong, using gene set enrichment analysis. Results. We identified 71 differentially expressed genes (DEGs) (defined by p-value ≤0.05 and fold change (FC) of ≤ -2 or ≥2). The alterations identified in placentas delivered by mothers who suffered an episode of COVID-19 disease could be mainly attributed to pathways related to organogenesis, extracellular matrix organization and oxygen transport. These alterations were also detected after exclusion of gestational diabetes mellitus (GDM) samples. Although none of the samples were taken from cases of preeclampsia, several of the relevant DEGs have been previously reported as dysregulated in hypertensive disorders of pregnancy including preeclampsia. Discussion. We propose that maternal SARS-CoV-2 infection causes alterations in gene expression that are indicative of vascular defects in the placenta
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Cytomegalovirus reactivation is associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation

  • Aguilera, Victoria
  • Romero Moreno, Sarai
  • Conde, Isabel
  • Rubín, Angel
  • Carvalho-Gomes, Angela
  • Romero, Mario
  • Zamora-Olaya, Javier
  • Gómez-Bravo, Miguel Angel
  • Fuentes-Valenzuela, Esteban
  • Dopazo, Cristina
  • Bilbao, Nikita
  • González, Antonio
  • Sánchez-Martínez, Ana
  • Pascual, Sonia
  • Rivera-Esteban, Jesús
  • Herrero, José Ignacio
  • Lorente, Sara
  • Cuadrado-Lavín, Antonio
  • Nogueras, Flor
  • Martínez-Arenas, Laura
  • González-Grande, Rocío
  • Berenguer, Marina
  • Rodriguez-Perálvarez, Manuel
In patients with hepatocellular carcinoma (HCC), undergoing liver transplantation (LT), cytomegalovirus reactivation (CMVr) may modulate the immune system to prevent tumor recurrence. In this multicenter retrospective study (2010–2015) involving 15 institutions, we assessed the effect of early CMVr in tumor recurrence rates among 771-LT HCC patients with tacrolimus-based immunosuppression (88% men, mean age 58 years). CMV prophylaxis was implemented for 19.7% of patients, while the rest were managed with preemptive therapy. The Milan criteria were met by 88% of patients. Microvascular invasion was present in 12.7% of explanted livers. The serum AFP level before transplantation was 5.1 (3–15) ng/mL. After a median follow-up of 7.4 years, 101 patients (13%) experienced HCC recurrence. CMVr occurred in 235 patients (30.5%) at a median of 41.5 days post-LT and 42 patients (5.6%) had CMV disease. Cumulative exposure to tacrolimus within the first 3 months after LT was similar among patients with and without CMVr. In a multivariate Cox regression analysis, factors associated with an increased rate of HCC recurrence included microvascular invasion [HR:2.82, CI95%:1.55–5.14; p 0.0001], donation after circulatory determination of death [HR:4.43,CI95%:1.52–12.9; p 0.006) and diameter of the main nodule at explant [HR:1.04, CI95%:1.02–1.06; p < 0.001]. Meanwhile CMVr [HR:0.46, CI95%:0.23–0.93, p 0.031] and MELD [HR:0.93, CI95%:0.87–0.99; p0.017] exhibited protective effects. In conclusion, early CMVr may protect against HCC recurrence. The underlying immune mechanisms warrant further investigation.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Towards an understanding of COVID-19-associated preeclampsia

  • Medel-Martinez, A.
  • Cebollada-Solanas, A.
  • Strunk, M.
  • Fabre, M.
  • Fernández-Soria, V. M.
  • Ramos-Ruiz, R.
  • Paules, C.
  • Oros, D.
  • Schoorlemmer, J.
Introduction SARS-CoV-2 infection during pregnancy has been associated with higher rates of preeclampsia (PE). While placental abnormalities resembling PE have been reported in COVID-19 pregnancies, the molecular mechanisms underlying the association remain unclear. Methods We conducted bulk RNA sequencing on placental tissues from four pregnancy groups: uneventful prepandemic (preCOVID-19), prepandemic PE (preCOVID-19 PE), COVID-19 without PE (COVID no PE), and COVID-19 complicated by PE or other hypertensive disorders (COVID PE). Differential expression was analyzed using Deseq2 likelihood ratio test (LRT), and gene set enrichment analysis identified dysregulated pathways. Results Clustering of LRT-significant differentially expressed genes (DEGs) identified a set of 16 genes (defined by the false discovery rate adjusted p-value < 0.05) across the four pregnancy groups, showing stepwise expression changes—lowest in preCOVID-19 uneventful, followed by those in COVID-19 without PE, then preCOVID-19 PE, and highest in COVID PE. This cluster included genes associated with placental dysfunction, such as LAMA5 and BTNL9. While morphogenesis-related pathways were enriched across all pathological groups, immune activation pathways were predominantly enriched in COVID PE, moderately in preCOVID-19 PE, and absent in COVID no PE. Discussion Our findings identify a COVID-19–associated placental signature that mirrors PE features and shows a progressive expression pattern defining a continuum of placental stress, with maternal SARS-CoV-2 infection potentially exacerbating underlying dysfunction.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Alterations of placental HERV expression as a result of gestational COVID-19 disease

  • Medel-Martinez, Ana
  • Bugatti, Mattia
  • Polychronopoulou, Mariana
  • Strunk, Mark
  • Macías-Redondo, Sofía
  • Bazo, Andrea
  • Garrido-Pontnou, Marta
  • Kitsou, Konstantina
  • Fabre, Marta
  • Paules, Cristina
  • Oros, Daniel
  • Pierquin, Justine
  • Brunel, Joanna
  • Charvet, Benjamin
  • Perron, Hervé
  • Facchetti, Fabio
  • Magiorkinis, Gkikas
  • Schoorlemmer, Jon
Introduction: Activation of human endogenous retroviral elements (HERV) is a well-documented phenomenon in inflammatory pathologies including COVID-19, with HERVW ENV frequently mentioned as a toxic protein. Given that COVID-19 during pregnancy has been associated with placental damage and a higher risk of adverse pregnancy outcomes (APOs), we investigated whether gestational COVID-19 alters placental HERV expression, and if such alterations correlate with placental damage or dysfunction. Methodology and results: We quantitively analyzed mRNA expression of HERV in placental samples using qPCR assays rigorously tested for efficiency and specificity or transcriptomic analysis. Combined qPCR and transcriptomic analyses of placentas from maternal COVID-19 cases revealed an overall trend toward reduced expression of several HERV elements, including HERVW ENV-related transcripts, with a more pronounced downregulation in SARS-CoV-2-positive placentas. HERVW ENV protein was detected by immunofluorescence in the syncytiotrophoblast (STB), co-staining with HCGβ, using conditions minimizing cross-reactivity with ERVWE1. HERVW ENV protein levels were diminished in COVID-19 patients, especially in those cases in which SARS-CoV-2 was present in the placenta. Conclusions and discussion: While HERV expression is reportedly induced in blood lymphocytes and other tissues as a response to SARS-CoV-2 infection, we detect unaltered or lower RNA levels of selected retroviral elements in the placenta of COVID-19 patients. HERVW ENV protein was present in non-COVID-19 placenta, and downregulated by maternal COVID-19 disease. The absence of HERVW ENV protein induction was confirmed by the careful study of cases with placental SARS-CoV-2 infection, as HERVW ENV was mostly absent from these samples, probably as an indirect result of placental damage. We identified two independent triggers for the downregulation of both HERVW ENV RNA and protein in placenta: maternal COVID-19 and local effects of SARS-CoV-2. Therefore, this HERV downregulation may represent part of the molecular response to placental SARS-CoV-2 infection, contributing to placental dysfunction and APOs.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Proteomic Analysis of Dysfunctional Liver Sinusoidal Endothelial Cells Reveals Substantial Differences in Most Common Experimental Models of Chronic Liver Diseases

  • Gil Soler, Mar
  • Azkargorta, Mikel
  • Fuster Ruiz, Carla
  • Martínez Gómez, María
  • Raurell Saborit, Immaculada
  • Barberá Bellés, Aurora
  • Hide, Diana
  • Martell Pérez-Alcalde, Maria
  • Pericas, Juan M
  • Genesca, Joan
Animal models; Chronic liver disease; Endothelial dysfunction, Models animals; Malaltia hepàtica crònica; Disfunció endotelial, Modelos animales; Enfermedad hepática crónica; Disfunción endotelial, Molecular markers of dedifferentiation of dysfunctional liver sinusoidal endothelial cells (LSEC) have not been fully elucidated. We aimed at deciphering the molecular profile of dysfunctional LSEC in different pathological scenarios. Flow cytometry was used to sort CD11b−/CD32b+ and CD11b−/CD32b− LSEC from three rat models of liver disease (bile duct ligation-BDL; inhaled carbon tetrachloride-CCl4; and high fat glucose/fructose diet-HFGFD). A full proteomic profile was performed applying nano-scale liquid chromatography tandem mass spectrometry (nLC-MS) and analyzed with PEAKS software. The percentage of CD32b− LSEC varied across groups, suggesting different capillarization processes. Both CD32+ and CD32b− LSEC from models are different from control LSEC, but differently expressed proteins in CD32b− LSEC are significantly higher. Heatmaps evidenced specific protein expression patterns for each model. Analysis of biological significance comparing dysfunctional CD32b− LSEC with specialized CD32b+ LSEC from controls showed central similarities represented by 45 common down-regulated proteins involved in the suppression of the endocytic machinery and 63 common up-regulated proteins associated with the actin-dependent cytoskeleton reorganization. In summary; substantial differences but also similarities in dysfunctional LSEC from the three most common models of liver disease were found, supporting the idea that LSEC may harbor different protein expression profiles according to the etiology or disease stage., This work was supported by grants PI18/00947 and AC18/00033 (ENM3 2018) and PI21/00691 from Instituto de Salud Carlos III (ISCIII) and cofounded by the European Union (ERDF/ESF, “Investing in your future”). J.G. is the recipient of a clinical intensification award and D.H. of a Sara Borrell grant, both from ISCIII. M.G. and A.B. have predoctoral fellowships from Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) and ISCIII respectively. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) is supported by ISCIII. The APC was funded by ISCIII.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Resequencing theVrs1 gene in Spanish barley landraces revealed reversion of six-rowed to two-rowed spike

  • Casas, Ana M.
  • Contreras-Moreira, Bruno
  • Cantalapiedra, Carlos P.
  • Sakuma, Shun
  • Gracia, María Pilar
  • Moralejo, Marian
  • Molina-Cano, José Luis
  • Komatsuda, Takao
  • Igartua, Ernesto
Six-rowed spike 1 (Vrs1) is a gene of major importance for barley breeding and germplasm management as it is the main gene determining spike row-type (2-rowed vs. 6-rowed). This is a widely used DUS trait, and has been often associated to phenotypic traits beyond spike type. Comprehensive re-sequencing Vrs1 revealed three two-rowed alleles (Vrs1.b2; Vrs1.b3; Vrs1.t1) and four six-rowed (vrs1.a1; vrs1.a2; vrs1.a3; vrs1.a4) in the natural population. However, the current knowledge about Vrs1 alleles and its distribution among Spanish barley subpopulations is still underexploited. We analyzed the gene in a panel of 215 genotypes, made of Spanish landraces and European cultivars. Among 143 six-rowed accessions, 57 had the vrs1.a1 allele, 83 were vrs1.a2, and three showed the vrs1.a3 allele. Vrs1.b3 was found in most two-rowed accessions, and a new allele was observed in 7 out of 50 two-rowed Spanish landraces. This allele, named Vrs1.b5, contains a ‘T’ insertion in exon 2, originally proposed as the causal mutation giving rise to the six-row vrs1.a2 allele, but has an additional upstream deletion that results in the change of 15 amino acids and a potentially functional protein. We conclude that eight Vrs1 alleles (Vrs1.b2, Vrs1.b3, Vrs1.b5, Vrs1.t1, vrs1.a1, vrs1.a2, vrs1.a3, vrs1.a4) discriminate two and six-rowed barleys. The markers described will be useful for DUS identification, plant breeders, and other crop scientists., info:eu-repo/semantics/acceptedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer

  • Yndestad, Synnøve
  • Engebrethsen, Christina
  • Nikolaienko, Oleksii
  • Vintermyr, Olav Karsten
  • Lillestøl, Reidun
  • Llop-Guevara, Alba
  • Herencia Ropero, Andrea
  • Serra, Violeta
Homologous recombination; Primary breast cancer, Recombinació homòloga; Càncer de mama primari, Recombinación homóloga; Cáncer de mama primario, PURPOSE Homologous recombination deficiency (HRD) is highly prevalent in triple-negative breast cancer (TNBC) and associated with response to PARP inhibition (PARPi). Here, we studied the prevalence of HRD in non-TNBC to assess the potential for PARPi in a wider group of patients with breast cancer. METHODS HRD status was established using targeted gene panel sequencing (360 genes) and BRCA1 methylation analysis of pretreatment biopsies from 201 patients with primary breast cancer in the phase II PETREMAC trial (ClinicalTrials.gov identifier: NCT02624973). HRD was defined as mutations in BRCA1, BRCA2, BRIP1, BARD1, or PALB2 and/or promoter methylation of BRCA1 (strict definition; HRD-S). In secondary analyses, a wider definition (HRD-W) was used, examining mutations in 20 additional genes. Furthermore, tumor BRCAness (multiplex ligation-dependent probe amplification), PAM50 subtyping, RAD51 nuclear foci to test functional HRD, tumor-infiltrating lymphocyte (TIL), and PD-L1 analyses were performed. RESULTS HRD-S was present in 5% of non-TNBC cases (n = 9 of 169), contrasting 47% of the TNBC tumors (n = 15 of 32). HRD-W was observed in 23% of non-TNBC (n = 39 of 169) and 59% of TNBC cases (n = 19 of 32). Of 58 non-TNBC and 30 TNBC biopsies examined for RAD51 foci, 4 of 4 (100%) non-TNBC and 13 of 14 (93%) TNBC cases classified as HRD-S had RAD51 low scores. In contrast, 4 of 17 (24%) non-TNBC and 15 of 19 (79%) TNBC biopsies classified as HRD-W exhibited RAD51 low scores. Of nine non-TNBC tumors with HRD-S status, only one had a basal-like PAM50 signature. There was a high concordance between HRD-S and either BRCAness, high TIL density, or high PD-L1 expression (each P < .001). CONCLUSION The prevalence of HRD in non-TNBC suggests that therapy targeting HRD should be evaluated in a wider breast cancer patient population. Strict HRD criteria should be implemented to increase diagnostic precision with respect to functional HRD., Supported by unrestricted grants from The K.G. Jebsen Foundation [SKGJ-MED-020 to H.P.E., S.K., P.E.L.], Helse Vest [912008 to P.E.L.], The Norwegian Research Council [273354 to P.E.L.] and The Norwegian Cancer Society [190281-2017 to S.K., 190275-2017 to P.E.L.]. Research funding was provided by Grieg Foundation (to H.P.E. and T.A.), Helse Vest [912252; Clinical researcher fellowship to H.P.E.], Generalitat de Catalunya [PERIS, SLT017/20/000081 to A.H.R.], “la Caixa” Foundation and European Institute of Innovation and Technology/Horizon 2020 [LCF/TR/CC19/52470003 to A.L.G.], Asociación Española Contra el Cáncer [AECC, INVES20095LLOP to A.L.G.], Generalitat de Catalunya (PERIS Fellowship SLT002/16/00477 to A.L.G.) ERA PerMed [2019-215 to V.S.] and Miguel Servet fellowship (CPII19/00033 to V.S.). Additional funding and study medication was provided by Illumina [grant number 9529854], Pfizer [WI206347] and AstraZeneca [ESR-14-10077] to H.P.E., S.K., P.E.L.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Role of VEGF Polymorphisms in the Susceptibility and Severity of Interstitial Lung Disease

  • Remuzgo-Martínez, Sara
  • Genre, Fernanda
  • Pulito-Cueto, Verónica
  • Atienza-Mateo, Belén
  • Mora Cuesta, Víctor Manuel
  • Iturbe Fernández, David
  • Berastegui Garcia, Cristina
Biomarker; Interstitial lung disease; Vascular endothelial growth factor, Biomarcador; Malaltia pulmonar intersticial; Factor de creixement endotelial vascular, Biomarcador; Enfermedad pulmonar intersticial; Factor de crecimiento vascular endotelial, The search for biomarkers that can help to establish an early diagnosis and prognosis of interstitial lung disease (ILD) is of potential interest. VEGF polymorphisms have been implicated in the development of several lung disorders. Consequently, we assessed, for the first time, the role of VEGF polymorphisms in the susceptibility and severity of ILD. A total of 436 Caucasian ILD patients (244 with idiopathic interstitial pneumonias (IIPs) and 192 with non-IIP) and 536 ethnically-matched healthy controls were genotyped for VEGF rs833061, rs1570360, rs2010963, rs3025020, and rs3025039 polymorphisms by TaqMan assays. Pulmonary function tests were collected from all the patients. VEGF serum levels were determined by ELISA in a subgroup of patients. No VEGF genotype, allele, carrier, or haplotype differences were found between ILD patients and controls as well as between IIP and non-IIP patients. However, an association of rs1570360 with IIP in women and also with lung function in IIP patients was found. None of the VEGF polymorphisms were associated with VEGF levels. In conclusion, our results suggest that VEGF does not seem to play a relevant role in ILD, although rs1570360 may influence the severity of ILD in women and a worse outcome in IIP patients., This research was partially supported by a grant from Spanish Society of Pulmonology and Thoracic Surgery (SEPAR 474-2017). S.R.-M. was supported by funds of the RETICS Program (RD16/0012/0009) from the “Instituto de Salud Carlos III” (ISCIII), co-funded by the European Regional Development Fund. V.P.-C. was supported by a pre-doctoral grant from IDIVAL (PREVAL 18/01). B.A.-M. was recipient of a “López Albo” post-residency program funded by Servicio Cántabro de Salud. L.L.-G. was supported by funds from IDIVAL (INNVAL 20/06). O.G. was beneficiary of a grant funded by Xunta de Galicia, Consellería de Educación, Universidade e Formación Profesional and Consellería de Economía, Emprego e Industria (GAIN), GPC IN607B2019/10. R.L.-M. was a recipient of a Miguel Servet type I program fellowship from the ISCIII, co-funded by the ESF, “Investing in your future” (grant CP16/00033).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenografts

  • Òdena, Andreu
  • Casals, Eloi
  • Molina, Cristina
  • Coşkun, Meriç
  • Guzman Torres, Marta
  • Brasó Maristany, Fara
  • García-Galea, Eduardo
  • Herencia Ropero, Andrea
  • Domènech Garcia, Heura
  • Rodríguez, Olga
  • Grueso, Judit
  • Dienstmann, Rodrigo
  • Oliveira, Mafalda
  • Monserrat, Laia
  • Serra, Violeta
Patritumab deruxtecan; Xenografts; Breast cancer, Patritumab deruxtecan; Xenoinjertos; Cáncer de mama, Patritumab deruxtecan; Xenoempelt; Càncer de mama, Novel antibody-drug conjugates (ADCs) have shown potent antitumor activity across multiple cancer types. However, the key determinants of therapeutic response remain under investigation. In this study, we aimed to identify potential determinants of long-term response to patritumab deruxtecan (HER3-DXd; MK-1022), a HER3-directed ADC linked to a potent topoisomerase I inhibitor (TOP1i) payload, using a cohort of thirty-one breast cancer (BC) patient-derived xenograft (PDX) models. Fourteen out of 31 (45%) PDXs exhibited a profound and sustained response to HER3-DXd. Basal-like PAM50 intrinsic subtype, limited prior exposure to chemotherapy and intrinsic sensitivity to the TOP1i irinotecan were associated with long-term response. Additionally, HER3-DXd showed sustained activity in BRCA1/BRCA2-mutated PARPi-resistant PDX models. Long-term responders exhibited persistent DNA damage and lacked early transcriptional activation of the G2/M cell cycle checkpoint that allow for DNA repair and RNA-DNA hybrid (R-loop) resolution, in parallel resulting in immune pathways transcriptional activation. Notably, characteristics linked to long-term response were primarily associated with the TOP1i payload activity., VHIO would like to acknowledge the State Agency for Research (Agencia Estatal de Investigación) for the financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment and the CERCA program from the Generalitat de Catalunya for their support on this research. This study was supported by the Asociación Española Cáncer de Mama Metastásico (AECMM) (III Metapremio M. Chiara Giorgetti 2021) and by the Catalan Agency AGAUR-FEDER (2021 SGR 01510 to V. Serra). V. Serra received funds from the Instituto de Salud Carlos III (ISCIII), and co-funded by the European Union (PI20/00892 and CPII19/00033). The FERO Foundation and GHD also provided support to V. Serra. A. Òdena and L. Monserrat received fellowships from the Agency for Management of University and Research Grants (2022 FI_B 00664 and AGAUR 2019 FI_B 01199, respectively). F. Brasó-Maristany received funding from Fundación científica AECC Ayudas Investigador AECC 2021 (INVES21943BRAS) and Fundación Contigo (HIMALAIA). A. Herencia-Ropero received funding from Generalitat de Catalunya (PERIS SLT017/20/000081). F. Pedretti received a fellowship from La Caixa Foundation (ID 100010434) (LCF/BQ/DI19/11730051). H. Domènech received a Severo Ochoa fellowship from the Spanish Ministry of Science and Innovation (PRE2021-099087). A. Esteve-Codina. reports that Institutional support to CNAG was provided by the Spanish Ministry of Science and Innovation through the Instituto de Salud Carlos III, and by the Generalitat de Catalunya through the Departament de Salut and the Departament de Recerca i Universitats. S. Chandarlapaty is supported by MSK Cancer Center Support Grant P30 CA008748 and the BCRF. A. Prat received funding from the Breast Cancer Research Foundation (BCRF-22-198, BCRF-23-198, BCRF-24-198), Beca Marta Santamaría, Fundación CRIS contra el Cancer (PR_EX_2021-14), Agència de Gestó d’Ajuts Universitaris I de Recerca (2021 SGR 01156), Fundación Fero (ONCOXXI21), Asociación Cáncer de Mama Metastásico (IV Premios M. Chiara Giorgetti), PI22/01017: funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and RESCUER: funded by European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement No. 847912. We would like to acknowledge Daiichi Sankyo and Merck Inc. for providing the HER3-DXd and the IgG-DXd and Astrazeneca Inc. for supplying the olaparib used in the study. Finally, we would like to acknowledge the patients who donate samples for the generation of the PDX models used in this study.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

  • Ring, Alistair
  • Kilburn, Lucy
  • Pearson, Alex
  • Moretti, Laura
  • Afshari-Mehr, Angelica
  • Wardley, Andrew
  • Llop Guevara, Alba
  • Serra, Violeta
Olaparib; Ceralasertib; Triple-negative advanced breast cancer, Olaparib; Ceralasertib; Càncer de mama avançat triple negatiu, Olaparib; Ceralasertib; Cáncer de mama avanzado triple negativo, Purpose: Approximately 10% to 15% of triple-negative breast cancers (TNBC) have deleterious mutations in BRCA1 and BRCA2 and may benefit from PARP inhibitor treatment. PARP inhibitors may also increase exogenous replication stress and thereby increase sensitivity to inhibitors of ataxia telangiectasia and Rad3-related (ATR) protein. This phase II study examined the activity of the combination of PARP inhibitor, olaparib, and ATR inhibitor, ceralasertib (AZD6738), in patients with advanced TNBC. Patients and Methods: Patients with TNBC on most recent biopsy who had received 1 or 2 lines of chemotherapy for advanced disease or had relapsed within 12 months of (neo)adjuvant chemotherapy were eligible. Treatment was olaparib 300 mg twice a day continuously and celarasertib 160 mg on days 1–7 on a 28-day cycle until disease progression. The primary endpoint was confirmed objective response rate (ORR). Tissue and plasma biomarker analyses were preplanned to identify predictors of response. Results: 70 evaluable patients were enrolled. Germline BRCA1/2 mutations were present in 10 (14%) patients and 3 (4%) patients had somatic BRCA mutations. The confirmed ORR was 12/70; 17.1% (95% confidence interval, 10.4–25.5). Responses were observed in patients without germline or somatic BRCA1/2 mutations, including patients with mutations in other homologous recombination repair genes and tumors with functional homologous recombination deficiency by RAD51 foci. Conclusions: The response rate to olaparib and ceralasertib did not meet prespecified criteria for activity in the overall evaluable population, but responses were observed in patients who would not be expected to respond to olaparib monotherapy., This research was funded by the Stand Up to Cancer Campaign for Cancer Research UK (CRUK/15/010, C30746/A19505; to S. Martin, H. Johnson, L. Moretti) with additional support from AstraZeneca, Guardant Health, Bio-Rad and Asociación Española Contra el Cáncer (AECC, INVES20095LLOP; to A. Llop-Guevara). The ICR Clinical Trials and Statistics Unit is supported by the Cancer Research UK core programme grant (C1491/A25351; to L.S. Kilburn). This study represents independent research supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden National Health Service Foundation Trust and the Institute of Cancer Research, London, UK. In addition, plasmaMATCH is supported by the NIHR Manchester Clinical Research Facility at the Christie Hospital, Manchester, UK, the NIHR UCLH Clinical Research Facility at University College London Hospitals NHS Foundation Trust, London, UK, the Cancer Research UK Cambridge Centre, Cambridge Biomedical Research Centre (BRC-1215–20014) and Cambridge Experimental Cancer Medicine Centre, Cambridge, UK. The RAD51 analysis was supported with grants from the Spanish Association of Cancer Research and Instituto de Salud Carlos III (ERAPERMED2019–215, CPII19/00033, and INVES20095LLOP). plasmaMATCH is supported at participating sites in England by the NIHR Clinical Research Network, in Scotland by the Chief Scientist Office, and in Wales by Health and Care Research Wales.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial

  • Carreira, Suzanne
  • Porta, Nuria
  • Arce-Gallego, Sara
  • Llop Guevara, Alba
  • Bianchini, Diletta
  • Serra Elizalde, Violeta
  • Mateo Valderrama, Joaquim
  • Seed, George
Pròstata; PARP; Biomarcadors, Próstata; PARP; Biomarcadores, Prostate; PARP; biomarkers, PARP inhibitors are approved for treating advanced prostate cancers (APCs) with various defective DNA repair genes; however, further studies to clinically qualify predictive biomarkers are warranted. Herein we analyzed TOPARP-B Phase II clinical trial samples, evaluating whole exome and low-pass whole genome sequencing and immunohistochemical assays evaluating ATM and RAD51 foci (testing homologous recombination repair function). BRCA1/2 germline and somatic pathogenic mutations associated with similar benefit from olaparib; greater benefit was observed with homozygous BRCA deletion. Biallelic, but not mono-allelic, PALB2 deleterious alterations were associated with clinical benefit. In the ATM cohort, loss of ATM protein by immunohistochemistry associated with better outcome. RAD51 foci loss identified tumors with biallelic BRCA and PALB2 alteration while most ATM- and CDK12-altered APCs had higher RAD51 foci levels. Overall, APCs with homozygous BRCA2 deletion are exceptional responders; PALB2 biallelic loss and loss of ATM immunohistochemical expression associated with clinical benefit., TOPARP is an investigator-initiated trial; we are grateful for the support and funding from AstraZeneca, and for the study grants from Cancer Research UK (CRUK/11/029; C12540/A12829; C12540/A13230; C12540/A20447). ICR-CTSU also receives program grant funding from Cancer Research UK (Grant number: C1491/A15955, C1491/A25351). We acknowledge research funding for this work from Cancer Research UK, Prostate Cancer UK, the Movember Foundation through the London Movember Centre of Excellence (CEO13_2-002), the Prostate Cancer Foundation, and the UK Department of Health through an Experimental Cancer Medicine Centre (ECMC) grant. Professor Johann de Bono is a National Institute for Health Research (NIHR) Senior Investigator. The views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health; research at the Royal Marsden Hospital is supported by a Biomedical Research Centre grant. Pasquale Rescigno was supported by a PCF Young Investigator Award 19YOUN19. The authors affiliated to VHIO acknowledge funding from “La Caixa” Foundation and European Institute of Innovation and Technology/Horizon 2020 (LCF/TR/CC19/52470003), Fundacion FERO and Fundacion Cellex. J. Mateo, A. Llop-Guevara and V. Serra received grants from Fundacion Cientifica AECC (LABAE16020PORTT) and an ERAPERMED2019-215. J. Mateo gratefully acknowledges funding from the European Union’s Horizon 2020 research and innovation program (Marie Skłodowska-Curie grant 837900), Instituto de Salud Carlos III (Grant PI18/01384), Fundación AECC, CRIS Cancer Foundation and the US Department of Defense CDMRP (Impact Award PC170510P1). S. Arce-Gallego Research. Downloaded from cancerdiscovery.aacrjournals.org on July 1, 2021. © 2021 American Association for Cancer Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 27, 2021; DOI: 10.1158/2159-8290.CD-21-0007 3 and V. Serra were supported by Instituto de Salud Carlos III (FI19/00280, CPII19/00033).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy

  • Carmona, F. David
  • Coit, Patrick
  • Saruhan-Direskeneli, Güher
  • Hernández-Rodríguez, José
  • Cid, María C.
  • Solans Laque, Roser
Estudis d'associació de genoma; Síndromes de vasculitis, Estudios de asociación de genoma; Síndromes de vasculitis, Genome-wide association studies; Vasculitis syndromes, Giant cell arteritis (GCA) and Takayasu’s arteritis (TAK) are major forms of large-vessel vasculitis (LVV) that share clinical features. To evaluate their genetic similarities, we analysed Immunochip genotyping data from 1,434 LVV patients and 3,814 unaffected controls. Genetic pleiotropy was also estimated. The HLA region harboured the main disease-specific associations. GCA was mostly associated with class II genes (HLA-DRB1/HLA-DQA1) whereas TAK was mostly associated with class I genes (HLA-B/MICA). Both the statistical significance and effect size of the HLA signals were considerably reduced in the cross-disease meta-analysis in comparison with the analysis of GCA and TAK separately. Consequently, no significant genetic correlation between these two diseases was observed when HLA variants were tested. Outside the HLA region, only one polymorphism located nearby the IL12B gene surpassed the study-wide significance threshold in the meta-analysis of the discovery datasets (rs755374, P = 7.54E-07; ORGCA = 1.19, ORTAK = 1.50). This marker was confirmed as novel GCA risk factor using four additional cohorts (PGCA = 5.52E-04, ORGCA = 1.16). Taken together, our results provide evidence of strong genetic differences between GCA and TAK in the HLA. Outside this region, common susceptibility factors were suggested, especially within the IL12B locus., This work was supported by SAF2012–34435 from the Spanish Ministry of Economy and Competitiveness, BIO-1395 from Junta de Andalucía, and RD12/0009/0004 from the RETICS Program (RIER) of Instituto de Salud Carlos III (ISCIII). FDC was recipient of a grant from the ‘Ramón y Cajal’ programme of the Spanish Ministry of Economy and Competitiveness (RYC-2014–16458). MCC and JHR are supported by Ministerio de Economía y Competitividad (SAF 14/57708R), cofunded by “Fondo Europeo de Desarrollo Regional, Unión Europea, Una manera de hacer Europa” [Instituto de Salud Carlos III and Fondo Europeo de desarrollo regional (FEDER) (PIE 13/00033)]. The Vasculitis Clinical Research Consortium has received support from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54AR057319), the National Center for Research Resources (U54 RR019497), the Office of Rare Diseases Research, and the National Center for Advancing Translational Science. The VCRC is part of the Rare Diseases Clinical Research Network (RDCRN).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

RAD51 as a biomarker for homologous recombination deficiency in high-grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test

  • Kramer, Claire
  • Yaniz-Galende, Elisa
  • Pellegrino, Benedetta
  • ter Haar, Natalja
  • Llop-Guevara, Alba
  • Herencia Ropero, Andrea
  • Serra, Violeta
Biomarker; High-hrade serous ovarian carcinoma; Homologous recombination deficiency, Biomarcador; Carcinoma de ovario seroso de alto grado; Deficiencia de recombinación homóloga, Biomarcador; Carcinoma d'ovari serós d'alt grau; Deficiència de recombinació homòloga, The RAD51 test is emerging as a promising biomarker for the assessment of functional homologous recombination deficiency (HRD). Yet, the robustness and reproducibility of the immunofluorescence-based RAD51 test, in different academic laboratories, have not been systematically investigated. Therefore, we tested the performance of the RAD51 assay in formalin-fixed paraffin-embedded (FFPE) high-grade serous ovarian carcinoma (HGSOC) samples in four European laboratories. Here, we confirm that subtle differences in staining procedures result in low variability of RAD51 and γH2AX scores. However, substantial variability in RAD51 scoring was observed in some samples, likely due to complicating technical and biological features, such as high RAD51 signal-to-noise ratio and RAD51 heterogeneity. These results support the need to identify and perform additional quality control steps and/or automating image analysis. Altogether, resolving technical issues should be a priority, as identifying tumours with functional HRD is urgently needed to guide the individual treatment of HGSOC patients. Follow-up studies are needed to define the key tissue quality requirements to assess HRD by RAD51 in FFPE tumour samples, as this test could help in guiding the individual treatment of HGSOC patients., This work was supported by the Dutch Cancer Society (KWF) (grant: 12995 to TB and MV) and by ERA PerMed (grant ERAPERMED2019-215 to VS). VS received funding from Instituto de Salud Carlos III (CPII19/00033). ALG received funding from Asociación Española Contra el Cáncer (AECC) (INVES20095LLOP) and AHR from Generalitat de Catalunya (PERIS SLT017/20/000081).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns

  • Mateo, Lidia
  • Duran-Frigola, Miquel
  • Palafox Sánchez, Marta
  • Scaltriti, Maurizio
  • Razavi, Pedram
  • Arribas López, Joaquin Vicente
  • Serra Elizalde, Violeta
  • Gris Oliver, Albert
  • Bellet Ezquerra, Meritxell
Biomarcadores de respuesta a fármacos; Redes de co-ocurrencia de conductores; Oncología de precisión, Biomarcadors de resposta a fàrmacs; Xarxes de co-ocurrència de conductors; Oncologia de precisió, Drug-response biomarkers; Driver co-occurrence networks; Precision oncology, Identification of actionable genomic vulnerabilities is key to precision oncology. Utilizing a large-scale drug screening in patient-derived xenografts, we uncover driver gene alteration connections, derive driver co-occurrence (DCO) networks, and relate these to drug sensitivity. Our collection of 53 drug-response predictors attains an average balanced accuracy of 58% in a cross-validation setting, rising to 66% for a subset of high-confidence predictions. We experimentally validated 12 out of 14 predictions in mice and adapted our strategy to obtain drug-response models from patients’ progression-free survival data. Our strategy reveals links between oncogenic alterations, increasing the clinical impact of genomic profiling., L.M. is a recipient of an FPI fellowship. P.A. acknowledges the support of the Spanish Ministerio de Economía y Competitividad (BIO2016-77038-R), the European Research Council (SysPharmAD: 614944), and the Generalitat de Catalunya (VEIS 001-P-001). V.S. is a recipient of a Miguel Servet grant from ISCIII (CPII19/00033) and receives funds from AGAUR (2017 SGR 540). The PDX program is supported by a GHD-Pink (FERO foundation) grant to V.S., A.G.-O. and M.P. received a FI-AGAUR and a Juan de la Cierva (MJCI-2015-25412) fellowship, respectively. M.S., P.R., and S.C. acknowledge the support of the NIH grants P30 CA008748, RO1CA190642, and the Breast Cancer Research Foundation. Additionally, P.R. receives funds from the Breast Cancer Alliance.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

  • Serra Elizalde, Violeta
  • Wang, Anderson T.
  • Castroviejo Bermejo, Marta
  • Polanska, Urszula M.
  • Palafox Sánchez, Marta
  • Llop Guevara, Alba
  • Guzman Torres, Marta
  • Rodriguez Ferreiro, Olga
  • Grueso Gragera, Judit
  • Arribas López, Joaquin Vicente
  • Cortés Castan, Javier
  • Cruz Zambrano, Cristina
  • Balmaña Gelpí, Judith
  • Saura Manich, Cristina
  • Herencia Ropero, Andrea
Cáncer de mama y de ovario; Inhibición WEE1, Càncer de mama i d'ovari; Inhibició WEE1, Breast and ovarian cancer; WEE1 inhibition, Purpose: PARP inhibitors (PARPi) induce synthetic lethality in homologous recombination repair (HRR)-deficient tumors and are used to treat breast, ovarian, pancreatic, and prostate cancers. Multiple PARPi resistance mechanisms exist, most resulting in restoration of HRR and protection of stalled replication forks. ATR inhibition was highlighted as a unique approach to reverse both aspects of resistance. Recently, however, a PARPi/WEE1 inhibitor (WEE1i) combination demonstrated enhanced antitumor activity associated with the induction of replication stress, suggesting another approach to tackling PARPi resistance. Experimental Design: We analyzed breast and ovarian patient-derived xenoimplant models resistant to PARPi to quantify WEE1i and ATR inhibitor (ATRi) responses as single agents and in combination with PARPi. Biomarker analysis was conducted at the genetic and protein level. Metabolite analysis by mass spectrometry and nucleoside rescue experiments ex vivo were also conducted in patient-derived models. Results: Although WEE1i response was linked to markers of replication stress, including STK11/RB1 and phospho-RPA, ATRi response associated with ATM mutation. When combined with olaparib, WEE1i could be differentiated from the ATRi/olaparib combination, providing distinct therapeutic strategies to overcome PARPi resistance by targeting the replication stress response. Mechanistically, WEE1i sensitivity was associated with shortage of the dNTP pool and a concomitant increase in replication stress. Conclusions: Targeting the replication stress response is a valid therapeutic option to overcome PARPi resistance including tumors without an underlying HRR deficiency. These preclinical insights are now being tested in several clinical trials where the PARPi is administered with either the WEE1i or the ATRi., This work was supported by the Spanish Instituto de Salud Carlos III (ISCIII), an initiative of the Spanish Ministry of Economy and Innovation partially supported by European Regional Development FEDER Funds (FIS PI17/01080 to V. Serra, PI12/02606 to J. Balmaña); European Research Area-NET, Transcan-2 (AC15/00063), Asociación Española contra el Cáncer (AECC; LABAE16020PORTT), the Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR; 2017 SGR 540), La Marató TV3 (654/C/2019), and ERAPERMED2019–215 to V. Serra. We also acknowledge the GHD-Pink program, the FERO Foundation, and the Orozco Family for supporting this study (to V. Serra). V. Serra was supported by the Miguel Servet Program (ISCIII; CPII19/00033); M. Castroviejo-Bermejo and C. Cruz (AIOC15152806CRUZ) by AECC; A. Herencia-Ropero by Generalitat de Catalunya-PERIS (SLT017/20/000081); M. Palafox by Juan de la Cierva (FJCI-2015–25412); A. Lau by AECC and Generalitat de Catalunya-PERIS (INVES20095LLOP, SLT002/16/00477); A. Gris-Oliver by FI-AGAUR (2015 FI_B 01075). This work was supported by Breast Cancer Research Foundation (BCRF-19–08), Instituto de Salud Carlos III Project Reference number AC15/00062, and the EC under the framework of the ERA-NET TRANSCAN-2 initiative co-financed by FEDER, Instituto de Salud Carlos III (CB16/12/00449 and PI19/01181), and Asociación Española Contra el Cáncer (to J. Arribas). The xenograft program in the Caldas laboratory was supported by Cancer Research UK and also received funding from an EU H2020 Network of Excellence (EuroCAN). The RPPA facility is funded by NCI #CA16672.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial

  • Capoluongo, Ettore Domenico
  • Pellegrino, B.
  • Califano, D.
  • Beltrame, L.
  • Serra Elizalde, Violeta
  • Llop Guevara, Alba
  • Scambia, Giovanni
Molecular testing; Ovarian cancer, Proves moleculars; Càncer d'ovaris, Pruebas moleculares; Cáncer de ovarios, Background The detection of homologous recombination deficiency (HRD) can identify patients who are more responsive to platinum and poly ADP ribose polymerase inhibitors (PARPi). MyChoice CDx (Myriad) is the most used HRD test in ovarian cancer (OC). However, some limitations of commercial tests exist, because of the high rate of inconclusive results, costs, and the impossibility of evaluating functional resistance mechanisms. Patients and methods Two academic genomic tests and a functional assay, the RAD51 foci, were evaluated to detect HRD. One hundred patients with high-grade OC enrolled in the MITO16A/MaNGO-OV2 trial and treated with first-line therapy with carboplatin, paclitaxel, and bevacizumab were analyzed. Results The failure rate of the two genomic assays was 2%. The sensitivity in detecting HRD when compared with Myriad was 98.1% and 90.6%, respectively. The agreement rate with Myriad was 0.92 and 0.87, with a Cohen’s κ coefficient corresponding to 0.84 and 0.74, respectively. For the RAD51 foci assay, the failure rate was 30%. When the test was successful, discordant results for deficient and proficient tumors were observed, and additional HRD patients were identified compared to Myriad; sensitivity was 82.9%, agreement rate was 0.65, and Cohen’s κ coefficient was 0.18. The HRD detected by genomic assays and residual tumor at primary surgery and stage was correlated with progression-free survival at multivariate analysis. Conclusions Results suggest the feasibility of academic tests for assessing HRD status that show robust concordance with Myriad and correlation with clinical outcome. The contribution of the functional information related to the RAD51 foci test to the genomic data needs further investigation., This work was supported by funding from the AIRC [grant numbers IG 2016 – ID. 18921 and IG 2021 – ID. 25932 projects – P.I. SP and CO-2018-12367051 (Ministero della Salute) P.I SP]; Ricerca Corrente grant M2/7 from Ministero della Salute to DC, Ricerca Corrente from Ministero della Salute to SP. SM is supported by the Italian Association for Cancer Research [grant number IG-2017 n: IG19997]. MITO16A/MaNGO-OV2 trial was partially supported by Roche. AL is a recipient of a grant from the Asociación Española contra el Cáncer (AECC) [grant number INVES20095LLOP]. VS is a recipient of a grant from the Instituto de Salud Carlos III [grant number CPII19/00033] and a European grant for personalized medicine [grant number ERAPERMED 2019-215]. BP is a recipient of a grant from GOIRC. BP was supported by ESMO with a Clinical Translational Fellowship aid supported by Roche. Any views, opinions, findings, conclusions, or recommendations expressed in this material are those solely of the authors and do not necessarily reflect those of ESMO or Roche. NC has received funding from AstraZeneca (to the institution). FP has received funding from Roche, AstraZeneca, Pfizer, Merck Sharp & Dome, Bayer, Incyte, Taiho Oncology, Janssen Cilag, Exelixis, Aileron, and Daiichi Sankyo (grants to the institution for clinical trial activities).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models

  • Rodriguez, María Jimena
  • Perrone, María Cecilia
  • Riggio, Marina
  • Palafox Sánchez, Marta
  • Salinas, Valeria
  • Elia, Andres
  • Serra Elizalde, Violeta
Cancer; Cell biology, Càncer; Biologia cel·lular, Cáncer; Biología celular, Resistance to therapy remains a major obstacle in cancer management. Although treatment with hormone and CDK4/6 inhibitors is successful in luminal breast cancer, resistance to these treatments is frequent, highlighting the need for novel therapeutic strategies to delay disease progression and improve patient survival. Here, we assessed the mechanisms of acquired resistance using T47D and MCF-7 tamoxifen- and palbociclib-resistant cell-line variants in culture and as xenografts, and patient-derived cells (PDCs) obtained from sensitive or resistant patient-derived xenografts (PDXs). In these models, we analyzed the effect of specific kinase inhibitors on survival, signaling and cellular aggressiveness. Our results revealed that mTOR inhibition is more effective than PI3K inhibition in overcoming resistance, irrespective of PIK3CA mutation status, by decreasing cell proliferation and tumor growth, as well as reducing cell migration and stemness. Moreover, a combination of mTOR and CDK4/6 inhibitors may prevent pathway reactivation downstream of PI3K, interfering with the survival of resistant cells and consequent tumor escape. In conclusion, we highlight the benefits of incorporating mTOR inhibitors into the current therapy in ER + breast cancer. This alternative therapeutic strategy not only enhances the antitumor response but may also delay the emergence of resistance and tumor recurrence., This work was supported by CONICET, ANPCYT (Grants PICT2509 & PICT0345), Instituto Nacional del Cáncer (Grants 2016 & 2018), Fundación Williams, Fundación Bunge & Born (Oster Grant) (Argentina); Instituto de Salud Carlos III (Grants PI20/00892 & CPII19/0033), Ministerio de Economía y Competitividad (FJCI-2015-25412) (Spain).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The CD200R1 microglial inhibitory receptor as a therapeutic target in the MPTP model of Parkinson’s disease

  • Serratosa, Joan
  • Bove Badell, Jordi
  • Vila Bover, Miquel
  • Saura, Josep
  • Solà, Carme
  • Rabaneda-Lombarte, Neus
Micròglia; Neuroinflamació; Malaltia de Parkinson, Microglía; Neuroinflamación; Enfermedad de Parkinson, Microglia; Neuroinflammation; Parkinson’s disease, Background It is suggested that neuroinflammation, in which activated microglial cells play a relevant role, contributes to the development of Parkinson’s disease (PD). Consequently, the modulation of microglial activation is a potential therapeutic target to be taken into account to act against the dopaminergic neurodegeneration occurring in this neurological disorder. Several soluble and membrane-associated inhibitory mechanisms contribute to maintaining microglial cells in a quiescent/surveillant phenotype in physiological conditions. However, the presence of activated microglial cells in the brain in PD patients suggests that these mechanisms have been somehow overloaded. We focused our interest on one of the membrane-associated mechanisms, the CD200-CD200R1 ligand-receptor pair. Methods The acute MPTP experimental mouse model of PD was used to study the temporal pattern of mRNA expression of CD200 and CD200R1 in the context of MPTP-induced dopaminergic neurodegeneration and neuroinflammation. Dopaminergic damage was assessed by tyrosine hydroxylase (TH) immunoreactivity, and neuroinflammation was evaluated by the mRNA expression of inflammatory markers and IBA1 and GFAP immunohistochemistry. The effect of the modulation of the CD200-CD200R1 system on MPTP-induced damage was determined by using a CD200R1 agonist or CD200 KO mice. Results MPTP administration resulted in a progressive decrease in TH-positive fibres in the striatum and TH-positive neurons in the substantia nigra pars compacta, which were accompanied by transient astrogliosis, microgliosis and expression of pro- and anti-inflammatory markers. CD200 mRNA levels rapidly decreased in the ventral midbrain after MPTP treatment, while a transient decrease of CD200R1 mRNA expression was repeatedly observed in this brain area at earlier and later phases. By contrast, a transient increase in CD200R1 expression was observed in striatum. The administration of a CD200R1 agonist resulted in the inhibition of MPTP-induced dopaminergic neurodegeneration, while microglial cells showed signs of earlier activation in CD200-deficient mice. Conclusions Collectively, these findings provide evidence for a correlation between CD200-CD200R1 alterations, glial activation and neuronal loss. CD200R1 stimulation reduces MPTP-induced loss of dopaminergic neurons, and CD200 deficiency results in earlier microglial activation, suggesting that the potentiation of CD200R1 signalling is a possible approach to controlling neuroinflammation and neuronal death in PD., This study was supported by grant PI15/00033 from the Instituto de Salud Carlos III (Spain) with joint financing by FEDER funds from the European Union. NRL was recipient of a predoctoral contract from the Spanish Ministerio de Educación. Cultura y Deporte FPU (FPU13/05491).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Resequencing the Vrs1 gene in Spanish barley landraces revealed reversion of six-rowed to two-rowed spike

  • Casas Cendoya, Ana Maria
  • Contreras‐Moreira, Bruno
  • Cantalapiedra, Carlos P.
  • Sakuma, Shun
  • Gracia Gimeno, Ma. Pilar
  • Moralejo Vidal, Mª Angeles
  • Molina Cano, José Luis
  • Komatsuda, Takao
  • Igartua Arregui, Ernesto
Six-rowed spike 1 (Vrs1) is a gene of major importance for barley breeding and germplasm management as it is the main gene determining spike row-type (2-rowed vs. 6-rowed). This is a widely used DUS trait, and has been often associated to phenotypic traits beyond spike type. Comprehensive re-sequencing Vrs1 revealed three two-rowed alleles (Vrs1.b2; Vrs1.b3; Vrs1.t1) and four six-rowed (vrs1.a1; vrs1.a2; vrs1.a3; vrs1.a4) in the natural population. However, the current knowledge about Vrs1 alleles and its distribution among Spanish barley subpopulations is still underexploited. We analyzed the gene in a panel of 215 genotypes, made of Spanish landraces and European cultivars. Among 143 six-rowed accessions, 57 had the vrs1.a1 allele, 83 were vrs1.a2, and three showed the vrs1.a3 allele. Vrs1.b3 was found in most two-rowed accessions, and a new allele was observed in 7 out of 50 two-rowed Spanish landraces. This allele, named Vrs1.b5, contains a ‘T’ insertion in exon 2, originally proposed as the causal mutation giving rise to the six-row vrs1.a2 allele, but has an additional upstream deletion that results in the change of 15 amino acids and a potentially functional protein. We conclude that eight Vrs1 alleles (Vrs1.b2, Vrs1.b3, Vrs1.b5, Vrs1.t1, vrs1.a1, vrs1.a2, vrs1.a3, vrs1.a4) discriminate two and six-rowed barleys. The markers described will be useful for DUS identification, plant breeders, and other crop scientists., This work was supported by the Spanish Ministry of Economy, Industry and Competitiveness grants AGL2010-21929, AGL2013-48756-R, RFP2012-00015-00-00, RTA2012-00033-C03-02, and EUI2009-04075 (national code for Plant-KBBE project ExpResBar). CPC was funded by the Spanish Ministry of Economy, Industry and Competitiveness grant no. BES-2011-045905 (linked to project AGL2010-21929). TK and SS were supported by a research fund by the Ministry of Agriculture, Forestry, and Fisheries of Japan (Genomics for Agricultural Innovation grants no. TRS1002). SS was supported by a Grant-in-Aid from the Japan Society for the Promotion of Science (JSPS) Postdoctoral Fellow for Research Abroad and a Grant-in-Aid for Young Scientists (B) (no. 16 K18635).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The ecology of predatory hoverflies as ecosystem-service providers in agricultural systems

  • Rodríguez-Gasol, Neus
  • Bover-Cid, Sara
  • Veronesi, Emiliano R.
  • Wratten, Steve
The main contemporary challenge for agriculture is to meet the food demands of the increasing world population while becoming more environmentally sustainable. One way to achieve this is through the promotion of functional biodiversity and the ecosystem (nature’s) services (ES) that it can provide. The Syrphinae subfamily is a widespread group of hoverflies with a high potential for that service. Hence, the present review aims to synthesize the existing literature on this group. This review is divided in three main sections. First, we focus on those aspects of the ecology of hoverflies that are relevant to their role in biological control. These are divided into nutrition, feeding preferences and prey detection of the different developmental stages, overwintering and the effect of landscape on their dispersal and efficacy. Second, we review the ES that predatory hoverflies can provide, particularly pollination and biological control. Finally, we discuss those farming practices that can affect the effectiveness of these Diptera as providers of ES. Overall, this review highlights the potential, as well as limitations and current gaps in knowledge, for enhancing the efficacy of hoverflies as ecosystem-service providers in agricultural systems., info:eu-repo/semantics/acceptedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers

  • Shah, Jennifer
  • Pueschl, Dana
  • Wubbenhorst, Bradley
  • Fan, Mengyao
  • Pluta, John
  • D’Andrea, Kurt
  • Llop Guevara, Alba
  • Serra Elizalde, Violeta
  • Balmaña Gelpí, Judith
Breast cancer; Cancer genetics; RNA sequencing, Cáncer de mama; Genética del cáncer; Secuenciación de ARN, Càncer de mama; Genètica del càncer; Seqüenciació d'ARN, Recurrence is a major cause of death among BRCA1/2 mutation carriers with breast (BrCa) and ovarian cancers (OvCa). Herein we perform multi-omic sequencing on 67 paired primary and recurrent BrCa and OvCa from 27 BRCA1/2 mutation carriers to identify potential recurrence-specific drivers. PARP1 amplifications are identified in recurrences (False Discovery Rate q = 0.05), and PARP1 is significantly overexpressed across primary BrCa and recurrent BrCa and OvCa, independent of amplification status. RNA sequencing analysis finds two BRCA2 isoforms, BRCA2-201/Long and BRCA2-001/Short, respectively predicted to be sensitive and insensitive to nonsense-mediated decay. BRCA2-001/Short is expressed more frequently in recurrences and associated with reduced overall survival in breast cancer (87 vs. 121 months; Hazard Ratio = 2.5 [1.18–5.5]). Loss of heterozygosity (LOH) status is discordant in 25% of patient’s primary and recurrent tumors, with switching between both LOH and lack of LOH found. Our study reveals multiple potential drivers of recurrent disease in BRCA1/2 mutation-associated cancer, improving our understanding of tumor evolution and suggesting potential biomarkers., This work was supported by the Tumor Tissue and Biospecimen Bank and the Next Generation Sequencing Core at the University of Pennsylvania (and in particular, we appreciated the help of Dr. Jonathan Schug). We would also like to thank Akoya Biosciences for their technical expertize regarding CODEX analyses. Lastly, the RNA sequencing pipeline used for this study was based on content from Dr. Dan Beiting’s DIY Transcriptomics class at the University of Pennsylvania (Spring 2021), for which we thank him as well. Figure 6 and Supplementary Fig. 15 were created using a licensed version of BioRender. This work was supported by the Basser Center for BRCA at the University of Pennsylvania (S.M.D., K.L.N.), the Gray Foundation Team Science Award (K.L.N.), the V Foundation for Cancer Research BRCA1/2 Convergence Team Award (K.L.N.), the Breast Cancer Research Foundation (S.M.D., K.L.N.) T32 HG009495 (A.K.), Miguel Servet Program (ISCIII) [CPII19/00033] (V.S.) and Asociación Española Contra el Cáncer (A.L.G.).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Rachis brittleness in a hybrid–parent barley (Hordeum vulgare) breeding germplasm with different combinations at the non‐brittle rachis genes

  • Fernández Calleja, Miriam
  • Casas Cendoya, Ana Maria
  • Pérez Torres, Antonio
  • Gracia Gimeno, Ma. Pilar
  • Igartua Arregui, Ernesto
Two dominant, closely linked and complementary genes, Btr1 and Btr2, control rachis brittleness in barley. Recessive mutations in any of these genes turn the fragile rachis (brittle) into a tough rachis phenotype (non‐brittle). The cross of parents with alternative mutations in the btr genes leads to a brittle F1 hybrid that presents grain retention problems. We evaluated rachis fragility through a mechanical test and under natural conditions, in F1 crosses with different compositions at the btr genes. Brittleness was significantly higher in Btr1btr1Btr2btr2 crosses compared to hybrids and inbred parents carrying one of the mutations (btr1btr1Btr2Btr2/Btr1Btr1btr2btr2). This fact could jeopardize the efficient harvest of hybrids bearing alternative mutations, reducing the choice of possible crosses for hybrid barley breeding and hindering the exploitation of potential heterotic patterns. Furthermore, non‐brittle hybrids showed higher brittleness than inbreds, suggesting the presence of other dominant factors affecting the trait. In conclusion, this work encourages a deeper study of the genetic control of the rachis brittleness trait and urges the consideration of rachis tenacity as a target for hybrid barley breeding., This work was supported by the Spanish Ministry of Economy, Industry and Competitiveness grants RFP2015 00006‐00‐00, and RTA2012‐00033‐C03‐02, and by the contract “Iberia region hybrid barley variety development and understanding effects of adaptation genes in hybrids,” between CSIC and Syngenta Crop Protection AG, which included funding for MFC PhD scholarship.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Synergic effect of atorvastatin and ambrisentan on sinusoidal and hemodynamic alterations in a rat model of NASH

  • Bravo Garmendia, Miren
  • Raurell Saborit, Immaculada
  • Barbera Belles, Aurora
  • Hide Alferez, Diana
  • Estrella Gonzalez, Federico
  • Salcedo Allende, Maria Teresa
  • Genescà Ferrer, Joan
  • Gil Soler, Mar
  • Martell Pérez-Alcalde, Maria
  • Augustin Recio, Salvador
Ambrisentan; Endotelina-1; Cèl·lules estelades hepàtiques, Ambrisentan; Endotelina-1; Células estrelladas hepáticas, Ambrisentan; Endothelin-1; Hepatic stellate cells, In non-alcoholic steatohepatitis (NASH), decreased nitric oxide and increased endothelin-1 (ET-1, also known as EDN1) released by sinusoidal endothelial cells (LSEC) induce hepatic stellate cell (HSC) contraction and contribute to portal hypertension (PH). Statins improve LSEC function, and ambrisentan is a selective endothelin-receptor-A antagonist. We aimed to analyse the combined effects of atorvastatin and ambrisentan on liver histopathology and hemodynamics, together with assessing the underlying mechanism in a rat NASH model. Diet-induced NASH rats were treated with atorvastatin (10 mg/kg/day), ambrisentan (30 mg/kg/day or 2 mg/kg/day) or a combination of both for 2 weeks. Hemodynamic parameters were registered and liver histology and serum biochemical determinations analysed. Expression of proteins were studied by immunoblotting. Conditioned media experiments were performed with LSEC. HSCs were characterized by RT-PCR, and a collagen lattice contraction assay was performed. Atorvastatin and ambrisentan act synergistically in combination to completely normalize liver hemodynamics and reverse histological NASH by 75%. Atorvastatin reversed the sinusoidal contractile phenotype, thus improving endothelial function, whereas ambrisentan prevented the contractile response in HSCs by blocking ET-1 response. Additionally, ambrisentan also increased eNOS (also known as Nos3) phosphorylation levels in LSEC, via facilitating the stimulation of endothelin-receptor-B in these cells. Furthermore, the serum alanine aminotransferase of the combined treatment group decreased to normal levels, and this group exhibited a restoration of the HSC quiescent phenotype. The combination of atorvastatin and ambrisentan remarkably improves liver histology and PH in a diet-induced NASH model. By recovering LSEC function, together with inhibiting the activation and contraction of HSC, this combined treatment may be an effective treatment for NASH patients., This work was supported by the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (European Regional Development Fund/European Social Fund, ‘Investing in your future’) [PI17/00310 to S.A., PI17/00754 to M.M., and PI18/00947 and AC18/00033 (ENM3 2018) to J.G.]. J.G. is a recipient of a clinical intensification award and D.H. is a recipient of a Sara Borrell grant (both from ISCIII). M.G. and A.B. have predoctoral fellowships from the Agència de Gestió d'Ajuts Universitaris i de Recerca and ISCIII, respectively. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) is supported by ISCIII.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Prospects for a survey of the galactic plane with the Cherenkov Telescope Array

  • Alvarez-Crespo, N.
  • Barrio Uña, Juan Abel
  • Contreras González, José Luis
  • Dinesh, A
  • Domínguez Díaz, Alberto
  • Láinez, M
  • Larriva, A.B.
  • López Moya, Marcos
  • Martinez, O.
  • Mas-Aguilar, A.
  • Miranda, J.M.
  • Miener, Tjark
  • Moralejo Olaizola, Abelardo
  • Morcuende Parrilla, Daniel
  • Nieto Castaño, Daniel
  • Rosado Vélez, Jaime
  • Zamanillo, V.M.
Approximately one hundred sources of very-high-energy (VHE) gamma rays are known in the Milky Way, detected with a combination of targeted observations and surveys. A survey of the entire Galactic Plane in the energy range from a few tens of GeV to a few hundred TeV has been proposed as a Key Science Project for the upcoming Cherenkov Telescope Array Observatory (CTAO). This article presents the status of the studies towards the Galactic Plane Survey (GPS). We build and make publicly available a sky model that combines data from recent observations of known gamma-ray emitters with state-of-the-art physically-driven models of synthetic populations of the three main classes of established Galactic VHE sources (pulsar wind nebulae, young and interacting supernova remnants, and compact binary systems), as well as of interstellar emission from cosmic-ray interactions in the Milky Way. We also perform an optimisation of the observation strategy (pointing pattern and scheduling) based on recent estimations of the instrument performance. We use the improved sky model and observation strategy to simulate GPS data corresponding to a total observation time of 1620 hours spread over ten years. Data are then analysed using the methods and software tools under development for real data. Under our model assumptions and for the realisation considered, we show that the GPS has the potential to increase the number of known Galactic VHE emitters by almost a factor of five. This corresponds to the detection of more than two hundred pulsar wind nebulae and a few tens of supernova remnants at average integral fluxes one order of magnitude lower than in the existing sample above 1 TeV, therefore opening the possibility to perform unprecedented population studies. The GPS also has the potential to provide new VHE detections of binary systems and pulsars, to confirm the existence of a hypothetical population of gamma-ray pulsars with an additional TeV emission component, and to detect bright sources capable of accelerating particles to PeV energies (PeVatrons). Furthermore, the GPS will constitute a pathfinder for deeper follow-up observations of these source classes. Finally, we show that we can extract from GPS data an estimate of the contribution to diffuse emission from unresolved sources, and that there are good prospects of detecting interstellar emission and statistically distinguishing different scenarios. Thus, a survey of the entire Galactic plane carried out from both hemispheres with CTAO will ensure a transformational advance in our knowledge of Galactic VHE source populations and interstellar emission.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

La «Comedia de Miseno», fuente de "La pobreza estimada", de Don Juan Manuel y Loyola a Lope de Vega

  • Fernández Rodríguez, Daniel|||0000-0001-7459-6167
El presente artículo pretende estudiar la influencia de la Comedia de Miseno en La pobreza estimada, de Lope de Vega. Un estudio detenido de ambas piezas revela una profunda relación intertextual entre la obra de Lope y la Comedia de Miseno, escrita por Loyola, un autor casi desconocido de finales del siglo xvi, y descubierta por Stefano Arata. Este artículo muestra asimismo la influencia del ejemplo XXV de El conde Lucanor sobre la Comedia de Miseno, al tiempo que descarta su influjo directo sobre La pobreza estimada, tradicionalmente señalado por la crítica., This paper studies the influence of the Comedia de Miseno on La pobreza estimada, by Lope de Vega. A careful study of both comedias shows a deep intertextual relationship between the play by Lope and the Comedia de Miseno, discovered by Stefano Arata. The Comedia de Miseno was written at the end of the 16th century by Loyola, an almost unknown author. This paper also shows the influence of the ejemplo XXV from El conde Lucanor on the Comedia de Miseno. At the same time, it rejects the direct influence of the ejemplo XXV on La pobreza estimada, as previously thought by critics., El presente trabajo forma parte de mi proyecto de tesis doctoral, realizado bajo la dirección de Alberto Blecua y Ramón Valdés gracias a una beca de Formación de Profesorado Universitario del Ministerio de Educación (FPU12/01052), y se beneficia de mi participación en los proyectos «Edición y estudio de treinta y seis comedias de Lope de Vega» FFI2012-35950 (MINECO), TC/12 «Patrimonio teatral clásico español. Textos e instrumentos de investigación» CSD2009-00033 (MICINN) y TETSO 2009 SGR 297 (AGAUR). Para este artículo he contado asimismo con la inestimable ayuda de Alberto Blecua, Alejandro García Reidy, Gonzalo Pontón, Guillermo Serés y Ramón Valdés, a los que quiero expresar mi agradecimiento.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Illuminating phenylazopyridines to photoswitch metabotropic glutamate receptors, from the flask to the animals

  • Gómez-Santacana, Xavier|||0000-0001-8830-0494
  • Pittolo, Silvia|||0000-0002-5673-1692
  • Rovira, Xavier|||0000-0002-9764-9927
  • Lopez, Marc
  • Zussy, Charleine
  • Dalton, James A. R.|||0000-0002-5279-4581
  • Faucherre, Adèle
  • Jopling, Chris
  • Pin, Jean-Philippe|||0000-0002-1423-345X
  • Ciruela, Francisco|||0000-0003-0832-3739
  • Goudet, Cyril|||0000-0002-8255-3535
  • Giraldo, Jesús|||0000-0001-7082-4695
  • Gorostiza, Pau|||0000-0002-7268-5577
  • Llebaria, Amadeu|||0000-0002-8200-4827
Phenylazopyridines are photoisomerizable compounds with high potential to control biological functions with light. We have obtained a series of phenylazopyridines with light dependent activity as negative allosteric modulators (NAM) of metabotropic glutamate receptor subtype 5 (mGlu). Here we describe the factors needed to achieve an operational molecular photoisomerization and its effective translation into in vitro and in vivo receptor photoswitching, which includes zebrafish larva motility and the regulation of the antinociceptive effects in mice. The combination of light and some specific phenylazopyridine ligands displays atypical pharmacological profiles, including light-dependent receptor overactivation, which can be observed both in vitro and in vivo. Remarkably, the localized administration of light and a photoswitchable compound in the peripheral tissues of rodents or in the brain amygdalae results in an illumination-dependent analgesic effect. The results reveal a robust translation of the phenylazopyridine photoisomerization to a precise photoregulation of biological activity. The cis - trans photoisomerization of phenylazopyridines, allowing mGlu receptor activity photoswitching in cells, is used in vivo to control zebrafish motility with light and analgesia in mice including peripheral and brain localized illumination.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Children's imaginaries of human-robot interaction in healthcare

  • Vallès-Peris, Núria|||0000-0003-4150-761X
  • Angulo, Cecilio|||0000-0001-9589-8199
  • Domènech i Argemí, Miquel|||0000-0003-2854-3659
This paper analyzes children's imaginaries of Human-Robots Interaction (HRI) in the context of social robots in healthcare, and it explores ethical and social issues when designing a social robot for a children's hospital. Based on approaches that emphasize the reciprocal relationship between society and technology, the analytical force of imaginaries lies in their capacity to be embedded in practices and interactions as well as to affect the construction and applications of surrounding technologies. The study is based on a participatory process carried out with six-year-old children for the design of a robot. Imaginaries of HRI are analyzed from a care-centered approach focusing on children's values and practices as related to their representation of care. The conceptualization of HRI as an assemblage of interactions, the prospective bidirectional care relationships with robots, and the engagement with the robot as an entity of multiple potential robots are the major findings of this study. The study shows the potential of studying imaginaries of HRI, and it concludes that their integration in the final design of robots is a way of including ethical values in it
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

ZmXTH1, a new xyloglucan endotransglucosylase/hydrolase in maize, affects cell wall structure and composition in Arabidopsis thaliana

  • Genovesi, Valeria
  • Fornalé, Silvia
  • Fry, Stephen C.
  • Ruel, Katia
  • Ferrer, Pau|||0000-0002-5287-4127
  • Encina, Antonio
  • Sonbol, Fathi-Mohamed
  • Bosch Argilagós, Josep|||0000-0002-2610-1120
  • Puigdomènech, Pere|||0000-0002-9866-861X
  • Rigau, Joan
  • Caparrós Ruiz, David|||0000-0002-7461-8888
Xyloglucan endotransglucosylase/hydrolases (XTHs; EC 2.4.1.207 and/or EC 3.2.1.151) are enzymes involved in the modification of cell wall structure by cleaving and, often, also re-joining xyloglucan molecules in primary plant cell walls. Using a pool of antibodies raised against an enriched cell wall protein fraction, a new XTH cDNA in maize, ZmXTH1, has been isolated from a cDNA expression library obtained from the elongation zone of the maize root. The predicted protein has a putative N-terminal signal peptide and possesses the typical domains of this enzyme family, such as a catalytic domain that is homologous to that of Bacillus macerans β-glucanase, a putative N-glycosylation motif, and four cysteine residues in the central and C terminal regions of the ZmXTH1 protein. Phylogenetic analysis of ZmXTH1 reveals that it belongs to subgroup 4, so far only reported from Poaceae monocot species. ZmXTH1 has been expressed in Pichia pastoris (a methylotrophic yeast) and the recombinant enzyme showed xyloglucan endotransglucosylase but not xyloglucan endohydrolase activity, representing the first enzyme belonging to subgroup 4 characterized in maize so far. Expression data indicate that ZmXTH1 is expressed in elongating tissues, modulated by culture conditions, and induced by gibberellins. Transient expression assays in onion cells reveal that ZmXTH1 is directed to the cell wall, although weakly bound. Finally, Arabidopsis thaliana plants expressing ZmXTH1 show slightly increased xyloglucan endohydrolase activity and alterations in the cell wall structure and composition.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A multiscale model of epigenetic heterogeneity-driven cell fate decision-making

  • Folguera Blasco, Núria|||0000-0003-1584-5885
  • Pérez Carrasco, Rubén
  • Cuyàs, Elisabet|||0000-0001-5353-440X
  • Menéndez, Javier A.|||0000-0001-8733-4561
  • Alarcón Cor, Tomás|||0000-0002-8566-3676
The inherent capacity of somatic cells to switch their phenotypic status in response to damage stimuli in vivo might have a pivotal role in ageing and cancer. However, how the entryexit mechanisms of phenotype reprogramming are established remains poorly understood. In an attempt to elucidate such mechanisms, we herein introduce a stochastic model of combined epigenetic regulation (ER)-gene regulatory network (GRN) to study the plastic phenotypic behaviours driven by ER heterogeneity. To deal with such complex system, we additionally formulate a multiscale asymptotic method for stochastic model reduction, from which we derive an efficient hybrid simulation scheme. Our analysis of the coupled system reveals a regime of tristability in which pluripotent stem-like and differentiated steady-states coexist with a third indecisive state, with ER driving transitions between these states. Crucially, ER heterogeneity of differentiation genes is for the most part responsible for conferring abnormal robustness to pluripotent stem-like states. We formulate epigenetic heterogeneity-based strategies capable of unlocking and facilitating the transit from differentiation- refractory (stem-like) to differentiation-primed epistates. The application of the hybrid numerical method validates the likelihood of such switching involving solely kinetic changes in epigenetic factors. Our results suggest that epigenetic heterogeneity regulates the mechanisms and kinetics of phenotypic robustness of cell fate reprogramming. The occurrence of tunable switches capable of modifying the nature of cell fate reprogramming might pave the way for new therapeutic strategies to regulate reparative reprogramming in ageing and cancer.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

In silico clinical trials for anti-aging therapies

  • Menéndez, Javier A.|||0000-0001-8733-4561
  • Cuyàs, Elisabet|||0000-0001-5353-440X
  • Folguera Blasco, Núria|||0000-0003-1584-5885
  • Verdura, Sara|||0000-0001-8980-0423
  • Martin-Castillo, Begoña
  • Joven, Jorge|||0000-0003-2749-4541
  • Alarcón Cor, Tomás|||0000-0002-8566-3676
Therapeutic strategies targeting the hallmarks of aging can be broadly grouped into four categories, namely systemic (blood) factors, metabolic manipulation (diet regimens and dietary restriction mimetics), suppression of cellular senescence (senolytics), and cellular reprogramming, which likely have common characteristics and mechanisms of action. In evaluating the potential synergism of combining such strategies, however, we should consider the possibility of constraining trade-off phenotypes such as impairment in wound healing and immune response, tissue dysfunction and tumorigenesis. Moreover, we are rapidly learning that the benefit/risk ratio of aging-targeted interventions largely depends on intra- and inter-individual variations of susceptibility to the healthspan-, resilience-, and/or lifespan-promoting effects of the interventions. Here, we exemplify how computationally-generated proxies of the efficacy of a given lifespan/healthspan-promoting approach can predict the impact of baseline epigenetic heterogeneity on the positive outcomes of ketogenic diet and mTOR inhibition as single or combined anti-aging strategies. We therefore propose that stochastic biomathematical modeling and computational simulation platforms should be developed as in silico strategies to accelerate the performance of clinical trials targeting human aging, and to provide personalized approaches and robust biomarkers of healthy aging at the individual-to-population levels.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns

  • Mateo, Lidia
  • Duran-Frigola, Miquel
  • Gris-Oliver, Albert|||0000-0003-1802-9541
  • Palafox, Marta|||0000-0002-1762-3250
  • Scaltriti, Maurizio|||0000-0002-5522-1447
  • Razavi, Pedram
  • Chandarlapaty, Sarat
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Bellet Ezquerra, Meritxell|||0000-0001-8859-8307
  • Serra, Violeta|||0000-0001-6620-1065
  • Aloy, Patrick|||0000-0002-3557-0236
Identification of actionable genomic vulnerabilities is key to precision oncology. Utilizing a large-scale drug screening in patient-derived xenografts, we uncover driver gene alteration connections, derive driver co-occurrence (DCO) networks, and relate these to drug sensitivity. Our collection of 53 drug-response predictors attains an average balanced accuracy of 58% in a cross-validation setting, rising to 66% for a subset of high-confidence predictions. We experimentally validated 12 out of 14 predictions in mice and adapted our strategy to obtain drug-response models from patients' progression-free survival data. Our strategy reveals links between oncogenic alterations, increasing the clinical impact of genomic profiling.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens

  • Vidal-Crespo, Anna
  • Matas-Céspedes, Alba
  • Rodriguez, Vanina
  • Rossi, Cédric
  • Valero, Juan G.
  • Serrat, Neus
  • Sanjuan-Pla, Alejandra
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Roué, Gaël|||0000-0003-0245-2257
  • López Guillermo, Armando|||0000-0002-8588-8381
  • Giné, Eva|||0000-0002-0532-1204
  • Campo, Elias|||0000-0001-9850-9793
  • Colomer, Dolors|||0000-0001-7486-8484
  • Bezombes, Christine
  • van Bueren, Jeroen Lammerts
  • Chiu, Christopher
  • Doshi, Parul
  • Pérez-Galán, Patricia|||0000-0003-3895-5024
CD38 is expressed in several types of non-Hodgkin lymphoma (NHL) and constitutes a promising target for antibody-based therapy. Daratumumab (Darzalex) is a first-in-class anti-CD38 antibody approved for the treatment of relapsed/refractory (R/R) multiple myeloma (MM). It has also demonstrated clinical activity in Waldenström macroglobulinaemia and amyloidosis. Here, we have evaluated the activity and mechanism of action of daratumumab in preclinical in vitro and in vivo models of mantle cell lymphoma (MCL), follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL), as monotherapy or in combination with standard chemo-immunotherapy. In vitro, daratumumab engages Fc-mediated cytotoxicity by antibody-dependent cell cytotoxicity and antibody-dependent cell phagocytosis in all lymphoma subtypes. In the presence of human serum, complement-dependent cell cytotoxicity was marginally engaged. We demonstrated by Selective Plane Illumination Microscopy that daratumumab fully penetrated a three-dimensional (3D) lymphoma organoid and decreased organoid volume. In vivo, daratumumab completely prevents tumor outgrowth in models of MCL and FL, and shows comparable activity to rituximab in a disseminated in vivo model of blastic MCL. Moreover, daratumumab improves overall survival (OS) in a mouse model of transformed CD20 FL, where rituximab showed limited activity. Daratumumab potentiates the antitumor activity of CHOP and R-CHOP in MCL and FL xenografts. Furthermore, in a patient-derived DLBCL xenograft model, daratumumab anti-tumor activity was comparable to R-CHOP and the addition of daratumumab to either CHOP or R-CHOP led to full tumor regression. In summary, daratumumab constitutes a novel therapeutic opportunity in certain scenarios and these results warrant further clinical development.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Point-of-care CAR T-cell production (ARI-0001) using a closed semi-automatic bioreactor, Experience from an academic phase i clinical trial

  • Castellà, Maria
  • Caballero-Baños, M.
  • Ortiz-Maldonado, Valentín|||0000-0003-4699-6862
  • González-Navarro, Europa Azucena|||0000-0003-3310-5557
  • Suñé, Guillermo|||0000-0002-4034-4348
  • Antoñana Vildosola, Asier|||0000-0002-1404-6398
  • Boronat Barado, Anna
  • Marzal, Berta
  • Millán, Lucía
  • Martín-Antonio, B.|||0000-0003-0612-2693
  • Cid Colom, Jordi|||0000-0002-6406-0585
  • Lozano, Miquel|||0000-0003-2593-833X
  • García, E.
  • Tabera, Jaime|||0000-0002-5430-0151
  • Trias, E.
  • Perpiña, U.
  • Canals, Josep M.|||0000-0001-6829-7670
  • Baumann, Tycho|||0000-0003-4421-0088
  • Benítez Ribas, Daniel|||0000-0002-2346-5324
  • Campo, Elias|||0000-0001-9850-9793
  • Yagüe, Jordi|||0000-0001-8210-1929
  • Urbano Ispizua, Álvaro|||0000-0002-7529-9399
  • Rives, S.
  • Delgado, Julio|||0000-0002-5157-4376
  • Juan, Manel|||0000-0002-3064-1648
Development of semi-automated devices that can reduce the hands-on time and standardize the production of clinical-grade CAR T-cells, such as CliniMACS Prodigy from Miltenyi, is key to facilitate the development of CAR T-cell therapies, especially in academic institutions. However, the feasibility of manufacturing CAR T-cell products from heavily pre-treated patients with this system has not been demonstrated yet. Here we report and characterize the production of 28 CAR T-cell products in the context of a phase I clinical trial for CD19+ B-cell malignancies (NCT03144583). The system includes CD4-CD8 cell selection, lentiviral transduction and T-cell expansion using IL-7/IL-15. Twenty-seven out of 28 CAR T-cell products manufactured met the full list of specifications and were considered valid products. Ex vivo cell expansion lasted an average of 8.5 days and had a mean transduction rate of 30.6 ± 13.44%. All products obtained presented cytotoxic activity against CD19+ cells and were proficient in the secretion of pro-inflammatory cytokines. Expansion kinetics was slower in patient's cells compared to healthy donor's cells. However, product potency was comparable. CAR T-cell subset phenotype was highly variable among patients and largely determined by the initial product. T and T were the predominant T-cell phenotypes obtained. 38.7% of CAR T-cells obtained presented a TN or T phenotype, in average, which are the subsets capable of establishing a long-lasting T-cell memory in patients. An in-depth analysis to identify individual factors contributing to the optimal T-cell phenotype revealed that ex vivo cell expansion leads to reduced numbers of T, T, and T cells, while T cells increase, both due to cell expansion and CAR-expression. Overall, our results show for the first time that clinical-grade production of CAR T-cells for heavily pre-treated patients using CliniMACS Prodigy system is feasible, and that the obtained products meet the current quality standards of the field. Reduced ex vivo expansion may yield CAR T-cell products with increased persistence in vivo.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cold stress protein RBM3 responds to hypothermia and is associated with good stroke outcome

  • Ávila-Gómez, Paulo
  • Vieites-Prado, Alba
  • Dopico-López, Antonio
  • Bashir, Saima
  • Fernández-Susavila, Héctor
  • Gubern, Carme|||0000-0001-8378-4477
  • Pérez-Mato, María
  • Correa-Paz, Clara
  • Iglesias-Rey, Ramón|||0000-0002-9985-9135
  • Sobrino, Tomás|||0000-0002-9760-8690
  • Bustamante, Alejandro|||0000-0003-4390-8900
  • Wellmann, Sven
  • Montaner, Joan|||0000-0003-4845-2279
  • Serena, Joaquín|||0000-0002-4478-7744
  • Castillo, José
  • Hervella, Pablo|||0000-0003-1249-6333
  • Campos, Francisco|||0000-0001-8665-1039
RNA-binding motif protein 3 is a molecular marker of hypothermia that has proved neuroprotective in neurodegenerative disease models. However, its relationship to the well-recognized therapeutic effect of hypothermia in ischaemic stroke had not been studied. In this work, the expression of RNA-binding motif protein 3 was investigated in ischaemic animal models subjected to systemic and focal brain hypothermia, specifically the effects of RNA-binding motif protein 3 silencing and overexpression on ischaemic lesions. Moreover, the association of RNA-binding motif protein 3 levels with body temperature and clinical outcome was evaluated in two independent cohorts of acute ischaemic stroke patients (n = 215); these levels were also determined in a third cohort of 31 patients derived from the phase III EuroHYP-1 trial of therapeutic cooling in ischaemic stroke. The preclinical data confirmed the increase of brain RNA-binding motif protein 3 levels in ischaemic animals subjected to systemic and focal hypothermia; this increase was selectively higher in the cooled hemisphere of animals undergoing focal brain hypothermia, thus confirming the direct effect of hypothermia on RNA-binding motif protein 3 expression, while RNA-binding motif protein 3 up-regulation in ischaemic brain regions led to functional recovery. Clinically, patients with body temperature <37.5°C in the first two cohorts had higher RNA-binding motif protein 3 values at 24 h and good outcome at 3 months post-ischaemic stroke, while RNA-binding motif protein 3 levels in the cooled third cohort tended to exceed those in placebo-treated patients. These results make RNA-binding motif protein 3 a molecular marker associated with the effect of hypothermia in ischaemic stroke and suggest its potential application as a promising protective target. Hypothermia is an effective neuroprotective treatment in stroke. We have demonstrated that the expression of RBM3 is increased under hypothermia treatment in animal models of ischaemia and stroke patients. These results evidence the potential application of RBM3 as a promising protective target against ischaemia
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Influence of MUC5B gene on antisynthetase syndrome

  • López-Mejías, Raquel|||0000-0003-0548-2689
  • Remuzgo-Martínez, Sara|||0000-0003-4455-7241
  • Genre, Fernanda|||0000-0003-3612-1448
  • Pulito-Cueto, Verónica|||0000-0002-3534-8467
  • Fernández Rozas, Sonia María
  • Llorca, Javier|||0000-0001-8569-861X
  • Iturbe, David|||0000-0002-5241-266X
  • Mora Cuesta, Víctor Manuel|||0000-0002-8161-0462
  • Ortego-Centeno, Norberto|||0000-0003-2325-0937
  • Gómez, Nair Pérez
  • Mera-Varela, Antonio
  • Martínez Barrio, Julia
  • López Longo, Francisco Javier
  • Mijares, Verónica
  • Lera-Gómez, Leticia
  • Usetti, María Piedad
  • Laporta, Rosalía
  • Pérez González, Virginia Luz
  • Gafas, Alicia De Pablo
  • Alfranca González, María Aránzazu
  • Calvo Alén, Jaime|||0000-0001-9378-8412
  • Romero-Bueno, Fredeswinda
  • Sánchez Pernaute, Olga
  • Nuno, Laura
  • Bonilla, Gema
  • Balsa, Alejandro|||0000-0001-8070-7062
  • Hernández-González, Fernanda
  • Grafia, Ignacio
  • Prieto-González, Sergio|||0000-0003-3179-597X
  • Narváez, Javier|||0000-0002-1614-8064
  • Trallero Araguás, Ernesto|||0000-0003-3365-4521
  • Selva O'Callaghan, Albert|||0000-0003-2823-9761
  • Gualillo, Oreste|||0000-0002-7154-1328
  • Castañeda, Santos|||0000-0002-7748-853X
  • Cavagna, Lorenzo|||0000-0003-3292-1528
  • Cifrián, José Manuel|||0000-0003-3682-0142
  • Gonzalez-Gay, MA.|||0000-0002-7924-7406
MUC5B rs35705950 (G/T) is strongly associated with idiopathic pulmonary fibrosis (IPF) and also contributes to the risk of interstitial lung disease (ILD) in rheumatoid arthritis (RA-ILD) and chronic hypersensitivity pneumonitis (CHP). Due to this, we evaluated the implication of MUC5B rs35705950 in antisynthetase syndrome (ASSD), a pathology characterised by a high ILD incidence. 160 patients with ASSD (142 with ILD associated with ASSD [ASSD-ILD+]), 232 with ILD unrelated to ASSD (comprising 161 IPF, 27 RA-ILD and 44 CHP) and 534 healthy controls were genotyped. MUC5B rs35705950 frequency did not significantly differ between ASSD-ILD+ patients and healthy controls nor when ASSD patients were stratified according to the presence/absence of anti Jo-1 antibodies or ILD. No significant differences in MUC5B rs35705950 were also observed in ASSD-ILD+ patients with a usual interstitial pneumonia (UIP) pattern when compared to those with a non-UIP pattern. However, a statistically significant decrease of MUC5B rs35705950 GT, TT and T frequencies in ASSD-ILD+ patients compared to patients with ILD unrelated to ASSD was observed. In summary, our study does not support a role of MUC5B rs35705950 in ASSD. It also indicates that there are genetic differences between ILD associated with and that unrelated to ASSD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epigenetic regulation of cell fate reprogramming in aging and disease, A predictive computational model

  • Folguera Blasco, Núria|||0000-0003-1584-5885
  • Cuyàs, Elisabet|||0000-0001-5353-440X
  • Menéndez, Javier A.|||0000-0001-8733-4561
  • Alarcón Cor, Tomás|||0000-0002-8566-3676
Understanding the control of epigenetic regulation is key to explain and modify the aging process. Because histone-modifying enzymes are sensitive to shifts in availability of cofactors (e.g. metabolites), cellular epigenetic states may be tied to changing conditions associated with cofactor variability. The aim of this study is to analyse the relationships between cofactor fluctuations, epigenetic landscapes, and cell state transitions. Using Approximate Bayesian Computation, we generate an ensemble of epigenetic regulation (ER) systems whose heterogeneity reflects variability in cofactor pools used by histone modifiers. The heterogeneity of epigenetic metabolites, which operates as regulator of the kinetic parameters promoting/preventing histone modifications, stochastically drives phenotypic variability. The ensemble of ER configurations reveals the occurrence of distinct epi-states within the ensemble. Whereas resilient states maintain large epigenetic barriers refractory to reprogramming cellular identity, plastic states lower these barriers, and increase the sensitivity to reprogramming. Moreover, fine-tuning of cofactor levels redirects plastic epigenetic states to re-enter epigenetic resilience, and vice versa. Our ensemble model agrees with a model of metabolism-responsive loss of epigenetic resilience as a cellular aging mechanism. Our findings support the notion that cellular aging, and its reversal, might result from stochastic translation of metabolic inputs into resilient/plastic cell states via ER systems.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy

  • Carmona, F. David|||0000-0002-1427-7639
  • Coit, Patrick
  • Saruhan-Direskeneli, Güher
  • Hernández Rodríguez, José|||0000-0002-2357-2015
  • Cid, María Cinta|||0000-0002-4730-0938
  • Solans, Roser|||0000-0002-0058-1293
  • Castañeda, Santos|||0000-0002-7748-853X
  • Vaglio, Augusto
  • Direskeneli, Haner
  • Merkel, Peter A.|||0000-0001-9284-7345
  • Boiardi, Luigi
  • Salvarani, Carlo|||0000-0001-5426-5133
  • Gonzalez-Gay, MA.|||0000-0002-7924-7406
  • Martín, Javier|||0000-0002-2202-0622
  • Sawalha, Amr H.
Giant cell arteritis (GCA) and Takayasu's arteritis (TAK) are major forms of large-vessel vasculitis (LVV) that share clinical features. To evaluate their genetic similarities, we analysed Immunochip genotyping data from 1,434 LVV patients and 3,814 unaffected controls. Genetic pleiotropy was also estimated. The HLA region harboured the main disease-specific associations. GCA was mostly associated with class II genes (HLA-DRB1 / HLA-DQA1) whereas TAK was mostly associated with class I genes (HLA-B/MICA). Both the statistical significance and effect size of the HLA signals were considerably reduced in the cross-disease meta-analysis in comparison with the analysis of GCA and TAK separately. Consequently, no significant genetic correlation between these two diseases was observed when HLA variants were tested. Outside the HLA region, only one polymorphism located nearby the IL12B gene surpassed the study-wide significance threshold in the meta-analysis of the discovery datasets (rs755374, P = 7.54E-07; OR = 1.19, OR = 1.50). This marker was confirmed as novel GCA risk factor using four additional cohorts (P = 5.52E-04, OR = 1.16). Taken together, our results provide evidence of strong genetic differences between GCA and TAK in the HLA. Outside this region, common susceptibility factors were suggested, especially within the IL12B locus.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Role of VEGF Polymorphisms in the Susceptibility and Severity of Interstitial Lung Disease

  • Remuzgo-Martínez, Sara|||0000-0003-4455-7241
  • Genre, Fernanda|||0000-0003-3612-1448
  • Pulito-Cueto, Verónica|||0000-0002-3534-8467
  • Atienza-Mateo, Belén|||0000-0001-7119-0786
  • Mora Cuesta, Víctor Manuel|||0000-0002-8161-0462
  • Iturbe, David|||0000-0002-5241-266X
  • Fernández Rozas, Sonia María
  • Lera-Gómez, Leticia
  • Alonso Lecue, Pilar
  • Ussetti, María Piedad
  • Laporta, Rosalía
  • Berastegui García, Cristina|||0000-0001-9774-9349
  • Solé, Amparo
  • Pérez González, Virginia Luz
  • De Pablo Gafas, Alicia
  • Gualillo, Oreste|||0000-0002-7154-1328
  • Cifrián, José Manuel|||0000-0003-3682-0142
  • López-Mejías, Raquel|||0000-0003-0548-2689
  • Gonzalez-Gay, MA.|||0000-0002-7924-7406
The search for biomarkers that can help to establish an early diagnosis and prognosis of interstitial lung disease (ILD) is of potential interest. VEGF polymorphisms have been implicated in the development of several lung disorders. Consequently, we assessed, for the first time, the role of VEGF polymorphisms in the susceptibility and severity of ILD. A total of 436 Caucasian ILD patients (244 with idiopathic interstitial pneumonias (IIPs) and 192 with non-IIP) and 536 ethnically-matched healthy controls were genotyped for VEGF rs833061, rs1570360, rs2010963, rs3025020, and rs3025039 polymorphisms by TaqMan assays. Pulmonary function tests were collected from all the patients. VEGF serum levels were determined by ELISA in a subgroup of patients. No VEGF genotype, allele, carrier, or haplotype differences were found between ILD patients and controls as well as between IIP and non-IIP patients. However, an association of rs1570360 with IIP in women and also with lung function in IIP patients was found. None of the VEGF polymorphisms were associated with VEGF levels. In conclusion, our results suggest that VEGF does not seem to play a relevant role in ILD, although rs1570360 may influence the severity of ILD in women and a worse outcome in IIP patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Synergic effect of atorvastatin and ambrisentan on sinusoidal and hemodynamic alterations in a rat model of NASH

  • Bravo, Miren|||0000-0001-5889-9125
  • Raurell, Imma|||0000-0003-4477-7367
  • Barberá Bellés, Aurora|||0000-0002-6201-2643
  • Hide, Diana
  • Gil, Mar
  • Estrella, Federico
  • Salcedo, Maria-Teresa|||0000-0002-4822-5060
  • Augustin Recio, Salvador|||0000-0002-3515-9033
  • Genescà Ferrer, Joan|||0000-0002-0831-8422
  • Martell, María|||0000-0002-0935-0029
In non-alcoholic steatohepatitis (NASH), decreased nitric oxide and increased endothelin-1 (ET-1, also known as EDN1) released by sinusoidal endothelial cells (LSEC) induce hepatic stellate cell (HSC) contraction and contribute to portal hypertension (PH). Statins improve LSEC function, and ambrisentan is a selective endothelin-receptor-A antagonist. We aimed to analyse the combined effects of atorvastatin and ambrisentan on liver histopathology and hemodynamics, together with assessing the underlying mechanism in a rat NASH model. Diet-induced NASH rats were treated with atorvastatin (10 mg/kg/day), ambrisentan (30 mg/kg/day or 2 mg/kg/day) or a combination of both for 2 weeks. Hemodynamic parameters were registered and liver histology and serum biochemical determinations analysed. Expression of proteins were studied by immunoblotting. Conditioned media experiments were performed with LSEC. HSCs were characterized by RT-PCR, and a collagen lattice contraction assay was performed. Atorvastatin and ambrisentan act synergistically in combination to completely normalize liver hemodynamics and reverse histological NASH by 75%. Atorvastatin reversed the sinusoidal contractile phenotype, thus improving endothelial function, whereas ambrisentan prevented the contractile response in HSCs by blocking ET-1 response. Additionally, ambrisentan also increased eNOS (also known as Nos3) phosphorylation levels in LSEC, via facilitating the stimulation of endothelin-receptor-B in these cells. Furthermore, the serum alanine aminotransferase of the combined treatment group decreased to normal levels, and this group exhibited a restoration of the HSC quiescent phenotype. The combination of atorvastatin and ambrisentan remarkably improves liver histology and PH in a diet-induced NASH model. By recovering LSEC function, together with inhibiting the activation and contraction of HSC, this combined treatment may be an effective treatment for NASH patients. Summary: Combining atorvastatin with ambrisentan is safe and effective in reducing intrahepatic resistance and portal hypertension in an experimental model of NASH. This liver histology amelioration highlights a promising therapeutic strategy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

TMAO and Gut Microbial-Derived Metabolites TML and γBB Are Not Associated with Thrombotic Risk in Patients with Venous Thromboembolism

  • Canyelles, Marina|||0000-0002-0278-5337
  • Plaza, Melania|||0000-0002-1471-3672
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Llobet, Dolors
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Mojal, Sergi|||0000-0003-0523-3869
  • Diaz-Ricart, Maribel|||0000-0003-1122-0052
  • Soria Fernández, José Manuel|||0000-0002-6226-4293
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Souto, Juan Carlos|||0000-0003-2092-5142
Background: The present work evaluates the association between circulating concentrations of Trimethylamine-N-oxide (TMAO), gamma butyrobetaine (γBB), and trimetyllisine (TML) in controls and patients with venous thromboembolism (VTE) with coagulation parameters. Methods: The study involved 54 VTE patients and 57 controls. Platelet function, platelet hyperreactivity, platelet adhesiveness, thrombosis-associated parameters, and thrombin generation parameters were studied. Plasma TMAO, γBB, and TML determination was performed using an ultra-high-performance liquid chromatography system coupled with mass spectrometry. Results: No differences were found for TMAO, γBB, or TML concentrations between controls and VTE patients. In thrombin generation tests, TMAO, γBB, and TML showed a positive correlation with lag time and time to peak. TMAO, γBB, and TML negatively correlated with peak height. No significant differences were observed regarding TMAO, γBB, and TML concentrations between the two blood withdrawals, nor when the control and VTE patients were analyzed separately. No correlation was observed between these gut metabolites and platelet function parameters. Conclusions: No differences were found regarding TMAO, γBB, and TML concentrations between the control and VTE groups. Some correlations were found; however, they were mild or went in the opposite direction of what would be expected if TMAO and its derivatives were related to VTE risk.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers

  • Shah, Jennifer B.|||0000-0001-9908-9874
  • Pueschl, Dana
  • Wubbenhorst, Bradley
  • Fan, Mengyao
  • Pluta, John
  • D'Andrea, Kurt
  • Hubert, Anna P.
  • Shilan, Jake S.
  • Zhou, Wenting
  • Kraya, Adam A.
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Ruan, Catherine
  • Serra, Violeta|||0000-0001-6620-1065
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Feldman, Michael
  • Morin, Pat J.
  • Nayak, Anupma
  • Maxwell, Kara N.|||0000-0001-8192-4202
  • Domchek, Susan M.|||0000-0002-5914-7272
  • Nathanson, Katherine L.|||0000-0002-6740-0901
Recurrence is a major cause of death among BRCA1/2 mutation carriers with breast (BrCa) and ovarian cancers (OvCa). Herein we perform multi-omic sequencing on 67 paired primary and recurrent BrCa and OvCa from 27 BRCA1/2 mutation carriers to identify potential recurrence-specific drivers. PARP1 amplifications are identified in recurrences (False Discovery Rate q = 0.05), and PARP1 is significantly overexpressed across primary BrCa and recurrent BrCa and OvCa, independent of amplification status. RNA sequencing analysis finds two BRCA2 isoforms, BRCA2-201/Long and BRCA2-001/Short, respectively predicted to be sensitive and insensitive to nonsense-mediated decay. BRCA2-001/Short is expressed more frequently in recurrences and associated with reduced overall survival in breast cancer (87 vs. 121 months; Hazard Ratio = 2.5 [1.18-5.5]). Loss of heterozygosity (LOH) status is discordant in 25% of patient's primary and recurrent tumors, with switching between both LOH and lack of LOH found. Our study reveals multiple potential drivers of recurrent disease in BRCA1/2 mutation-associated cancer, improving our understanding of tumor evolution and suggesting potential biomarkers. Carriers of pathogenic BRCA1/2 variants have a higher risk of breast and ovarian cancers, which recur frequently. Here, the authors sequence primary and recurrent tumours of BRCA1/2 mutation carriers, finding PARP1 amplifications, differential BRCA2 isoform usage, and discordant loss of heterozygosity that are associated with recurrence.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The capacity of APOB-depleted plasma in inducing ATP-binding cassette A1/G1-mediated macrophage cholesterol efflux-but not gut microbial-derived metabolites-is independently associated with mortality in patients with ST-segment elevation myocardial infarction

  • Canyelles, Marina|||0000-0002-0278-5337
  • García Osuna, Álvaro|||0000-0002-6682-0226
  • Junza, Alexandra
  • Yanes, Oscar|||0000-0003-3695-7157
  • Puig Grifol, Núria|||0000-0002-4699-3162
  • Ordóñez, J. (Jordi)|||0000-0003-4896-5832
  • Sionis, Alessandro|||0000-0003-0843-9512
  • Sans-Roselló, Jordi|||0000-0003-3176-6191
  • Alquézar-Arbé, A.|||0000-0003-4164-274X
  • Santos, David|||0000-0003-1157-4969
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
Impaired HDL-mediated macrophage cholesterol efflux and higher circulating concentrations of trimethylamine N-oxide (TMAO) levels are independent risk factors for cardiovascular mortality. The TMAO precursors, γ-butyrobetaine (γBB) and Trimethyllysine (TML), have also been recently associated with cardiovascular death, but their interactions with HDL-mediated cholesterol efflux remain unclear. We aimed to determine the associations between APOB depleted plasma-mediated macrophage cholesterol efflux and plasma TMAO, γBB, and TML concentrations and explore their association with two-year follow-up mortality in patients with acute ST-elevation myocardial infarction (STEMI) and unstable angina (UA). Baseline and ATP-binding cassette transporter ABCA1 and ABCG1 (ABCA1/G1)-mediated macrophage cholesterol efflux to APOB-depleted plasma was decreased in patients with STEMI, and the latter was further impaired in those who died during follow-up. Moreover, the circulating concentrations of TMAO, γBB, and TML were higher in the deceased STEMI patients when compared with the STEMI survivors or UA patients. However, after statistical adjustment, only ABCA1/G1-mediated macrophage cholesterol efflux remained significantly associated with mortality. Furthermore, neither the TMAO, γBB, nor TML levels altered the HDL-mediated macrophage cholesterol efflux in vitro. We conclude that impaired ABCA1/G1-mediated macrophage cholesterol efflux is independently associated with mortality at follow-up in STEMI patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical consequences of BRCA2 hypomorphism

  • Castells Roca, Laia|||0000-0002-4604-9999
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Bonache, Sandra|||0000-0002-7395-8143
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Carrasco, Estela|||0000-0003-1964-7675
  • Aza-Carmona, Miriam|||0000-0003-4448-9541
  • Montalban, Gemma|||0000-0002-6958-4759
  • Muñoz-Subirana, N.
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Cruz Zambrano, Cristina|||0000-0002-6474-7504
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Ramírez de Haro, Ma. José|||0000-0003-1417-7731
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Lasa, Adriana|||0000-0001-9957-9646
  • Serra, Violeta|||0000-0001-6620-1065
  • Diez, Orland|||0000-0001-7339-0570
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Surralles, Jordi|||0000-0002-4041-7519
The tumor suppressor FANCD1/BRCA2 is crucial for DNA homologous recombination repair (HRR). BRCA2 biallelic pathogenic variants result in a severe form of Fanconi anemia (FA) syndrome, whereas monoallelic pathogenic variants cause mainly hereditary breast and ovarian cancer predisposition. For decades, the co-occurrence in trans with a clearly pathogenic variant led to assume that the other allele was benign. However, here we show a patient with biallelic BRCA2 (c.1813dup and c.7796 A.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Divergent Effects of Glycemic Control and Bariatric Surgery on Circulating Concentrations of TMAO in Newly Diagnosed T2D Patients and Morbidly Obese

  • Canyelles, Marina|||0000-0002-0278-5337
  • Pérez, Antonio|||0000-0001-5528-1143
  • Junza, Alexandra
  • Miñambres, Inka|||0000-0002-0899-3938
  • Yanes, Oscar|||0000-0003-3695-7157
  • Sardà, Helena|||0000-0002-0138-8217
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
High circulating concentrations of the gut microbiota-derived metabolite trimethylamine N-oxide (TMAO) are significantly associated with the risk of obesity and type 2 diabetes (T2D). We aimed at evaluating the impact of glycemic control and bariatric surgery on circulating concentrations of TMAO and its microbiota-dependent intermediate, γ-butyrobetaine (γBB), in newly diagnosed T2D patients and morbidly obese subjects following a within-subject design. Based on HbA1c concentrations, T2D patients achieved glycemic control. However, the plasma TMAO and γBB concentrations were significantly increased, without changes in estimated glomerular filtration rate. Bariatric surgery was very effective in reducing weight in obese subjects. Nevertheless, the surgery reduced plasma γBB concentrations without affecting TMAO concentrations and the estimated glomerular filtration rate. Considering these results, an additional experiment was carried out in male C57BL/6J mice fed a Western-type diet for twelve weeks. Neither diet-induced obesity nor insulin resistance were associated with circulating TMAO and γBB concentrations in these genetically defined mice strains. Our findings do not support that glycemic control or bariatric surgery improve the circulating concentrations of TMAO in newly diagnosed T2D and morbidly obese patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Gut Microbiota-Derived TMAO, A Causal Factor Promoting Atherosclerotic Cardiovascular Disease?

  • Canyelles, Marina|||0000-0002-0278-5337
  • Borràs, Carla|||0000-0002-0998-7855
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
Trimethylamine-N-oxide (TMAO) is the main diet-induced metabolite produced by the gut microbiota, and it is mainly eliminated through renal excretion. TMAO has been correlated with an increased risk of atherosclerotic cardiovascular disease (ASCVD) and related complications, such as cardiovascular mortality or major adverse cardiovascular events (MACE). Meta-analyses have postulated that high circulating TMAO levels are associated with an increased risk of cardiovascular events and all-cause mortality, but the link between TMAO and CVD remains not fully consistent. The results of prospective studies vary depending on the target population and the outcome studied, and the adjustment for renal function tends to decrease or reverse the significant association between TMAO and the outcome studied, strongly suggesting that the association is substantially mediated by renal function. Importantly, one Mendelian randomization study did not find a significant association between genetically predicted higher TMAO levels and cardiometabolic disease, but another found a positive causal relationship between TMAO levels and systolic blood pressure, which-at least in part-could explain the link with renal function. The mechanisms by which TMAO can increase this risk are not clearly elucidated, but current evidence indicates that TMAO induces cholesterol metabolism alterations, inflammation, endothelial dysfunction, and platelet activation. Overall, there is no fully conclusive evidence that TMAO is a causal factor of ASCVD, and, especially, whether TMAO induces or just is a marker of hypertension and renal dysfunction requires further study.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

MiR-125b downregulates macrophage scavenger receptor type B1 and reverse cholesterol transport

  • Hueso, Miguel|||0000-0002-1824-9141
  • Griñán, Raquel|||0000-0002-9457-3365
  • Mallen, Adrián
  • Navarro, Estanislao
  • Purqueras, Elvira
  • Gomà-Gállego, Montserrat
  • Sbraga, Fabrizio
  • Blasco-Lucas, Arnau|||0000-0002-2796-7428
  • Revilla, Giovanna|||0000-0003-2971-5651
  • Santos, David|||0000-0003-1157-4969
  • Canyelles, Marina|||0000-0002-0278-5337
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Rotllan, Noemi|||0000-0002-0587-8045
Objective: To determine whether miR-125b regulates cholesterol efflux in vivo and in vitro through the regulation of scavenger receptor type B1 (SR-B1). Approach and results: We demonstrated that miR-125b is up-regulated in the human aortas of patients with CAD and is located in macrophages and vascular smooth muscle cells (VSMCs). We identified SCARB1 as a direct target of miR-125b by repressing the activity of the SCARB1 3'-untranslated region reporter construct. Moreover, the overexpression of miR-125b in both human and mouse macrophages as well as VSMCs was found to downregulated the expression of the SCARB1 and the SR-B1 protein levels, thereby impairing α-HDL-mediated macrophage cholesterol efflux in vitro. The in vivo reverse cholesterol transport (RCT) rate from non-cholesterol-loaded macrophages transfected with miR-125b to feces was also found to be decreased when compared with that of control mimic-transfected macrophages. Conclusions: Together, these results provide evidence that miR-125b downregulates SCARB1 and SR-B1 in both human and mouse macrophages as well as VSMCs, thereby impairing macrophage cholesterol efflux in vitro and the whole macrophage-specific RCT pathway in vivo.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Development of a Novel Anti-CD19 Chimeric Antigen Receptor, A Paradigm for an Affordable CAR T Cell Production at Academic Institutions

  • Castellà, Maria
  • Boronat, Anna|||0000-0003-0852-3634
  • Martín-Ibáñez, Raquel
  • Rodríguez, Vanina
  • Suñé, Guillermo|||0000-0002-4034-4348
  • Caballero Baños, Miguel|||0000-0002-2313-7988
  • Marzal, Berta
  • Pérez-Amill, Lorena|||0000-0003-0674-4660
  • Martín-Antonio, B.|||0000-0003-0612-2693
  • Castaño Cardoso, Julio|||0000-0002-0712-5856
  • Bueno, Clara|||0000-0003-1442-6216
  • Balagué, Olga|||0000-0002-5099-3675
  • González-Navarro, Europa Azucena|||0000-0003-3310-5557
  • Serra-Pages, Carles
  • Engel, Pablo|||0000-0001-8410-252X
  • Vilella, Ramon
  • Benítez Ribas, Daniel|||0000-0002-2346-5324
  • Ortiz-Maldonado, Valentín|||0000-0003-4699-6862
  • Cid, Joan|||0000-0001-5445-4508
  • Tabera, Jaime|||0000-0002-5430-0151
  • Canals, Josep M.|||0000-0001-6829-7670
  • Lozano, Miquel|||0000-0003-2593-833X
  • Baumann, Tycho|||0000-0003-4421-0088
  • Vilarrodona, Ana|||0000-0001-6984-1834
  • Trias, Esteve|||0000-0001-7635-4428
  • Campo, Elias|||0000-0001-9850-9793
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Urbano Ispizua, Álvaro|||0000-0002-7529-9399
  • Yagüe, Jordi|||0000-0001-8210-1929
  • Pérez-Galán, Patricia|||0000-0003-3895-5024
  • Rives, Susana|||0000-0002-5658-1831
  • Delgado, Julio|||0000-0002-5157-4376
  • Juan, Manel|||0000-0002-3064-1648
Genetically modifying autologous T cells to express an anti-CD19 chimeric antigen receptor (CAR) has shown impressive response rates for the treatment of CD19+ B cell malignancies in several clinical trials (CTs). Making this treatment available to our patients prompted us to develop a novel CART19 based on our own anti-CD19 antibody (A3B1), followed by CD8 hinge and transmembrane region, 4-1BB- and CD3z-signaling domains. We show that A3B1 CAR T cells are highly cytotoxic and specific against CD19+ cells in vitro, inducing secretion of pro-inflammatory cytokines and CAR T cell proliferation. In vivo, A3B1 CAR T cells are able to fully control disease progression in an NOD.Cg-Prkdc Il2rd/SzJ (NSG) xenograph B-ALL mouse model. Based on the pre-clinical data, we conclude that our CART19 is clearly functional against CD19+ cells, to a level similar to other CAR19s currently being used in the clinic. Concurrently, we describe the implementation of our CAR T cell production system, using lentiviral vector and CliniMACS Prodigy, within a medium-sized academic institution. The results of the validation phase show our system is robust and reproducible, while maintaining a low cost that is affordable for academic institutions. Our model can serve as a paradigm for similar institutions, and it may help to make CAR T cell treatment available to all patients.